2015 ESC/ERS Guidelines for the diagnosis and treatme

European Respiratory Journal
46, 903-975
DOI: 10.1183/13993003.01032-2015

Citation Report

#	Article	IF	Citations
2	Alzheimer?s disease: the impact of age-related changes in reproductive hormones. Cellular and Molecular Life Sciences, 2005, 62, 257-270.	2.4	144
3	Imaging the heart in pulmonary hypertension: an update. European Respiratory Review, 2015, 24, 653-664.	3.0	40
4	From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2015, 29, 756-769.	1.4	5
5	Gaining insights into pulmonary hypertension in respiratory diseases. European Respiratory Journal, 2015, 46, 1247-1250.	3.1	8
6	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed Research International, 2015, 2015, 1-10.	0.9	60
8	Under pressure: pulmonary hypertension associated with left heart disease. European Respiratory Review, 2015, 24, 665-673.	3.0	24
9	Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. European Respiratory Review, 2015, 24, 642-652.	3.0	147
10	Challenges in pulmonary hypertension: managing the unexpected. European Respiratory Review, 2015, 24, 674-681.	3.0	9
11	Chronic thromboembolic pulmonary hypertension. Presse Medicale, 2015, 44, e409-e416.	0.8	26
13	Pulmonary Artery Denervation for Pulmonary Artery Hypertension. JACC: Cardiovascular Interventions, 2015, 8, 2024-2025.	1.1	5
14	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	13.9	790
15	Pulmonary embolism: An update. Presse Medicale, 2015, 44, e373-e376.	0.8	1
16	The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. European Respiratory Journal, 2015, 46, 879-882.	3.1	67
17	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731.	3.1	80
18	Riociguat for the treatment of pulmonary hypertension. Expert Review of Respiratory Medicine, 2015, 9, 679-695.	1.0	15
19	Echocardiography and Other Noninvasive Imaging Techniques in the Selection and Management of Patients with Cardiac Resynchronization Therapy. , 2016, , .		0
21	Recent advances in the management of pulmonary arterial hypertension. F1000Research, 2016, 5, 2755.	0.8	15
22	Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. Drug Design, Development and Therapy, 2016, Volume 10, 3747-3754.	2.0	15

#	Article	IF	Citations
23	Transition to routine use of venoarterial extracorporeal oxygenation during lung transplantation could improve early outcomes. Journal of Thoracic Disease, 2016, 8, 1712-1720.	0.6	35
24	Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis. Stem Cells International, 2016, 2016, 1-12.	1.2	33
25	Kinetics of Cardiac Output at the Onset of Exercise in Precapillary Pulmonary Hypertension. BioMed Research International, 2016, 2016, 1-8.	0.9	7
26	Automated 3D Volumetry of the Pulmonary Arteries based on Magnetic Resonance Angiography Has Potential for Predicting Pulmonary Hypertension. PLoS ONE, 2016, 11, e0162516.	1.1	15
27	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. Chest, 2016, 150, 256-258.	0.4	12
28	Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 39.	1.6	94
29	Left ventricular diastolic dysfunction and increased left ventricular mass index related to pulmonary hypertension in patients with systemic autoimmune disease without pericardial effusion. International Journal of Cardiology, 2016, 220, 268-272.	0.8	5
30	Pulmonary arterial hypertension in idiopathic inflammatory myopathies. Medicine (United States), 2016, 95, e4911.	0.4	40
31	Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 68, 2525-2536.	1.2	160
32	BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681.	3.1	68
33	Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. European Respiratory Journal, 2016, 48, 1658-1667.	3.1	63
34	To stress or not to stress? Exercise pulmonary haemodynamic testing in systemic sclerosis. European Respiratory Journal, 2016, 48, 1549-1552.	3.1	3
35	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 408-417.	3.0	53
36	Pulmonary hypertension: the importance of correctly diagnosing the cause. European Respiratory Review, 2016, 25, 372-380.	3.0	9
39	Patient engagement and self-management in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 399-407.	3.0	39
40	Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms. Methodist DeBakey Cardiovascular Journal, 2021, 12, 195.	0.5	7
41	BNP, troponin I, and YKL-40 as screening markers in extremely preterm infants at risk for pulmonary hypertension associated with bronchopulmonary dysplasia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L1076-L1081.	1.3	19
42	Risk assessment in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 390-398.	3.0	39

#	Article	IF	Citations
43	Pregnancy in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 431-437.	3.0	103
44	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. European Respiratory Journal, 2016, 48, 1517-1519.	3.1	44
45	Complex inheritance in Pulmonary Arterial Hypertension patients with several mutations. Scientific Reports, 2016, 6, 33570.	1.6	15
46	Pulmonary arterial hypertension in schistosomiasis. Current Opinion in Pulmonary Medicine, 2016, 22, 408-414.	1.2	20
47	Interferon-induced pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2016, 22, 415-420.	1.2	28
48	Pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2016, 22, 399.	1.2	1
49	Mission CPLF 2016 : les pneumopathies interstitielles Ã lâ€™honneur !. Revue Des Maladies Respiratoires Actualites, 2016, 8, 176-179.	0.0	0
50	Cas clinique nÂ° 2 : Interactions cÅ“ur-poumons â€“ hypertension pulmonaire et maladies cardiaques gauches. Revue Des Maladies Respiratoires Actualites, 2016, 8, 15-19.	0.0	0
52	Cas clinique nÂ° 6 : Une fibrose pulmonaire idiopathique qui sâ€™essouffle. Revue Des Maladies Respiratoires Actualites, 2016, 8, 49-59.	0.0	0
54	Towards a molecular classification of pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 987-989.	3.1	2
55	Practical considerations for therapies targeting the prostacyclin pathway. European Respiratory Review, 2016, 25, 418-430.	3.0	33
56	In Situ Expression of Bclâ€2Âin Pulmonary Artery Endothelial Cells Associates with Pulmonary Arterial Hypertension Relative to Heart Failure with Preserved Ejection Fraction. Pulmonary Circulation, 2016, 6, 551-556.	0.8	10
57	Pulmonary veno-occlusive disease. European Respiratory Journal, 2016, 47, 1518-1534.	3.1	289
58	Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736.	3.1	124
60	Update on pulmonary arterial hypertension pharmacotherapy. Postgraduate Medicine, 2016, 128, 460-473.	0.9	21
61	Homoarginine predicts mortality in treatment-naive patients with pulmonary arterial hypertension. International Journal of Cardiology, 2016, 217, 12-15.	0.8	10
62	Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation. Heart Failure Reviews, 2016, 21, 347-356.	1.7	10
63	Echocardiographic findings associated with mortality or transplant in patients with pulmonary arterial hypertension: AÂsystematic review and meta-analysis. Netherlands Heart Journal, 2016, 24, 374-389.	0.3	13

#	Article	IF	Citations
64	Pulmonary haemodynamics during recovery from maximum incremental cycling exercise. European Respiratory Journal, 2016, 48, 158-167.	3.1	27
65	Impact of macitentan on right ventricular myocardial function in pulmonary arterial hypertension. International Journal of Cardiology, 2016, 214, 438-441.	0.8	3
66	Adaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands. Netherlands Heart Journal, 2016, 24, 417-424.	0.3	9
67	Pulmonary hypertension. European Respiratory Review, 2016, 25, 4-11.	3.0	44
69	Residual Pulmonary Hypertension After Pulmonary Endarterectomy. Circulation, 2016, 133, 1731-1733.	1.6	13
70	Changes in surface electrocardiogram in patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary endarterectomy. Correlations with hemodynamic and echocardiographic improvements after surgery. Journal of Electrocardiology, 2016, 49, 223-230.	0.4	13
71	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	5.2	307
72	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 361-371.	5.2	97
73	Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 372-380.	5.2	130
74	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1273-1285.	2.5	88
75	MR phase-contrast imaging in pulmonary hypertension. British Journal of Radiology, 2016, 89, 20150995.	1.0	42
76	Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1747-1760.	1.6	75
77	Pulmonary hypertension: diagnostic approach and optimal management. Cmaj, 2016, 188, 804-812.	0.9	17
78	Involvement of CapG in proliferation and apoptosis of pulmonary arterial smooth muscle cells and in hypoxia-induced pulmonary hypertension rat model. Experimental Lung Research, 2016, 42, 142-153.	0.5	10
79	Operability assessment in CTEPH: Lessons from the CHEST-1 study. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 669-674.e3.	0.4	57
80	How to define pulmonary hypertension due to left heart disease. European Respiratory Journal, 2016, 48, 553-555.	3.1	36
81	The Pulmonary Hypertension Consult. Chest, 2016, 150, 705-713.	0.4	6
82	Near infrared spectroscopy for the assessment of peripheral tissue oxygenation in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1224-1227.	3.1	6

#	Article	IF	Citations
83	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respiratory Medicine,the, 2016, 4, 894-901.	5.2	59
84	Hemodynamic Evidence of Vascular Remodeling in Combined Postâ€•and Precapillary Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 313-321.	0.8	38
85	Towards Infrastructure for Knowledge-based Decision Support in Clinical Practice. Procedia Computer Science, 2016, 100, 907-914.	1.2	7
87	Clinical Impact of Emphysema Evaluated by High-Resolution Computed Tomography on Idiopathic Pulmonary Fibrosis Diagnosed by Surgical Lung Biopsy. Respiration, 2016, 92, 220-228.	1.2	17
88	Clinical usefulness of end-tidal CO2 profiles during incremental exercise in patients with chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2016, 120, 70-77.	1.3	15
89	Catheter-Based Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	1
90	The difficult diagnosis of pulmonary vascular disease in heart failure. European Respiratory Journal, 2016, 48, 311-314.	3.1	10
91	The Evolving Landscape of Exercise-Induced Pulmonary Hypertension. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 41.	0.4	1
92	The difficult diagnosis of pulmonary vascular disease in heart failure. European Respiratory Journal, 2016, 48, 308-310.	3.1	10
94	The Real Face of Borderline Pulmonary Hypertension in Connective Tissue Disease. Annals of the American Thoracic Society, 2016, 13, 1428-1430.	1.5	7
95	Group 4 Pulmonary Hypertension. Cardiology Clinics, 2016, 34, 435-441.	0.9	51
96	Pulmonary vasculature in COPD: The silent component. Respirology, 2016, 21, 984-994.	1.3	67
97	The Warburg effect: A new story in pulmonary arterial hypertension. Clinica Chimica Acta, 2016, 461, 53-58.	0.5	20
98	Neutrophil Extracellular Traps Promote Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2078-2087.	1.1	158
99	Patent foramen ovale in idiopathic pulmonary arterial hypertension: Long-term risk and morbidity. Respiratory Medicine, 2016, 118, 53-57.	1.3	10
100	Pulmonary Capillary Hemangiomatosis and Pulmonary Veno-occlusive Disease. Clinics in Chest Medicine, 2016, 37, 523-534.	0.8	36
101	Pulmonary arterial hypertension associated with a von Hippel-Lindau gene mutation. Journal of Heart and Lung Transplantation, 2016, 35, 1138-1139.	0.3	11
102	Cerebral microvascular blood flow and CO 2 reactivity in pulmonary arterial hypertension. Respiratory Physiology and Neurobiology, 2016, 233, 60-65.	0.7	15

#	Article	IF	Citations
104	Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1386-1395.	3.1	23
106	Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertensionã€€â€“ Insights From the IBUKI and AIR Studies â€“. Circulation Journal, 2016, 80, 835-842.	0.7	22
107	Effects of Balloon Pulmonary Angioplasty on Oxygenation in Patients With Chronic Thromboembolic Pulmonary Hypertensionã€€â€“ Importance of Intrapulmonary Shunt â€“. Circulation Journal, 2016, 80, 2227-2234.	0.7	39
108	Beneficial Therapeutic Effects of Balloon Pulmonary Angioplasty on Biventricular Function in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation Journal, 2016, 80, 1326-1327.	0.7	3
109	Pharmacokinetic Interaction Study between Riociguat and the Combined Oral Contraceptives Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women. Pulmonary Circulation, 2016, 6, S97-S102.	0.8	12
110	Why We Should Care about the Mysteries of Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 249-250.	0.8	0
111	Expression Profiling Elucidates a Molecular Gene Signature for Pulmonary Hypertension in Sarcoidosis. Pulmonary Circulation, 2016, 6, 465-471.	0.8	10
112	Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1434-1436.	2.5	12
113	Chronic Thromboembolic Pulmonary Hypertension. Epidemiology and Risk Factors. Annals of the American Thoracic Society, 2016, 13, S201-S206.	1.5	101
114	Future Directions in Chronic Thromboembolic Pulmonary Hypertension. Disease at a Crossroads?. Annals of the American Thoracic Society, 2016, 13, S255-S258.	1.5	6
115	Provocative testing of the pulmonary circulation: advances and unresolved issues. European Respiratory Journal, 2016, 48, 18-20.	3.1	1
116	Right atrial contractile dynamics are impaired in patients with postcapillary pulmonary hypertension. Experimental and Therapeutic Medicine, 2016, 12, 792-798.	0.8	6
117	Pulmonary Hypertension in Children. Cardiology Clinics, 2016, 34, 451-472.	0.9	43
118	Pulmonary artery denervation improves pulmonary arterial hypertension induced right ventricular dysfunction by modulating the local renin-angiotensin-aldosterone system. BMC Cardiovascular Disorders, 2016, 16, 192.	0.7	22
119	Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era. JAMA Cardiology, 2016, 1, 1056.	3.0	99
121	Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension. BMC Pulmonary Medicine, 2016, 16, 145.	0.8	18
127	Transthoracic Echocardiography and Chest Computed Tomography Arteriography in Patients with Acute Pulmonary Embolism: A Two-Year Follow-Up Study. Respiration, 2016, 92, 235-240.	1.2	5
129	A critical appraisal of transpulmonary and diastolic pressure gradients. Physiological Reports, 2016, 4, e12910.	0.7	24

#	Article	IF	Citations
131	Pulmonary tumour thrombotic microangiopathy. Current Opinion in Pulmonary Medicine, 2016, 22, 421-428.	1.2	58
132	Does exercise pulmonary hypertension exist?. Current Opinion in Pulmonary Medicine, 2016, 22, 400-407.	1.2	5
133	PulmoCor: national registry for pulmonary hypertension. Netherlands Heart Journal, 2016, 24, 425-430.	0.3	3
134	Expression and role of connexin-based gap junctions in pulmonary inflammatory diseases. , 2016, 164, 105-119.		25
135	Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science. European Respiratory Journal, 2016, 47, 1615-1617.	3.1	7
136	Connective tissue disease-related pulmonary arterial hypertension. Best Practice and Research in Clinical Rheumatology, 2016, 30, 22-38.	1.4	38
137	Special considerations in pregnant systemic sclerosis patients. Expert Review of Clinical Immunology, 2016, 12, 1161-1173.	1.3	19
138	Bodily isomerism is an independent risk factor for pulmonary hypertension in adults with congenital heart disease. Therapeutic Advances in Respiratory Disease, 2016, 10, 194-199.	1.0	7
139	Combined Pulmonary Fibrosis and Emphysema, a clinical review. COPD Research and Practice, 2016, 2, .	0.7	5
140	Pulmonary hypertension associated with thalassemia syndromes. Annals of the New York Academy of Sciences, 2016, 1368, 127-139.	1.8	46
141	Local and systemic reninâ€“angiotensin system participates in cardiopulmonaryâ€“renal interactions in monocrotaline-induced pulmonary hypertension in the rat. Molecular and Cellular Biochemistry, 2016, 418, 147-157.	1.4	16
142	Systemic sclerosis: An update in 2016. Autoimmunity Reviews, 2016, 15, 417-426.	2.5	126
143	Reconciling paradigms of abnormal pulmonary blood flow and quasi-malignant cellular alterations in pulmonary arterial hypertension. Vascular Pharmacology, 2016, 83, 17-25.	1.0	7
144	Common long-term complications of adult congenital heart disease: avoid falling in a H.E.A.P.. Expert Review of Cardiovascular Therapy, 2016, 14, 445-462.	0.6	37
145	Letter by Hoeper and GaliÃ¨ Regarding Article, â€œHemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Studyâ€• Circulation: Cardiovascular Interventions, 2016, 9, e003422.	1.4	14
146	Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability. Redox Biology, 2016, 7, 48-57.	3.9	31
147	Resting pulmonary artery pressure of 21â€“24â€…mmHg predicts abnormal exercise haemodynamics. European Respiratory Journal, 2016, 47, 1436-1444.	3.1	44
148	Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study. European Respiratory Journal, 2016, 47, 1737-1749.	3.1	31

#	Article	IF	Citations
149	BMPR2 revisited: are bigger data better?. Lancet Respiratory Medicine,the, 2016, 4, 87-89.	5.2	0
150	Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation, 2016, 133, 1240-1248.	1.6	289
151	Resident PW1 ⁺ Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. Circulation Research, 2016, 118, 822-833.	2.0	34
152	Monitoring of Lung Involvement in Rheumatologic Disease. Respiration, 2016, 91, 89-98.	1.2	18
153	Improving definitions for an index of cumulative organ damage in patients with the antiphospholipid syndrome (DIAPS). Lupus, 2016, 25, 671-672.	0.8	5
154	Î²-blockers in pulmonary arterial hypertension: generation might matter. European Respiratory Journal, 2016, 47, 682-684.	3.1	3
155	Earlier diagnosis and international registries may improve outcomes in pulmonary tumour thrombotic microangiopathy. European Respiratory Journal, 2016, 47, 690-691.	3.1	5
156	Genetic testing in pulmonary hypertension: how should our clinical practice reflect recent advances?. European Respiratory Journal, 2016, 47, 388-389.	3.1	2
157	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. Chest, 2016, 149, 1482-1493.	0.4	63
158	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Current Rheumatology Reports, 2016, 18, 10.	2.1	38
159	Treatment of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 323-336.	5.2	97
160	A global view of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 306-322.	5.2	523
161	Connective tissue diseases, multimorbidity and the ageing lung. European Respiratory Journal, 2016, 47, 1535-1558.	3.1	37
162	Surgery remains treatment of choice for CTEPH. Nature Reviews Cardiology, 2016, 13, 188-189.	6.1	1
163	Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 291-305.	5.2	190
164	Comentarios a la guÃa ESC/ERS 2015 sobre el diagnÃ³stico y tratamiento de la hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia, 2016, 69, 102-108.	0.6	14
165	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385.	1.6	141
166	A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. European Respiratory Review, 2016, 25, 93-96.	3.0	7

#	Article	IF	Citations
167	Diffusion Capacity and Mortality in PatientsÂWith Pulmonary Hypertension DueÂto Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 441-449.	1.9	95
168	Patientsâ€™, relativesâ€™, and practitionersâ€™ views of pulmonary arterial hypertension: A qualitative study. Presse Medicale, 2016, 45, e11-e27.	0.8	18
169	Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension. Pharmacoeconomics, 2016, 34, 751-770.	1.7	28
170	Exercise testing can unmask right ventricular dysfunction in systemic sclerosis patients with normal resting pulmonary artery pressure. International Journal of Cardiology, 2016, 204, 179-186.	0.8	19
171	Age-related upper limits of normal for maximum upright exercise pulmonary haemodynamics. European Respiratory Journal, 2016, 47, 1179-1188.	3.1	72
172	The ambition of the European Respiratory Journal: chapter 4. European Respiratory Journal, 2016, 47, 1-4.	3.1	4
173	Genetic counselling in a national referral centre for pulmonary hypertension. European Respiratory Journal, 2016, 47, 541-552.	3.1	87
174	Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis. European Respiratory Journal, 2016, 47, 673-676.	3.1	33
175	Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?. Thorax, 2016, 71, 107-109.	2.7	5
176	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.4	79
177	Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation, 2017, 36, 166-174.	0.3	89
178	Update on chronic thromboembolic pulmonary hypertension. Trends in Cardiovascular Medicine, 2017, 27, 29-37.	2.3	34
180	Exercise-based rehabilitation programmes for pulmonary hypertension. The Cochrane Library, 2017, 2017, CD011285.	1.5	54
181	Fibrosis pulmonar idiopÃ¡tica. Medicina ClÃnica, 2017, 148, 170-175.	0.3	26
183	Diagnostic accuracy of cardiovascular magnetic resonance imaging for assessment of right ventricular morphology and function in pulmonary artery hypertension. The Egyptian Journal of Chest Diseases and Tuberculosis, 2017, 66, 477-486.	0.1	2
184	Valor pronÃ³stico del pH en el condensado de aire exhalado y de la fracciÃ³n exhalada de Ã³xido nÃtrico en la enfermedad pulmonar intersticial asociada a esclerosis sistÃ©mica. Archivos De Bronconeumologia, 2017, 53, 120-127.	0.4	4
185	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134.	5.2	123
186	To screen or not to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thrombosis Research, 2017, 151, 1-7.	0.8	45

#	Article	IF	Citations
187	Pulmonary vascular and cardiac impairment in interstitial lung disease. European Respiratory Review, 2017, 26, 160053.	3.0	36
188	Pregnancy and Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2017, , .	0.2	3
189	Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study. Radiology, 2017, 283, 381-390.	3.6	161
190	Predicting the future from the past. European Respiratory Journal, 2017, 49, 1601854.	3.1	3
191	Endothelin Receptor Antagonist. , 2017, , 153-169.		0
192	Medical Therapy for Chronic Thromboembolic Pulmonary Hypertension. , 2017, , 185-192.		0
193	Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost. Respiratory Care, 2017, 62, 489-496.	0.8	13
194	Investigating the value of right heart echocardiographic metrics for detection of pulmonary hypertension in patients with advanced lung disease. International Journal of Cardiovascular Imaging, 2017, 33, 825-835.	0.7	13
195	5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77. Inflammation, 2017, 40, 806-817.	1.7	8
196	New Cardiac Imaging Tools and Invasive Techniques in Systemic Autoimmune Diseases (Part II). Handbook of Systemic Autoimmune Diseases, 2017, 14, 209-226.	0.1	0
197	Pulmonary hypertension in connective tissue diseases: an update. International Journal of Rheumatic Diseases, 2017, 20, 5-24.	0.9	42
198	Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Archives of Cardiovascular Diseases, 2017, 110, 303-316.	0.7	37
199	Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. European Respiratory Journal, 2017, 49, 1601792.	3.1	339
200	Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension. European Respiratory Journal, 2017, 49, 1601897.	3.1	32
201	Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2017, 49, 1602522.	3.1	32
202	Epoprostenol and pulmonary arterial hypertension: 20â€…years of clinical experience. European Respiratory Review, 2017, 26, 160055.	3.0	70
203	Easily measurable, noninvasive, and novel finding for pulmonary hypertension: Hypertrophy of the basal segment of septomarginal trabeculation of right ventricle. Echocardiography, 2017, 34, 290-295.	0.3	6
204	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Annals of the Rheumatic Diseases, 2017, 76, 422-426.	0.5	108

#	Article	IF	Citations
205	Representative Chest Auscultation Findings in Pulmonary Hypertension: Phonocardiograms and Sound Clips. Annals of the American Thoracic Society, 2017, 14, e1-e3.	1.5	2
206	Editorial commentary: â€œDiscovery of a Murine Model of clinical pulmonary arterial hypertension: Mission impossible?â€•by Dai and Zhao. Trends in Cardiovascular Medicine, 2017, 27, 237-238.	2.3	2
207	Subcutaneous treprostinil was effective and tolerable in a patient with severe pulmonary hypertension associated with chronic kidney disease on hemodialysis. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 129-130.	0.8	5
208	Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. Scientific Reports, 2017, 7, 41650.	1.6	24
209	The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Review of Respiratory Medicine, 2017, 11, 491-503.	1.0	55
210	Systemic sclerosis. Lancet, The, 2017, 390, 1685-1699.	6.3	1,423
211	Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. Clinical Research in Cardiology, 2017, 106, 776-783.	1.5	18
212	<scp>CT</scp>â€determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis. Respirology, 2017, 22, 1393-1399.	1.3	41
213	A simple echocardiographic score for the diagnosis of pulmonary vascular disease in heart failure. Journal of Cardiovascular Medicine, 2017, 18, 237-243.	0.6	18
215	Pulmonary arterial hypertension: screening challenges in systemic sclerosis and future directions. European Respiratory Journal, 2017, 49, 1700522.	3.1	7
216	Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. European Respiratory Journal, 2017, 49, 1602275.	3.1	50
217	Novelties in the Treatment of Pulmonary Hypertension. Archivos De Bronconeumologia, 2017, 53, 235-236.	0.4	0
218	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. European Respiratory Journal, 2017, 49, 1700178.	3.1	9
219	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolarÂproteinosis and fibrosis. European Respiratory Journal, 2017, 49, 1700407.	3.1	8
220	Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respiratory Medicine, 2017, 128, 50-56.	1.3	31
221	Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentanâ€. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 254-259.	0.5	10
222	Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure. Pulmonary Circulation, 2017, 7, 654-665.	0.8	38
223	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	5.2	99

#	Article	IF	Citations
224	Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class <scp>IV</scp> Chronic Thromboembolic Pulmonary Hypertension. Pharmacotherapy, 2017, 37, e76-e81.	1.2	12
225	Early Onset Noninfectious Pulmonary Syndromes after Hematopoietic Cell Transplantation. Clinics in Chest Medicine, 2017, 38, 233-248.	0.8	22
226	Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension. Lung, 2017, 195, 489-496.	1.4	24
227	Pulmonary arterial hypertension â€“ progress in understanding the disease and prioritizing strategies for drug development. Journal of Internal Medicine, 2017, 282, 129-141.	2.7	21
228	Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension. Scientific Reports, 2017, 7, 1923.	1.6	16
229	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. Annals of Thoracic Surgery, 2017, 104, 404-411.	0.7	29
230	Rare respiratory diseases are ready for primetime: from Rare Disease Day to the European Reference Networks. European Respiratory Journal, 2017, 49, 1700085.	3.1	30
231	Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2017, 129, 124-129.	1.3	11
232	Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. Pulmonary Circulation, 2017, 7, 588-597.	0.8	3
233	Pulmonary Hypertension in Women: What Does the Cardiologist Need to Know?. Current Cardiovascular Risk Reports, 2017, 11, 1.	0.8	1
234	Epidemiology and treatment of pulmonary arterial hypertension. Nature Reviews Cardiology, 2017, 14, 603-614.	6.1	310
235	Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension andÂAngina. Journal of the American College of Cardiology, 2017, 69, 2808-2817.	1.2	91
236	Year in review 2016: Interstitial lung disease, pulmonary vascular disease, pulmonary function, paediatric lung disease, cystic fibrosis and sleep. Respirology, 2017, 22, 1022-1034.	1.3	2
237	Lung Density and Pulmonary Artery Diameter are Predictors of Pulmonary Hypertension in Systemic Sclerosis. Journal of Thoracic Imaging, 2017, 32, 391-397.	0.8	9
238	Consequences of Venous Thromboembolism, Including Chronic Thromboembolic Pulmonary Hypertension. Critical Care Nursing Quarterly, 2017, 40, 260-275.	0.4	4
239	Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2017, 49, 1601419.	3.1	37
240	Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. Pulmonary Circulation, 2017, 7, 409-420.	0.8	31
241	A systematic review of transition studies of pulmonary arterial hypertension specific medications. Pulmonary Circulation, 2017, 7, 326-338.	0.8	22

#	Article	IF	Citations
242	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulmonary Circulation, 2017, 7, 312-325.	0.8	37
243	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. European Respiratory Journal, 2017, 49, 1602409.	3.1	178
244	Diagnostic and Prognostic Implications of Exercise Treadmill and Rest First-Pass Radionuclide Angiography in Patients With Pulmonary Hypertension. Clinical Nuclear Medicine, 2017, 42, e392-e399.	0.7	3
245	Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressureâ€overloaded human right heart. Pulmonary Circulation, 2017, 7, 339-347.	0.8	8
246	Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 399-408.	0.8	12
247	The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 505-513.	0.8	20
249	Medical management of chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160107.	3.0	52
250	Use of Î²-Blockers in Pulmonary Hypertension. Circulation: Heart Failure, 2017, 10, .	1.6	56
251	An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. European Respiratory Review, 2017, 26, 160121.	3.0	156
252	Critical care management of pulmonary hypertension. BJA Education, 2017, 17, 228-234.	0.6	16
253	Normativa sobre el tratamiento farmacolÃ³gico de la fibrosis pulmonar idiopÃ¡tica. Archivos De Bronconeumologia, 2017, 53, 263-269.	0.4	40
254	Novelties in the Treatment of Pulmonary Hypertension. Archivos De Bronconeumologia, 2017, 53, 235-236.	0.4	2
257	A Case of Pulmonary Hypertension Due to Fistulas Between Multiple Systemic Arteries and the Right Pulmonary Artery in an Adult Discovered for Occulted Dyspnoea. Heart Lung and Circulation, 2017, 26, e54-e58.	0.2	3
258	Evaluation of Reperfusion Pulmonary Edema by Extravascular Lung Water Measurements After Pulmonary Endarterectomy. Critical Care Medicine, 2017, 45, e409-e417.	0.4	15
259	Cardiopulmonary Exercise Testing in Pulmonary Hypertension. Annals of the American Thoracic Society, 2017, 14, S84-S92.	1.5	81
261	Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis. Archivos De Bronconeumologia, 2017, 53, 263-269.	0.4	21
262	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160119.	3.0	183
263	Very Small Embryonic-like Stem Cells Are Mobilized in Human Peripheral Blood during Hypoxemic COPD Exacerbations and Pulmonary Hypertension. Stem Cell Reviews and Reports, 2017, 13, 561-566.	5.6	20

#	Article	IF	Citations
264	Reversible Pulmonary Arterial Hypertension Induced by Dasatinib in a Patient With Chronic Myeloid Leukemia. Journal of Diagnostic Medical Sonography, 2017, 33, 284-289.	0.1	1
265	Diagnosis of chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160108.	3.0	114
266	Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160111.	3.0	229
267	Changing Landscape of Congenital Heart Disease. Circulation Research, 2017, 120, 908-922.	2.0	213
268	Altered synchrony of right ventricular contraction in borderline pulmonary hypertension. International Journal of Cardiovascular Imaging, 2017, 33, 1331-1339.	0.7	46
269	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine, 2017, 122, S18-S22.	1.3	15
270	Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. Expert Opinion on Therapeutic Targets, 2017, 21, 181-190.	1.5	34
271	Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component. Journal of Heart and Lung Transplantation, 2017, 36, 754-762.	0.3	49
272	Prognostic Role of Exhaled Breath Condensate pH and Fraction Exhaled Nitric Oxide in Systemic Sclerosis Related Interstitial Lung Disease. Archivos De Bronconeumologia, 2017, 53, 120-127.	0.4	4
273	Complications of pulmonary hypertension: a pictorial review. British Journal of Radiology, 2017, 90, 20160745.	1.0	9
274	EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension. Chest, 2017, 151, 821-828.	0.4	53
275	Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension. Radiologia Medica, 2017, 122, 257-264.	4.7	8
276	Diagnosis and Treatment of Pulmonary Hypertension. , 2017, , .		1
277	HIV and Nonischemic Heart Disease. Journal of the American College of Cardiology, 2017, 69, 83-91.	1.2	50
278	Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 267-279.	1.3	42
279	Comparing the Efficacy of Tadalafil Versus Placebo on Pulmonary Artery Systolic Pressure and Right Ventricular Function in Patients with Beta-Thalassaemia Intermedia. Heart Lung and Circulation, 2017, 26, 677-683.	0.2	8
280	Longâ€term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology, 2017, 65, 1683-1692.	3.6	68
281	Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension. Internal and Emergency Medicine, 2017, 12, 319-326.	1.0	11

#	Article	IF	Citations
282	Favorable Evolution of a Patient with Thromboembolic Pulmonary Hypertension. ARS Medica Tomitana, 2017, 23, 94-98.	0.0	0
283	Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. JAMA Cardiology, 2017, 2, 1361.	3.0	122
284	Wave reflection correlates with pulmonary vascular wall thickening in rats with pulmonary arterial hypertension. International Journal of Cardiology, 2017, 249, 396-401.	0.8	6
285	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosisÂâ€“Â2017 update. Full-length version. Revue Des Maladies Respiratoires, 2017, 34, 900-968.	1.7	51
287	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosisÂâ€“Â2017 update. Short-length version. Revue Des Maladies Respiratoires, 2017, 34, 852-899.	1.7	2
289	Pavia Experience in Reoperative Pulmonary Endarterectomy. Seminars in Thoracic and Cardiovascular Surgery, 2017, 29, 464-468.	0.4	6
290	Performance of computed tomography-derived pulmonary vasculature metrics in the diagnosis and haemodynamic assessment of pulmonary arterial hypertension. European Journal of Radiology, 2017, 96, 31-38.	1.2	14
291	Macitentan in Pulmonary Arterial Hypertension Associated with Congenital Heart Defects. Heart Lung and Circulation, 2017, 26, 1006-1007.	0.2	2
292	Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
293	Differences in right ventricular morphology, not function, indicate the nature of increased afterload in pulmonary hypertensive subjects with normal left ventricular function. Echocardiography, 2017, 34, 1584-1592.	0.3	16
294	Pulmonary hypertension in systemic sclerosis: different phenotypes. European Respiratory Review, 2017, 26, 170056.	3.0	97
295	Prise en charge de lâ€™hypertension artÃ©rielle pulmonaire postembolique en 2017Â: apport de lâ€™angioplastie percutanÃ©e au ballon. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2017, 2017, 2-5.	0.0	0
296	A 63-Year-Old Woman With Neurofibromatosis Type 1 and Pulmonary Hypertension With Worsening Hypoxemia. Chest, 2017, 152, e89-e93.	0.4	6
297	Compromised Cerebrovascular Regulation and Cerebral Oxygenation in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2017, 6, .	1.6	32
298	Biomarkers in Pulmonary Vascular Disease: Gauging Response to Therapy. American Journal of Cardiology, 2017, 120, S89-S95.	0.7	11
299	Screening of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 596-605.	0.8	2
300	Pathology and Pathobiology of Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 571-584.	0.8	33
301	Chronic Thromboembolic Pulmonary Hypertension: Advances in Therapy. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 677-685.	0.8	0

#	Article	IF	Citations
302	Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 606-618.	0.8	5
303	Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. American Journal of Respiratory and Critical Care Medicine, 2017, 196, e32-e47.	2.5	36
304	Portopulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 651-661.	0.8	30
305	Evolving Concepts in Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 559-560.	0.8	0
306	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. European Respiratory Journal, 2017, 50, 1700465.	3.1	111
307	Evaluation of the hemodynamics and right ventricular function in pulmonary hypertension by echocardiography compared with right-sided heart catheterization. Experimental and Therapeutic Medicine, 2017, 14, 3616-3622.	0.8	6
308	Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?. Current Hypertension Reports, 2017, 19, 86.	1.5	19
309	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. Rheumatology, 2017, 56, v33-v37.	0.9	4
310	Natural Antioxidants as Potential Therapy, and a Promising Role for Melatonin Against Pulmonary Hypertension. Advances in Experimental Medicine and Biology, 2017, 967, 161-178.	0.8	21
311	How prostacyclin therapy improves right ventricular function in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700764.	3.1	36
313	New insights into the recognition, classification and management of systemic sclerosis-associated pulmonary hypertension. Current Opinion in Rheumatology, 2017, 29, 561-567.	2.0	4
314	Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment. , 2017, , 129-143.		0
315	Hypertension pulmonaire et grossesse. Praticien En Anesthesie Reanimation, 2017, 21, 192-203.	0.0	1
316	Humanistic and cost burden of systemic sclerosis: A review of the literature. Autoimmunity Reviews, 2017, 16, 1147-1154.	2.5	39
317	Reversible Interferon-Induced Pulmonary Arterial Hypertension in a Patient With Multiple Sclerosis. Archivos De Bronconeumologia, 2017, 53, 596-597.	0.4	3
318	Pulmonary arterial hypertension, a novelty in idiopathic inflammatory myopathies: insights and first experiences with vasoactive therapy. RMD Open, 2017, 3, e000331.	1.8	6
319	Heritable pulmonary hypertension: from bench to bedside. European Respiratory Review, 2017, 26, 170037.	3.0	24
320	The effective systematic heparin pre-treatment on thrombus formation on pulmonary artery catheter tips during pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a randomized, double-blind study. Journal of Thrombosis and Thrombolysis, 2017, 44, 335-340.	1.0	2

#	Article	IF	Citations
321	Challenging the concept of adding more drugs in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1701527.	3.1	7
322	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal, 2017, 50, 1602425.	3.1	113
323	Are indexed values better for defining exercise pulmonary hypertension?. European Respiratory Journal, 2017, 50, 1700240.	3.1	4
324	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. Thorax, 2017, 72, 1035-1045.	2.7	30
325	Pulmonary Hypertension in Idiopathic Interstitial Pneumonias. , 2017, , 103-128.		0
326	Evaluation of criteria for exercise-induced pulmonary hypertension in patients with resting pulmonary hypertension. European Respiratory Journal, 2017, 50, 1700784.	3.1	7
327	Admission for COPD Exacerbation Is Associated with the Clinical Diagnosis of Pulmonary Hypertension: Results from a Retrospective Longitudinal Study of a Veteran Population. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 484-489.	0.7	36
328	Replacing a phosphodiesteraseâ€5Âinhibitor with riociguat in patients with connective tissue diseaseâ€associated pulmonary arterial hypertension: a case series. Pulmonary Circulation, 2017, 7, 741-746.	0.8	13
329	Resistive or dynamic exercise stress testing of the pulmonary circulation and the right heart. European Respiratory Journal, 2017, 50, 1700151.	3.1	16
330	Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study. European Respiratory Journal, 2017, 50, 1601708.	3.1	28
331	HipertensiÃ³n arterial pulmonar reversible en una paciente con esclerosis mÃºltiple asociada a tratamiento con interferÃ³n. Archivos De Bronconeumologia, 2017, 53, 596-597.	0.4	4
332	Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil. Cardiovascular Therapeutics, 2017, 35, e12281.	1.1	9
333	Is there a vanishing pulmonary capillary syndrome?. Lancet Respiratory Medicine,the, 2017, 5, 676-678.	5.2	22
334	Sarcoidosis-Associated Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 450-462.	0.8	29
335	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal, 2017, 50, 1700217.	3.1	89
336	Long-term management of patients with end-stage lung diseases. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2017, 31, 167-178.	1.7	6
337	Incremental value of right atrial strain for early diagnosis of hemodynamic deterioration in pulmonary hypertension. Journal of Cardiovascular Medicine, 2017, 18, 866-874.	0.6	4
338	Galectin-3 mediates pulmonary vascular remodeling in hypoxia-induced pulmonary arterial hypertension. Journal of the American Society of Hypertension, 2017, 11, 673-683.e3.	2.3	31

#	Article	IF	Citations
339	Effect of hypoxia and hyperoxia on exercise performance in healthy individuals and in patients with pulmonary hypertension: a systematic review. Journal of Applied Physiology, 2017, 123, 1657-1670.	1.2	29
340	A case report of PVOD patient combined with pulmonary embolism. Medicine (United States), 2017, 96, e6507.	0.4	1
341	Left Ventricular Myocardial Fibrosis, Atrophy, and Impaired Contractility in Patients With Pulmonary Arterial Hypertension and a Preserved Left Ventricular Function. Journal of Thoracic Imaging, 2017, 32, 36-42.	0.8	40
342	Assessing risk in pulmonary arterial hypertension: what we know, what we don't. European Respiratory Journal, 2017, 50, 1701353.	3.1	25
343	Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. Internal and Emergency Medicine, 2017, 12, 923-934.	1.0	4
344	Uncovering Small Secrets in Big Data Sets. Circulation Research, 2017, 121, 317-319.	2.0	3
345	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2209-2221.	2.9	17
346	Intratracheal administration of isosorbide dinitrate improves pulmonary artery pressure and ventricular remodeling in a rat model of heart failure following myocardial infarction. Experimental and Therapeutic Medicine, 2017, 14, 1399-1408.	0.8	3
348	Diagnosing and managing scleroderma-related pulmonary arterial hypertension. JAAPA: Official Journal of the American Academy of Physician Assistants, 2017, 30, 11-18.	0.1	3
349	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Annals of the Rheumatic Diseases, 2017, 76, 1931-1940.	0.5	67
350	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal, 2017, 50, 1700740.	3.1	489
351	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700889.	3.1	527
352	More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. European Respiratory Journal, 2017, 50, 1700354.	3.1	25
353	Impact of Intrathoracic Pressure in the Assessment of Pulmonary Hypertension in Overweight Patients. Annals of the American Thoracic Society, 2017, 14, 1861-1863.	1.5	17
354	Reoperative Pulmonary Endarterectomy: Past Failures of Patient Selection Can Assist in Future Practice of Informed Consent. Seminars in Thoracic and Cardiovascular Surgery, 2017, 29, 469-470.	0.4	0
355	Management of late presentation congenital heart disease. Cardiology in the Young, 2017, 27, S31-S39.	0.4	27
356	Exercise Facilitates Early Recognition of Cardiac and Vascular Remodeling in Chronic Thrombo-Embolic Pulmonary Hypertension in a Novel CTEPH Swine Model. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, ajpheart.00380..	1.5	9
357	Pulmonary arterial hypertension and acute respiratory distress syndrome in a patient with adult-onset stills disease. Pulmonary Circulation, 2017, 7, 797-802.	0.8	11

#	Article	IF	Citations
358	Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26, 170092.	3.0	48
359	Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease. Presse Medicale, 2017, 46, 1223-1225.	0.8	5
360	The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study. Pulmonary Circulation, 2017, 7, 684-691.	0.8	10
361	Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study. Lung, 2017, 195, 529-536.	1.4	15
362	Balancing the positives and negatives of the diastolic pulmonary gradient. European Journal of Heart Failure, 2017, 19, 98-100.	2.9	10
363	Treatment response in patients with idiopathic pulmonary arterial hypertension and a severely reduced diffusion capacity. Pulmonary Circulation, 2017, 7, 137-144.	0.8	6
364	MDCT Assessment of Pulmonary Arterial Hypertension. Current Radiology Reports, 2017, 5, 1.	0.4	1
365	Time-resolved tracking of the atrioventricular plane displacement in Cardiovascular Magnetic Resonance (CMR) images. BMC Medical Imaging, 2017, 17, 19.	1.4	35
366	Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension. BMC Pulmonary Medicine, 2017, 17, 72.	0.8	30
367	Imatinib relaxes the pulmonary venous bed of guinea pigs. Respiratory Research, 2017, 18, 32.	1.4	17
368	Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. Orphanet Journal of Rare Diseases, 2017, 12, 74.	1.2	34
369	Genetics of pulmonary hypertension in the clinic. Current Opinion in Pulmonary Medicine, 2017, 23, 386-391.	1.2	16
370	A study of clinical and physiological relations of daily physical activity in precapillary pulmonary hypertension. Journal of Applied Physiology, 2017, 123, 851-859.	1.2	5
371	Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension. European Respiratory Journal, 2017, 49, 1700007.	3.1	63
372	Measuring the effects of treatment in patients with PAH: should we image theÂrightÂventricle?. European Respiratory Journal, 2017, 49, 1700805.	3.1	2
373	Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension: Similarities and disparities. American Heart Journal, 2017, 192, 120-127.	1.2	35
376	Activation of GPER ameliorates experimental pulmonary hypertension in male rats. European Journal of Pharmaceutical Sciences, 2017, 97, 208-217.	1.9	34
377	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. Journal of Cardiac Failure, 2017, 23, 29-35.	0.7	25

#	Article	IF	Citations
378	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. Journal of Heart and Lung Transplantation, 2017, 36, 386-398.	0.3	15
379	Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respiratory Medicine, 2017, 123, 56-62.	1.3	119
380	Gas exchange responses during 6-min walk test in patients with pulmonary arterial hypertension. Respirology, 2017, 22, 165-171.	1.3	7
381	Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH): Dual-energy CT experience in 31 patients. European Radiology, 2017, 27, 1631-1639.	2.3	63
382	Bi-ventricular interplay in patients with systemic sclerosis-associated pulmonary arterial hypertension: Detection by cardiac magnetic resonance. Modern Rheumatology, 2017, 27, 481-488.	0.9	5
383	Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respiratory Medicine,the, 2017, 5, 72-84.	5.2	137
384	Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2017, 36, 193-201.	0.3	50
385	Efficacy and Safety of Statins for Pulmonary Hypertension: A Meta-Analysis of Randomised Controlled Trials. Heart Lung and Circulation, 2017, 26, 425-432.	0.2	9
386	Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial). Heart Lung and Circulation, 2017, 26, 433-441.	0.2	64
387	Reference ranges and determinants of right ventricle outflow tract acceleration time in healthy adults by two-dimensional echocardiography. International Journal of Cardiovascular Imaging, 2017, 33, 219-226.	0.7	17
388	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation, 2017, 135, 460-475.	1.6	154
389	The evolving landscape of combination therapy for pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2017, 11, 91-95.	1.0	2
390	Prognostic and pathophysiological marker for patients with chronic thromboembolic pulmonary hypertension: Usefulness of diffusing capacity for carbon monoxide at diagnosis. Respirology, 2017, 22, 179-186.	1.3	22
391	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 583-595.	2.5	113
393	Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review. Scientific Reports, 2017, 7, 16218.	1.6	13
394	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. European Respiratory Journal, 2017, 50, 1700578.	3.1	222
395	59-Year-Old Woman With Fatigue, Dyspnea, and Lower Extremity Edema. Mayo Clinic Proceedings, 2017, 92, e167-e171.	1.4	0
398	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155.	1.0	65

#	Article	IF	Citations
399	Advanced pulmonary arterial hypertension: mechanical support and lung transplantation. European Respiratory Review, 2017, 26, 170089.	3.0	23
400	Pulmonary arterial hypertension: tailoring treatment to risk in the current era. European Respiratory Review, 2017, 26, 170095.	3.0	32
401	The changing landscape of chronic thromboembolic pulmonary hypertension management. European Respiratory Review, 2017, 26, 170105.	3.0	69
402	Prevalence and incidence of pulmonary arterial hypertension: 10-year follow-up of an unselected systemic sclerosis cohort. Journal of Scleroderma and Related Disorders, 2017, 2, 196-202.	1.0	9
403	Interferon Therapy Exacerbated Pulmonary Hypertension in a Patient with Hepatitis C Virus Infection: Pathogenic Interplay among Multiple Risk Factors. Internal Medicine, 2017, 56, 1061-1065.	0.3	8
404	Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension. Chinese Medical Journal, 2017, 130, 382-391.	0.9	11
405	Surgical Management of Chronic Pulmonary Embolism. , 0, , .		0
407	A nationwide evaluation of off-label drug utilization in Turkey. Turkish Journal of Medical Sciences, 2017, 47, 1229-1238.	0.4	3
408	Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension. Circulation Journal, 2017, 81, 1360-1367.	0.7	19
409	Prognostic Value of Pulmonary Artery Compliance in Patients with Pulmonary Arterial Hypertension Associated with Adult Congenital Heart Disease. International Heart Journal, 2017, 58, 731-738.	0.5	14
410	A review of pediatric pulmonary hypertension with new guidelines. Turkish Journal of Medical Sciences, 2017, 47, 375-380.	0.4	5
411	The Dark Side of the Moon: The Right Ventricle. Journal of Cardiovascular Development and Disease, 2017, 4, 18.	0.8	28
412	The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature. Frontiers in Immunology, 2017, 8, 707.	2.2	39
413	Differential expression of hepatocyte growth factor in patients with systemic sclerosis-associated pulmonary arterial hypertension. Journal of Scleroderma and Related Disorders, 2017, 2, 225-230.	1.0	0
414	Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Design, Development and Therapy, 2017, Volume11, 1195-1207.	2.0	25
415	Accuracy of echocardiographic indices for serial monitoring of right ventricular systolic function in patients with precapillary pulmonary hypertension. PLoS ONE, 2017, 12, e0187806.	1.1	7
416	Pulmonary Artery Diameter Predicts Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension. International Heart Journal, 2017, 58, 584-588.	0.5	3
417	Prevalence and etiologies of pulmonary hypertension in Africa: a systematic review and meta-analysis. BMC Pulmonary Medicine, 2017, 17, 183.	0.8	25

#	Article	IF	Citations
418	Using omics approaches to understand pulmonary diseases. Respiratory Research, 2017, 18, 149.	1.4	90
419	Novel Predictor of Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension. International Heart Journal, 2017, 58, 470-471.	0.5	0
421	Sudden Death in a Patient with Pulmonary Veno-occlusive Disease (PVOD) and Severe Pulmonary Hypertension. Internal Medicine, 2017, 56, 2025-2031.	0.3	0
422	Increased Serum Levels of Fetal Tenascin-C Variants in Patients with Pulmonary Hypertension: Novel Biomarkers Reflecting Vascular Remodeling and Right Ventricular Dysfunction?. International Journal of Molecular Sciences, 2017, 18, 2371.	1.8	13
423	Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells. International Journal of Medical Sciences, 2017, 14, 820-828.	1.1	10
424	Evaluating respiratory musculature, quality of life, anxiety, and depression among patients with indeterminate chronic Chagas disease and symptoms of pulmonary hypertension. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 194-198.	0.4	8
425	3rd GUIDELINE FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION OF THE BRAZILIAN SOCIETY OF CARDIOLOGY. Arquivos Brasileiros De Cardiologia, 2017, 109, 1-104.	0.3	21
426	Exercise Doppler echocardiography for the diagnosis of pulmonary hypertension: renewed interest and evolving roles. Journal of Thoracic Disease, 2017, 9, 2856-2861.	0.6	0
427	Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. Clinical Research in Cardiology, 2018, 107, 548-553.	1.5	77
428	Ventilatory response to exercise in cardiopulmonary disease: the role of chemosensitivity and dead space. European Respiratory Journal, 2018, 51, 1700860.	3.1	73
429	Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy. European Respiratory Journal, 2018, 51, 1702576.	3.1	7
430	Prevention and treatment of the chronic thromboembolic pulmonary hypertension. Thrombosis Research, 2018, 164, 150-156.	0.8	4
431	Pulmonary Arterial Hypertension: Combination Therapy in Practice. American Journal of Cardiovascular Drugs, 2018, 18, 249-257.	1.0	51
432	Right Ventricular Dysfunction and Its Contribution to Morbidity and Mortality in Left Ventricular Heart Failure. Current Heart Failure Reports, 2018, 15, 94-105.	1.3	19
433	Role of right ventricular reverse remodeling in risk assessment of pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 182-183.	0.3	0
434	Hepatopulmonary Syndrome and Portopulmonary Hypertension in Children: Recent Advances in Diagnosis and Management. Journal of Pediatrics, 2018, 196, 14-21.e1.	0.9	21
435	Endothelial dysfunction in pulmonary arterial hypertension: loss of cilia length regulation upon cytokine stimulation. Pulmonary Circulation, 2018, 8, 1-9.	0.8	27
436	An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. Current Rheumatology Reports, 2018, 20, 10.	2.1	27

#	Article	IF	Citations
437	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration, 2018, 95, 244-250.	1.2	17
438	Prophylactic function of excellent compliance with LTOT in the development of pulmonary hypertension due to COPD with hypoxemia. Pulmonary Circulation, 2018, 8, 1-7.	0.8	3
439	GuÃa de diagnÃ³stico y tratamiento de la hipertensiÃ³n pulmonar: resumen de recomendaciones. Archivos De Bronconeumologia, 2018, 54, 205-215.	0.4	26
440	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. Journal of Heart and Lung Transplantation, 2018, 37, 836-843.	0.3	29
442	Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids. Chest, 2018, 154, 532-540.	0.4	17
443	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. European Respiratory Review, 2018, 27, 180004.	3.0	21
444	The prevalence of pulmonary arterial hypertension before and after atrial septal defect closure at adult age: A systematic review. American Heart Journal, 2018, 201, 63-71.	1.2	25
445	Complications of adult-onset Stillâ€™s disease and their management. Expert Review of Clinical Immunology, 2018, 14, 351-365.	1.3	51
446	Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702606.	3.1	67
448	S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. Respirology, 2018, 23, 771-779.	1.3	18
449	Pulmonary haemodynamics and mortality in chronic hypersensitivity pneumonitis. European Respiratory Journal, 2018, 51, 1800430.	3.1	8
450	Characteristics and risk factors of pulmonary arterial hypertension in patients with primary SjÃ¶gren's syndrome. International Journal of Rheumatic Diseases, 2018, 21, 1068-1075.	0.9	21
451	Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. European Respiratory Journal, 2018, 51, 1800307.	3.1	16
452	Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702310.	3.1	79
453	Secondary pulmonary arterial hypertension. Current Opinion in Organ Transplantation, 2018, 23, 324-329.	0.8	1
454	Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study. European Journal of Cardiovascular Nursing, 2018, 17, 612-618.	0.4	4
455	Lung Transplantation in Pulmonary Hypertension: A Multidisciplinary Unit's Management Experience. Transplantation Proceedings, 2018, 50, 1496-1503.	0.3	12
456	Vessel Stretching Is a Cause of Lumen Enlargement Immediately After Balloon Pulmonary Angioplasty. Circulation: Cardiovascular Interventions, 2018, 11, e006010.	1.4	32

#	Article	IF	Citations
457	Liver fibrosis marker, 7S domain of collagen type IV, in patients with pre-capillary pulmonary hypertension. International Journal of Cardiology, 2018, 258, 269-274.	0.8	19
458	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2018, 154, 126-135.	0.4	40
459	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	1.2	82
460	Impact of psychological factors on the health-related quality of life of patients treated for pulmonary arterial hypertension. Journal of Psychosomatic Research, 2018, 105, 45-51.	1.2	16
461	Approach to Pulmonary Hypertension: From CT to Clinical Diagnosis. Radiographics, 2018, 38, 357-373.	1.4	61
462	NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. Circulation, 2018, 137, 2371-2389.	1.6	75
463	Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis. European Respiratory Journal, 2018, 51, 1702427.	3.1	42
464	The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clinical Research in Cardiology, 2018, 107, 460-470.	1.5	29
465	Balloon pulmonary angioplasty: does it have a role in CTED?. Pulmonary Circulation, 2018, 8, 1-4.	0.8	8
466	Screening for pulmonary hypertension in interstitial lung disease: Many reasons to ECHO!. Respirology, 2018, 23, 646-647.	1.3	1
467	Will we be singing a different tune on combined post- and pre-capillary pulmonary hypertension?. European Respiratory Journal, 2018, 51, 1702589.	3.1	2
468	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 166-174.	2.5	17
469	The prognosis of pulmonary arterial hypertension associated with primary SjÃ¶gren's syndrome: a cohort study. Lupus, 2018, 27, 1072-1080.	0.8	23
470	Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Reviews, 2018, 32, 289-299.	2.8	67
471	A scoring system to predict the elevation of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 51, 1701311.	3.1	20
472	The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 51, 1702596.	3.1	12
473	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension. Chest, 2018, 154, 136-147.	0.4	18
474	HipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica: caracterizaciÃ³n, endarterectomÃa pulmonar y nuevas opciones terapÃ©uticas. Cirugia Cardiovascular, 2018, 25, 93-101.	0.1	0

#	Article	IF	Citations
475	Long-Term Follow-up of Adults Following the Atrial Switch Operation for Transposition of the Great Arteries â€“ A Contemporary Cohort. Heart Lung and Circulation, 2018, 27, 1011-1017.	0.2	24
476	Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial. American Journal of Cardiovascular Drugs, 2018, 18, 1-11.	1.0	37
477	Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension. Chest, 2018, 153, 1142-1152.	0.4	4
478	FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension. Journal of Molecular Medicine, 2018, 96, 223-235.	1.7	62
479	Out of proportion pulmonary hypertension in obstructive lung diseases. Current Opinion in Pulmonary Medicine, 2018, 24, 161-172.	1.2	6
480	The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 860-868.	2.5	45
481	Human factors and usability engineering in the development of SMT-101 for the treatment of pulmonary arterial hypertension. Expert Opinion on Drug Delivery, 2018, 15, 325-333.	2.4	2
482	Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. Respirology, 2018, 23, 687-694.	1.3	39
484	Balloon pulmonary angioplasty in sarcoid-related pulmonary hypertension. European Respiratory Journal, 2018, 51, 1701502.	3.1	5
485	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47.	1.0	69
486	Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. Respiration, 2018, 95, 188-200.	1.2	273
487	Extrinsic compression of left main coronary artery by aneurysmal pulmonary artery in severe pulmonary hypertension: its correlates, clinical impact, and management strategies. European Heart Journal Cardiovascular Imaging, 2018, 19, 1302-1308.	0.5	18
488	Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem. Pulmonary Circulation, 2018, 8, 1-3.	0.8	6
489	The role of cardiopulmonary exercise tests in pulmonary arterial hypertension. European Respiratory Review, 2018, 27, 170134.	3.0	53
490	Study protocol for a randomised controlled trial of exercise training in pulmonary hypertension (ExTra_PH). BMC Pulmonary Medicine, 2018, 18, 40.	0.8	5
491	Volume Management in Pulmonary Arterial Hypertension Patients: An Expert Pulmonary Hypertension Clinician Perspective. Pulmonary Therapy, 2018, 4, 13-27.	1.1	13
492	Symptom severity and its effect on health-related quality of life over time in patients with pulmonary hypertension: a multisite longitudinal cohort study. BMJ Open Respiratory Research, 2018, 5, e000263.	1.2	28
493	Deeper S Wave in Lead V5 and Broader Extent of T Wave Inversions in the Precordial Leads are Clinically Useful Electrocardiographic Parameters for Predicting Pulmonary Hypertension. International Heart Journal, 2018, 59, 136-142.	0.5	7

#	Article	IF	Citations
494	Anthropometric Evaluation and Functional Assessment of Patients with Pulmonary Hypertension and its Relationship with Pulmonary Circulation Parameters and Functional Performance. Journal of the American College of Nutrition, 2018, 37, 423-428.	1.1	1
495	Hemodynamic Mechanisms of Exercise-Induced Pulmonary Hypertension inÂPatients with Lymphangioleiomyomatosis: The Role of Exercise Stress Echocardiography. Journal of the American Society of Echocardiography, 2018, 31, 888-901.	1.2	9
496	Pulmonary hypertension in patients with interstitial lung disease. Pulmonary Pharmacology and Therapeutics, 2018, 50, 38-46.	1.1	21
497	Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. Circulation Research, 2018, 122, 1021-1032.	2.0	111
498	Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800279.	3.1	26
499	Right ventricular septomarginal trabeculation hypertrophy is associated with disease severity in patients with pulmonary arterial hypertension. International Journal of Cardiovascular Imaging, 2018, 34, 1439-1449.	0.7	9
501	The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Medicine (United States), 2018, 97, e0122.	0.4	0
502	Hematocrit-corrected Pulmonary Vascular Resistance. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 305-309.	2.5	33
503	Physiological insights of exercise hyperventilation in arterial and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2018, 259, 178-182.	0.8	40
504	Role of Pro-Brain Natriuretic Peptide Serum Concentration in the Detection of Pulmonary Hypertension in Patients With End-Stage Lung Diseases Referred for Lung Transplantation. Transplantation Proceedings, 2018, 50, 2044-2047.	0.3	4
506	Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENTâ€1/â€2 studies. Pulmonary Circulation, 2018, 8, 1-4.	0.8	26
507	Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. Archivos De Bronconeumologia, 2018, 54, 205-215.	0.4	30
508	Interventional Therapies in Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed), 2018, 71, 565-574.	0.4	6
509	Pulmonary hypertension in combined pulmonary fibrosis and emphysema: A tale of two cities. Respirology, 2018, 23, 556-557.	1.3	2
510	The role of an activity monitor in the objective evaluation of patients with pulmonary hypertension. Clinical Respiratory Journal, 2018, 12, 119-125.	0.6	22
511	Rapid Inpatient Titration of Intravenous Treprostinil for Pulmonary Arterial Hypertension: Safe and Tolerable. American Journal of Therapeutics, 2018, 25, e213-e217.	0.5	8
512	Pulmonary hypertension associated with combined fibrosing mediastinitis and bronchial anthracofibrosis: A retrospective analysis in a single Chinese hospital. Clinical Respiratory Journal, 2018, 12, 1134-1140.	0.6	5
513	Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 <scp>ESC</scp>/<scp>ERS</scp> guidelines and insights for future changes. European Journal of Heart Failure, 2018, 20, 248-255.	2.9	85

#	Article	IF	Citations
514	Validation of impedance cardiography in pulmonary arterial hypertension. Clinical Physiology and Functional Imaging, 2018, 38, 254-260.	0.5	12
515	Medical Therapy Versus Balloon Angioplasty for CTEPH: A Systematic Review and Meta-Analysis. Heart Lung and Circulation, 2018, 27, 89-98.	0.2	26
516	Anti-coagulation complications in pregnancies with severe pulmonary arterial hypertension. Journal of Maternal-Fetal and Neonatal Medicine, 2018, 31, 1209-1213.	0.7	10
517	Safety of regadenoson stress testing in patients with pulmonary hypertension. Journal of Nuclear Cardiology, 2018, 25, 820-827.	1.4	9
518	Validation of a risk assessment instrument for pulmonary arterial hypertension. European Heart Journal, 2018, 39, 4182-4185.	1.0	16
519	Pulmonary Hypertension in Parenchymal Lung Diseases. Chest, 2018, 153, 217-223.	0.4	32
520	Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension. Thrombosis Research, 2018, 164, 136-144.	0.8	23
521	Macitentan Use in a Neurofibromatosis Type 1 Patient With Pulmonary Hypertension and External Jugular Phlebectasia. American Journal of Therapeutics, 2018, 25, e587-e590.	0.5	1
522	Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat. Clinical Pharmacokinetics, 2018, 57, 647-661.	1.6	43
523	Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 195-205.	0.3	46
524	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704.	1.6	155
525	Dual ET_A/ET_B blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-15.	0.8	19
526	Inhaled nebulized sodium nitrite decreases pulmonary artery pressure in Î²-thalassemia patients with pulmonary hypertension. Nitric Oxide - Biology and Chemistry, 2018, 76, 174-178.	1.2	10
527	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.4	68
528	Chronic Thromboembolic Pulmonary Hypertension. Cardiology in Review, 2018, 26, 62-72.	0.6	27
529	Ethnicity in Pulmonary Arterial Hypertension. Chest, 2018, 153, 310-320.	0.4	24
530	A Switch in TGF-Î² Signaling Explains Contradictory Findings in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 157-159.	2.5	3
531	A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: a pilot study. Pulmonary Circulation, 2018, 8, 1-12.	0.8	24

#	Article	IF	Citations
532	Management of Adults With Congenital Heart Disease and Pulmonary Arterial Hypertension in the UK: Survey of Current Practice, Unmet Needs and Expert Commentary. Heart Lung and Circulation, 2018, 27, 1018-1027.	0.2	7
533	Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review. Respiratory Medicine, 2018, 134, 42-46.	1.3	18
534	Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. Respirology, 2018, 23, 593-599.	1.3	29
535	Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Cardiology in the Young, 2018, 28, 542-547.	0.4	16
536	Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 509-516.	2.5	145
537	Hypoxiaâ€induced microRNAâ€26b inhibition contributes to hypoxic pulmonary hypertension via CTGF. Journal of Cellular Biochemistry, 2018, 119, 1942-1952.	1.2	19
538	Pulmonary Arterial Hypertension Emergency Complications and Evaluation. Advanced Emergency Nursing Journal, 2018, 40, 246-259.	0.2	4
539	Ein Bewertungssystem zur Vorhersage der ErhÃ¶hung des mittleren Pulmonalarteriendrucks bei idiopathischer Lungenfibrose. Karger Kompass Pneumologie, 2018, 6, 238-240.	0.0	0
540	The pulsatile component of left atrial pressure has little effect on pulmonary artery impedance estimation in normal rats. Physiological Reports, 2018, 6, e13946.	0.7	1
541	A case report of pulmonary arterial hypertension in pregnancy and complications of anticoagulation therapy. Medicine (United States), 2018, 97, e11810.	0.4	2
542	Impact of comorbidities and delay in diagnosis in elderly patients with pulmonary hypertension. ERJ Open Research, 2018, 4, 00100-2018.	1.1	18
543	Prognostic value of pre-transplant mean pulmonary arterial pressure in lung transplant recipients: a single-institution experience. Journal of Thoracic Disease, 2018, 10, 1578-1587.	0.6	8
544	Pregnancy and pulmonary hypertension. Medicine (United States), 2018, 97, e13035.	0.4	19
545	Right Heart Catheterization During Exercise in Patients with COPDâ€"An Overview of Clinical Results and Methodological Aspects. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 588-599.	0.7	1
546	Chronic pulmonary embolism: diagnosis. Cardiovascular Diagnosis and Therapy, 2018, 8, 253-271.	0.7	25
547	Small Airway Disease in Pulmonary Hypertensionâ€"Additional Diagnostic Value of Multiple Breath Washout and Impulse Oscillometry. Journal of Clinical Medicine, 2018, 7, 532.	1.0	9
548	miR-190a-5p participates in the regulation of hypoxia-induced pulmonary hypertension by targeting KLF15 and can serve as a biomarker of diagnosis and prognosis in chronic obstructive pulmonary disease complicated with pulmonary hypertension. International Journal of COPD, 2018, Volume 13, 3777-3790.	0.9	23
549	Obstructive sleep apnea in patients with chronic thromboembolic pulmonary hypertension. Journal of Thoracic Disease, 2018, 10, 5804-5812.	0.6	6

#	Article	IF	Citations
550	A modified risk score in one-year survival rate assessment of group 1 pulmonary arterial hypertension. BMC Pulmonary Medicine, 2018, 18, 161.	0.8	11
551	Pulmonary thromboendarterectomy is a curative resolution for chronic thromboembolic pulmonary hypertension associated with antiphospholipid syndrome: a retrospective cohort study. Lupus, 2018, 27, 2206-2214.	0.8	7
552	Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities. Mediators of Inflammation, 2018, 2018, 1-11.	1.4	44
553	Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. Circulation Journal, 2018, 82, 275-282.	0.7	78
554	Relationship Between Noninvasive Assessment of Lung Fluid Volume and Invasively Measured Cardiac Hemodynamics. Journal of the American Heart Association, 2018, 7, e009175.	1.6	49
555	Right ventricular afterload predicts longâ€term transition from parenteral to oral treprostinil in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	5
556	Palliative care in pulmonary arterial hypertension: an underutilised treatment. European Respiratory Review, 2018, 27, 180069.	3.0	25
557	Editorial: Molecular Mechanisms in Pulmonary Hypertension and Right Ventricle Dysfunction. Frontiers in Physiology, 2018, 9, 1777.	1.3	1
558	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 4105.	1.8	21
559	Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respiratory Research, 2018, 19, 258.	1.4	39
560	LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through AT1R via sponging let-7b in monocrotaline-induced pulmonary arterial hypertension. Respiratory Research, 2018, 19, 254.	1.4	76
561	Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS. Journal of Visualized Experiments, 2018, , .	0.2	4
562	Effects of Oral Supplementation With Nitrate-Rich Beetroot Juice in Patients With Pulmonary Arterial Hypertensionâ€"Results From BEET-PAH, an Exploratory Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Journal of Cardiac Failure, 2018, 24, 640-653.	0.7	22
563	NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis. , 2018, 9, 843.		7
564	Cologne consensus conference on pulmonary hypertension â€“ Update 2018. International Journal of Cardiology, 2018, 272, 1-3.	0.8	10
565	New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions. European Journal of Applied Physiology, 2018, 118, 195-203.	1.2	6
566	Lessons from pulmonary hypertension registries. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 759-761.	0.2	0
567	Pulmonary arterial hypertension and the potential roles of metallothioneins: A focused review. Life Sciences, 2018, 214, 77-83.	2.0	7

#	Article	IF	Citations
568	3â€²-Deoxy-3â€²-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. Circulation: Cardiovascular Imaging, 2018, 11, e007402.	1.3	14
569	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. European Respiratory Journal, 2018, 52, 1800272.	3.1	21
571	Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 834-842.	0.5	31
573	Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. European Respiratory Journal, 2018, 52, 1800248.	3.1	61
574	Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?. International Journal of Molecular Sciences, 2018, 19, 3162.	1.8	61
576	Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1801745.	3.1	5
577	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800678.	3.1	60
579	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 379, 1722-1731.	13.9	207
580	Safety of right heart catheterization for pulmonary hypertension in very elderly patients. Pulmonary Circulation, 2018, 8, 1-4.	0.8	7
581	Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?. European Respiratory Journal, 2018, 52, 1801287.	3.1	6
582	Should the 6-Minute Walk Test Be Stopped If Oxyhemoglobin Saturation Falls Below 80%?. Archives of Physical Medicine and Rehabilitation, 2018, 99, 2370-2372.	0.5	9
583	Comorbidities and Complications in Idiopathic Pulmonary Fibrosis. Medical Sciences (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	2.3	16
584	Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension: Updated Recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 20-29.	0.8	31
585	Mechanisms, biomarkers and targets for adult-onset Stillâ€™s disease. Nature Reviews Rheumatology, 2018, 14, 603-618.	3.5	245
586	Pulmonary hypertension associated with neurofibromatosis type 1. European Respiratory Review, 2018, 27, 180053.	3.0	25
587	The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension. Frontiers in Physiology, 2018, 9, 1167.	1.3	28
588	Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. Journal of Heart and Lung Transplantation, 2018, 37, 1410-1417.	0.3	15
590	Lessons from pulmonary hypertension registries. Revista Portuguesa De Cardiologia, 2018, 37, 759-761.	0.2	1

#	Article	IF	Citations
591	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 37-45.	0.8	56
592	Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study. ERJ Open Research, 2018, 4, 00060-2018.	1.1	17
593	Definition, clinical classification and initial diagnosis of pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 11-19.	0.8	66
595	Pulmonary hypertension in Takayasu arteritis. International Journal of Rheumatic Diseases, 2018, 21, 1634-1639.	0.9	24
596	Hematopoietic stem cell transplantation alters susceptibility to pulmonary hypertension in Bmpr2â€deficient mice. Pulmonary Circulation, 2018, 8, 1-9.	0.8	6
597	New Therapeutic Approaches in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 2390-2392.	1.6	5
598	Dart to the target: an alternative bullâ€™s eye parametric display for European Society of Cardiology / European Respiratory Society goalâ€orientated risk reduction strategy in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-7.	0.8	3
599	Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. Respiratory Medicine, 2018, 139, 72-78.	1.3	55
600	Pulmonary embolism. Nature Reviews Disease Primers, 2018, 4, 18028.	18.1	208
601	Interpreting risk reduction in clinical trials for pulmonary arterial hypertension. European Respiratory Review, 2018, 27, 180020.	3.0	3
602	Identifying early pulmonary arterial hypertension in patients with systemic sclerosis. European Respiratory Journal, 2018, 51, 1800495.	3.1	6
603	Cardiac involvement in systemic sclerosis. Journal of Cardiovascular Medicine, 2018, 19, 393-395.	0.6	5
604	More on Single-Beat Estimation of Right Ventriculoarterial Coupling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 816-818.	2.5	63
605	Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2018, 154, 521-531.	0.4	22
606	Effects of Riociguat on Right Ventricular Remodelling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study. Canadian Journal of Cardiology, 2018, 34, 1137-1144.	0.8	9
608	Right heart catheterisation is still a fundamental part of the follow-up assessment of pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800738.	3.1	15
609	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS ONE, 2018, 13, e0197112.	1.1	47
610	Factors predicting outcome after pulmonary endarterectomy. PLoS ONE, 2018, 13, e0198198.	1.1	29

#	Article	IF	Citations
611	Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1090-1093.	2.5	3
613	Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 1235-1244.	0.3	26
614	Pulmonary Arterial Hypertension. Heart Failure Clinics, 2018, 14, 255-269.	1.0	56
615	Exercise Training and Rehabilitation in Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 425-430.	1.0	21
616	Use of Extracorporeal Membrane Oxygenation in Postpartum Management of a Patient with Pulmonary Arterial Hypertension. Case Reports in Pulmonology, 2018, 2018, 1-4.	0.2	6
617	Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 327-331.	1.0	5
618	Chronic Thromboembolic Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 339-351.	1.0	19
619	Invasive and Noninvasive Evaluation for the Diagnosis of Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 353-360.	1.0	2
620	Imaging the Right Heart-Pulmonary Circulation Unit. Heart Failure Clinics, 2018, 14, 377-391.	1.0	11
621	Exercise cardiac MRI unmasks right ventricular dysfunction in acute hypoxia and chronic pulmonary arterial hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H950-H957.	1.5	25
622	Right Heart Catheterization. , 2018, , 79-89.		0
623	Should patients with pulmonary hypertension fly and climb?. International Journal of Cardiology, 2018, 270, 276-277.	0.8	1
624	Sensitivity of a Simple Noninvasive Screening Algorithm for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism. TH Open, 2018, 02, e89-e95.	0.7	17
625	Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	13
626	Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data. Frontiers in Medicine, 2018, 5, 175.	1.2	19
627	A pilot randomised controlled trial investigating a mindfulness-based stress reduction (MBSR) intervention in individuals with pulmonary arterial hypertension (PAH): the PATHWAYS study. Pilot and Feasibility Studies, 2018, 4, 78.	0.5	14
628	Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children. Children, 2018, 5, 44.	0.6	15
629	Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension. Diseases (Basel, Switzerland), 2018, 6, 33.	1.0	20

#	Article	IF	Citations
630	Is right heart catheterisation still a fundamental part of the follow-up assessment of pulmonary arterial hypertension? The argument against. European Respiratory Journal, 2018, 52, 1800996.	3.1	7
631	Levosimendan in pulmonary hypertension and right heart failure. Pulmonary Circulation, 2018, 8, 1-7.	0.8	50
632	Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. International Journal of Cardiology, 2018, 269, 283-288.	0.8	20
633	Heart Failure, Exercise Intolerance, and Physical Training. , 2018, , 77-87.		0
634	A Step Closer to Understanding How Riociguat Results in Remodelling of the Right Ventricle in Chronic Thromboembolic Pulmonary Hypertension. Canadian Journal of Cardiology, 2018, 34, 1098-1101.	0.8	0
635	Impact of Balloon Pulmonary Angioplasty on Hemodynamics and Clinical Outcomes in Patients with Chronic Thromboembolic Pulmonary Hypertension: the Initial Korean Experience. Journal of Korean Medical Science, 2018, 33, e24.	1.1	19
636	Post-pulmonary tuberculosis complications in South Africa and a potential link with pulmonary hypertension: Premise for clinical and scientific investigations. South African Medical Journal, 2018, 108, 529.	0.2	10
637	Nothing but a Number? Age and Precision Treatment in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 986-988.	2.5	0
638	The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2018, 52, 1800589.	3.1	87
639	Whatâ€™s HIF Got to Do with It? HIF-2 Inhibition and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1363-1365.	2.5	1
640	Age, risk and outcomes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800629.	3.1	9
641	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011.	2.5	111
642	Hypertension pulmonaire et connectivites. Revue Du Rhumatisme Monographies, 2018, 85, 210-220.	0.0	0
643	Current and emerging techniques for the diagnosis of hypersensitivity pneumonitis. Expert Review of Respiratory Medicine, 2018, 12, 493-507.	1.0	14
644	Correlation between Echocardiographic Pulmonary Artery Pressure Estimates and Right Heart Catheterization Measurement in Liver Transplant Candidates. Journal of Cardiovascular Imaging, 2018, 26, 75.	0.2	16
645	Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 63-68.	0.8	34
646	The influence of anemia on one-year exacerbation rate of patients with COPD-PH. BMC Pulmonary Medicine, 2018, 18, 143.	0.8	10
647	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. International Journal of Clinical Pharmacy, 2018, 40, 790-794.	1.0	5

#	Article	IF	Citations
648	Major lung complications of systemic sclerosis. Nature Reviews Rheumatology, 2018, 14, 511-527.	3.5	60
649	What Is the True Relationship Between Spontaneous Portosystemic Shunts and Portopulmonary Hypertension in Cirrhotic Patients?. Gastroenterology, 2018, 155, 1647-1648.	0.6	2
650	Sex-specific cardiopulmonary exercise testing indices to estimate the severity of inoperable chronic thromboembolic pulmonary hypertension. International Journal of COPD, 2018, Volume 13, 385-397.	0.9	14
651	Risk stratification in pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2018, 24, 407-415.	1.2	18
652	Hepatic safety of ambrisentan alone and in combination with tadalafil: a postâ€hoc analysis of the AMBITION trial. Pulmonary Circulation, 2018, 8, 1-8.	0.8	4
653	Pulmonary Disease and Right Ventricular Function. , 2018, , 391-415.		0
654	Heart, Lung, and Heartâ€“Lung Transplant. , 2018, , 755-787.		0
655	Fractal Analysis of Right Ventricular Trabeculae in Pulmonary Hypertension. Radiology, 2018, 288, 386-395.	3.6	23
656	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702638.	3.1	183
657	Inhalation of repurposed drugs to treat pulmonary hypertension. Advanced Drug Delivery Reviews, 2018, 133, 34-44.	6.6	14
658	Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component. PLoS ONE, 2018, 13, e0199164.	1.1	29
659	Chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: to screen or not to screen?. European Respiratory Journal, 2018, 51, 1800440.	3.1	3
660	Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2018, 270, 262-267.	0.8	30
661	Balloon Pulmonary Angioplasty for Inoperable Patients With Chronic Thromboembolic Pulmonary Hypertension. Observational Study in a Referral Unit. Revista Espanola De Cardiologia (English Ed), 2019, 72, 224-232.	0.4	14
662	Relating exercise-induced desaturation and gas-exchange in pulmonary artery hypertension. Respiratory Physiology and Neurobiology, 2019, 259, 58-62.	0.7	2
663	Inflammasomes: a novel therapeutic target in pulmonary hypertension?. British Journal of Pharmacology, 2019, 176, 1880-1896.	2.7	31
665	The effect of a multidisciplinary team on the implementation rates of major diagnostic and therapeutic procedures of chronic thromboembolic pulmonary hypertension. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 28-33.	0.8	6
666	Influence of riociguat treatment on pulmonary arterial hypertension. Herz, 2019, 44, 637-643.	0.4	5

#	Article	IF	Citations
667	GuÃa de prÃ¡ctica clÃnica para el manejo del lupus eritematoso sistÃ©mico propuesta por el Colegio Mexicano de ReumatologÃa. ReumatologÃa ClÃnica, 2019, 15, 3-20.	0.2	14
668	Cardiopulmonary exercise testing with ventilatory gas analysis for evaluation of chronic thromboembolic pulmonary hypertension: Unmasking its role after a therapeuthic intervention. International Journal of Cardiology, 2019, 296, 155-156.	0.8	2
671	Collaborative Cardiology and Pulmonary Management of Pulmonary Hypertension. Chest, 2019, 156, 200-202.	0.4	3
672	Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. European Journal of Internal Medicine, 2019, 68, 71-75.	1.0	16
673	Pulmonary Veno-occlusive Disease: A Surgical Lung Biopsy-proven and Autopsied Case Radiologically Mimicking Hypersensitivity Pneumonitis at the Time of a Transbronchial Lung Biopsy. Internal Medicine, 2019, 58, 955-964.	0.3	1
674	Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis. Clinical Drug Investigation, 2019, 39, 1031-1044.	1.1	8
675	Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study. Clinical Respiratory Journal, 2019, 13, 693-699.	0.6	7
676	Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients. PLoS ONE, 2019, 14, e0220490.	1.1	17
677	Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease. Clinics in Chest Medicine, 2019, 40, 501-518.	0.8	32
678	Balloon Pulmonary Angioplasty for the Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension: Single-Center Experience with Low Initial Complication Rate. Journal of Vascular and Interventional Radiology, 2019, 30, 1265-1272.	0.2	27
679	COPD beyond proximal bronchial obstruction: phenotyping and related tools at the bedside. European Respiratory Review, 2019, 28, 190010.	3.0	13
680	Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. Chest, 2019, 156, 1176-1186.	0.4	32
681	The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome. European Respiratory Journal, 2019, 54, 1901401.	3.1	18
682	Screening for pulmonary arterial hypertension in systemic sclerosis. European Respiratory Review, 2019, 28, 190023.	3.0	59
683	Diaphragm function does not independently predict exercise intolerance in patients with precapillary pulmonary hypertension after adjustment for right ventricular function. Bioscience Reports, 2019, 39, .	1.1	8
684	Treatment of pediatric pulmonary arterial hypertension: A focus on the NOâ€sGCâ€cGMP pathway. Pediatric Pulmonology, 2019, 54, 1516-1526.	1.0	19
685	Vena cava backflow and right ventricular stiffness in pulmonary arterial hypertension. European Respiratory Journal, 2019, 54, 1900625.	3.1	25
686	Value of heart rate recovery in female patients with pulmonary arterial hypertension due to systemic lupus erythematosus. Clinical Respiratory Journal, 2019, 13, 545-554.	0.6	3

#	Article	IF	Citations
687	Pathophysiology of right ventricular failure in acute pulmonary embolism and chronic thromboembolic pulmonary hypertension: a pictorial essay for the interventional radiologist. Insights Into Imaging, 2019, 10, 18.	1.6	39
688	Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L361-L368.	1.3	11
689	The Clinical Value of Proposed Risk Stratification Tools in Pediatric Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1312-1315.	2.5	18
690	Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical Practiceâ€"The PADIS-PE Trial. Thrombosis and Haemostasis, 2019, 119, 1489-1497.	1.8	17
691	Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice. Advances in Therapy, 2019, 36, 2351-2363.	1.3	14
692	Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension. Brazilian Journal of Medical and Biological Research, 2019, 52, e8513.	0.7	5
693	Cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review for use in patients with pulmonary hypertension in Colombia. Jornal Brasileiro De Pneumologia, 2019, 45, e20180332.	0.4	3
694	Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights. International Journal of Medical Sciences, 2019, 16, 967-980.	1.1	22
695	Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients. Thrombosis and Haemostasis, 2019, 119, 1403-1408.	1.8	28
696	Unraveling the Causes of Unexplained Dyspnea. Clinics in Chest Medicine, 2019, 40, 471-499.	0.8	30
697	The Year in Thoracic Anesthesia: Selected Highlights From 2018. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 2909-2919.	0.6	1
698	Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. European Respiratory Journal, 2019, 54, 1900586.	3.1	41
699	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling. European Respiratory Journal, 2019, 54, 1802400.	3.1	25
700	Left ventricular peak early diastolic strain rate detected by two-dimensional speckle tracking echocardiography and disease severity in pre-capillary pulmonary hypertension. Pulmonary Circulation, 2019, 9, ???.	0.8	2
701	Noninvasive Assessment of Right Ventricular Function in Patients with Pulmonary Arterial Hypertension and Left Ventricular Assist Device. Current Cardiology Reports, 2019, 21, 82.	1.3	8
702	Response to Letter to the Editor Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH). Heart Lung and Circulation, 2019, 28, e149-e150.	0.2	1
703	Pharmacotherapy for pulmonary arterial hypertension. Journal of Thoracic Disease, 2019, 11, S1767-S1781.	0.6	46
704	In vitroâ€"in vivo correlation of the drugâ€"drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 975-984.	1.5	5

#	Article	IF	Citations
705	Acute response to rapid iloprost inhalation using the Breelibâ„¢ nebulizer in pulmonary arterial hypertension: the Breelibâ„¢ acute study. Pulmonary Circulation, 2019, 9, 1-3.	0.8	4
706	Evaluation and classification of pulmonary arterial hypertension. Journal of Thoracic Disease, 2019, 11, S1789-S1799.	0.6	38
707	Impact of Pulmonary Hypertension Hemodynamic Status on Long-Term Outcome After Transcatheter AorticÂValve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 2155-2168.	1.1	38
708	Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty. Respiratory Research, 2019, 20, 250.	1.4	38
709	Multicentre trials on specialised exercise training and rehabilitation are useful in patients with pulmonary hypertension. European Respiratory Journal, 2019, 54, 1901631.	3.1	2
710	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. European Respiratory Journal, 2019, 54, 1901030.	3.1	33
711	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine,the, 2019, 7, 780-790.	5.2	139
712	Impact of Simulated Hyperventilation and Periodic Breathing on Sympatho-Vagal Balance and Hemodynamics in Patients with and without Heart Failure. Respiration, 2019, 98, 482-494.	1.2	8
713	Multisystem Healthcare Use among U.S. Veterans with Pulmonary Hypertension. Annals of the American Thoracic Society, 2019, 16, 1072-1074.	1.5	2
714	Practical management of riociguat in patients with pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661986893.	1.0	6
715	Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article. International Journal of Molecular Sciences, 2019, 20, 4329.	1.8	35
716	Epidemiology and initial management of pulmonary arterial hypertension: realâ€world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Pulmonary Circulation, 2019, 9, 1-12.	0.8	21
717	Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2019, 12, e009047.	1.3	222
718	Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension. European Respiratory Journal, 2019, 54, 1900342.	3.1	21
719	Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. JAMA Cardiology, 2019, 4, 1112.	3.0	73
720	Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology, 2019, 15, 1009-1017.	1.3	42
721	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 1286-1295.	0.3	62
722	15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation. Clinical Hypertension, 2019, 25, 22.	0.7	7

#	Article	IF	Citations
723	Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 177-198.	0.2	13
724	Idiopathic, heritable and veno-occlusive pulmonary arterial hypertension in childhood: computed tomography angiography features in the initial assessment of the disease. Pediatric Radiology, 2019, 49, 575-585.	1.1	7
725	Soluble neprilysin does not correlate with prognosis in pulmonary hypertension. ESC Heart Failure, 2019, 6, 291-296.	1.4	6
726	Perioperative Management of Pulmonary Endarterectomyâ€"Perspective from the UK National Health Service. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 3101-3109.	0.6	3
727	Elevated pulmonary arterial pressure in Zucker diabetic fatty rats. PLoS ONE, 2019, 14, e0211281.	1.1	13
728	Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol. American Journal of Cardiovascular Drugs, 2019, 19, 99-105.	1.0	10
729	Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases. International Journal of Molecular Sciences, 2019, 20, 327.	1.8	27
730	Pulmonary Hypertension Associated With Sarcoidosis. , 2019, , 285-303.		0
731	Pulmonary hypertension in the global population of adolescents and adults living with HIV: a systematic review and meta-analysis. Scientific Reports, 2019, 9, 7837.	1.6	16
732	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	0.9	8
733	Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2019, 4, 219-224.	1.0	3
734	Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?. European Respiratory Journal, 2019, 53, 1900843.	3.1	14
735	Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Annals of the Rheumatic Diseases, 2019, 78, 1101-1106.	0.5	54
736	Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity. Health and Quality of Life Outcomes, 2019, 17, 103.	1.0	1
737	Diagnosing complications and co-morbidities of fibrotic interstitial lung disease. Expert Review of Respiratory Medicine, 2019, 13, 645-658.	1.0	12
738	Analysis of Biphasic Right Ventricular Outflow Doppler Waveform in Patients with Pulmonary Hypertension. International Heart Journal, 2019, 60, 108-114.	0.5	1
739	Oral treprostinil in transition or as addâ€on therapy in pediatric pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-8.	0.8	14
740	Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 208-226.	0.8	14

#	Article	IF	Citations
741	Pulmonary Hypertension Associated with Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 173-183.	0.8	33
742	Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 748-756.	0.3	29
743	A crossroads between the heart and lungs: air pollution and pulmonary hypertension. European Respiratory Journal, 2019, 53, 1900654.	3.1	3
744	Cas clinique nÂ° 4 : Une hypertension pulmonaire familiale. Revue Des Maladies Respiratoires Actualites, 2019, 11, 27-31.	0.0	0
745	T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease. European Respiratory Journal, 2019, 54, 1900388.	3.1	16
746	Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and metaâ€analysis. Clinical Cardiology, 2019, 42, 741-752.	0.7	24
747	Computed tomographic and clinical features of pulmonary veno-occlusive disease: raising the radiologist's awareness. Clinical Radiology, 2019, 74, 655-662.	0.5	14
748	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulmonary Circulation, 2019, 9, 204589401985169.	0.8	7
749	Mesenchymal stem/stromal cell therapy for pulmonary arterial hypertension: Comprehensive review of preclinical studies. Journal of Cardiology, 2019, 74, 304-312.	0.8	24
750	Validation of the <scp>REVEAL</scp> Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosisâ€“Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatology, 2019, 71, 1691-1700.	2.9	15
751	Elevated plasma Pimâ€1 and its clinical significance in patients with pulmonary arterial hypertension. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 752-760.	0.9	3
752	Active and Passive Vaccination for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2019, 73, 2581-2583.	1.2	2
753	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 833-842.	0.3	57
754	Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?. Blood Reviews, 2019, 37, 100579.	2.8	16
757	Partial anomalous pulmonary venous return: A case series with management approach. Respiratory Medicine Case Reports, 2019, 27, 100833.	0.2	18
758	Involvement of pulmonary arteriopathy in the development and severity of reperfusion pulmonary edema after pulmonary endarterectomy. Pulmonary Circulation, 2019, 9, 1-9.	0.8	6
759	Barriers to physical activity in patients with pulmonary hypertension. Pulmonary Circulation, 2019, 9, 204589401984789.	0.8	16
760	Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults. Pulmonary Circulation, 2019, 9, 204589401984864.	0.8	7

#	Article	IF	Citations
761	Pulmonary Veno-Occlusive Disease: A Rare Cause of Pulmonary Hypertension. Journal of Investigative Medicine High Impact Case Reports, 2019, 7, 232470961984037.	0.3	5
762	Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension. Chest, 2019, 156, 53-63.	0.4	42
763	The Postâ€"Pulmonary Embolism Syndrome: Real or Ruse?. Annals of the American Thoracic Society, 2019, 16, 811-814.	1.5	26
764	â€œTreat-to-closeâ€• Non-repairable ASD-PAH in the adult. International Journal of Cardiology, 2019, 291, 127-133.	0.8	35
765	Two-dimensional speckle tracking echocardiography assessed right ventricular function and exercise capacity in pre-capillary pulmonary hypertension. International Journal of Cardiovascular Imaging, 2019, 35, 1499-1508.	0.7	8
766	Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2019, 6, 24.	1.1	23
767	Laparoscopic Rectopexy in a Patient With Pulmonary Hypertension Associated With Scleroderma: A Case Report. A&A Practice, 2019, 12, 313-316.	0.2	1
768	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802095.	3.1	173
769	The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. Current Hypertension Reports, 2019, 21, 45.	1.5	20
770	Pulmonary arterial pressure at rest and during exercise in chronic mountain sickness: a meta-analysis. European Respiratory Journal, 2019, 53, 1802040.	3.1	18
771	Genetic linkage analysis of a large family identifies FIGN as a candidate modulator of reduced penetrance in heritable pulmonary arterial hypertension. Journal of Medical Genetics, 2019, 56, 481-490.	1.5	3
772	Highlights from the ERS International Congress 2018: Assembly 13 â€" Pulmonary Vascular Diseases. ERJ Open Research, 2019, 5, 00202-2018.	1.1	0
774	Three-dimensional echocardiographic evaluation of the right ventricle in patients with uncomplicated systemic lupus erythematosus. Lupus, 2019, 28, 538-544.	0.8	8
775	Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum. Anesthesia and Analgesia, 2019, 129, 1607-1612.	1.1	12
776	Activation of K_v7 channels as a novel mechanism for NO/cGMPâ€induced pulmonary vasodilation. British Journal of Pharmacology, 2019, 176, 2131-2145.	2.7	23
778	Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open Research, 2019, 5, 00218-2018.	1.1	8
779	Exercise in Pulmonary Vascular Diseases. , 2019, , 111-129.		0
780	Seeing the Forest for the (Arterial) Tree: Vascular Pruning and the Chronic Obstructive Pulmonary Disease Pulmonary Vascular Phenotype. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 406-408.	2.5	12

#	Article	IF	Citations
781	Predictors of exercise-induced pulmonary hypertension in patients with connective tissue disease. Heart and Vessels, 2019, 34, 1509-1518.	0.5	5
782	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilanceâ€“pharmacodynamic study. European Respiratory Journal, 2019, 53, 1802472.	3.1	37
783	Iloprost delivered via the BREELIBTM nebulizer: a review of the clinical evidence for efficacy and safety. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661983549.	1.0	8
784	Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. Chest, 2019, 156, 33-44.	0.4	37
785	Prognostic Value of Left Ventricular Function and Mechanics in Pulmonary Hypertension: A Pilot Cardiovascular Magnetic Resonance Feature Tracking Study. Medicina (Lithuania), 2019, 55, 73.	0.8	17
786	Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. Journal of Heart and Lung Transplantation, 2019, 38, 731-738.	0.3	54
787	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation, 2019, 139, 2440-2450.	1.6	67
788	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. European Respiratory Journal, 2019, 53, 1802445.	3.1	25
789	The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. European Respiratory Journal, 2019, 53, 1900038.	3.1	44
790	Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study. Arthritis Research and Therapy, 2019, 21, 82.	1.6	29
791	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802004.	3.1	68
792	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. European Respiratory Journal, 2019, 53, 1801429.	3.1	31
793	A Prospective Evaluation of the DiagnosticÂAccuracy of the Physical Examination for Pulmonary Hypertension. Chest, 2019, 155, 982-990.	0.4	27
794	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circulation Journal, 2019, 83, 842-945.	0.7	132
795	Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?. Pulmonary Circulation, 2019, 9, 204589401984561.	0.8	6
796	Pulmonary Hypertension. Medical Clinics of North America, 2019, 103, 413-423.	1.1	43
797	Exercise energy expenditure in patients with idiopathic pulmonary arterial hypertension: Impact on clinical severity and survival. Respiratory Physiology and Neurobiology, 2019, 264, 33-39.	0.7	2
798	Chronic Thromboembolic Pulmonary Hypertension Cases Cluster in Families. Chest, 2019, 155, 384-390.	0.4	10

#	Article	IF	Citations
799	Tumoral pulmonary hypertension. European Respiratory Review, 2019, 28, 180065.	3.0	46
800	Artificial intelligence outperforms pulmonologists in the interpretation ofÂpulmonary function tests. European Respiratory Journal, 2019, 53, 1801660.	3.1	102
801	Role and management of extracorporeal life support after surgery of chronic thromboembolic pulmonary hypertension. Annals of Cardiothoracic Surgery, 2019, 8, 84-92.	0.6	14
802	Shortening Hospital Stay Is Feasible and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension Treated With Balloon Pulmonary Angioplasty. Canadian Journal of Cardiology, 2019, 35, 193-198.	0.8	8
803	Pharmacological characterization of a highly selective Rho kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension. European Journal of Pharmacology, 2019, 850, 126-134.	1.7	14
804	Pulmonary hypertension in lupus. Lupus, 2019, 28, 440-441.	0.8	0
805	Quantitative CT assessment of bronchial and vascular alterations in severe precapillary pulmonary hypertension . International Journal of COPD, 2019, Volume 14, 381-389.	0.9	10
806	Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization. Journal of Visualized Experiments, 2019, , .	0.2	1
807	Rehabilitation in chronic respiratory diseases: Live your life to the max. Respirology, 2019, 24, 828-829.	1.3	3
808	Exercise and Sports Pulmonology. , 2019, , .		1
809	Chinese herbal medicine Qing-Dai-induced pulmonary arterial hypertension in a patient with ulcerative colitis: A case report and experimental investigation. Respiratory Medicine Case Reports, 2019, 26, 265-269.	0.2	8
810	Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000783.	1.8	30
812	Echocardiographic evaluation of diastolic function in the setting of pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-11.	0.8	9
813	Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1339-1349.	2.9	54
814	Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy. African Journal of Thoracic and Critical Care Medicine, 2019, 25, 14.	0.3	0
815	Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation. ERJ Open Research, 2019, 5, 00037-2019.	1.1	17
816	Updates in pulmonary hypertension and other pulmonary vascular diseases. Breathe, 2019, 15, 241-243.	0.6	2
817	Occult malignancy underlying a case of â€œhyperacuteâ€•onset of severe pulmonary hypertension. ERJ Open Research, 2019, 5, 00157-2019.	1.1	1

#	Article	IF	Citations
818	Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients. Journal of Cardiovascular Medicine, 2019, 20, 771-779.	0.6	6
819	Exercise Training in Pulmonary Hypertension. , 2019, , .		0
820	Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?. BMC Pulmonary Medicine, 2019, 19, 257.	0.8	6
821	Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study. European Respiratory Journal, 2019, 54, 1900897.	3.1	41
822	Involvement of immune responses in pulmonary arterial hypertension; lessons from rodent models. Laboratory Animal Research, 2019, 35, 22.	1.1	5
823	Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy. Journal of Thoracic Disease, 2019, 11, 5362-5371.	0.6	7
824	Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. European Respiratory Review, 2019, 28, 190044.	3.0	66
825	â€œRehab for all!â€•Is it too early in pulmonary arterial hypertension?. European Respiratory Journal, 2019, 54, 1901558.	3.1	2
826	Rebuttal From Drs Humbert and Lau. Chest, 2019, 156, 1045-1046.	0.4	0
827	CTPA, DECT, MRI, V/Q Scan, and SPECT/CT V/Q for the noninvasive diagnosis of chronic thromboembolic pulmonary hypertension. Medicine (United States), 2019, 98, e16787.	0.4	5
828	Screening strategies for pulmonary arterial hypertension. European Heart Journal Supplements, 2019, 21, K9-K20.	0.0	44
829	Management of pulmonary arterial hypertension in patients aged over 65 years. European Heart Journal Supplements, 2019, 21, K29-K36.	0.0	9
830	The revised definition of pulmonary hypertension: exploring the impact on patient management. European Heart Journal Supplements, 2019, 21, K4-K8.	0.0	55
831	Pulmonary thromboendarterectomy. Nurs Crit Care (Ambler), 2019, 14, 6-13.	0.3	0
832	Congenital heart disease, pulmonary arterial hypertension and the UKâ€™s Drivers and Vehicle Licensing Agency: controversial new guidance. Pulmonary Circulation, 2019, 9, 1-2.	0.8	0
833	Pulmonary artery involvement in Takayasuâ€™s arteritis: diagnosis before pulmonary hypertension. BMC Pulmonary Medicine, 2019, 19, 225.	0.8	26
834	POINT: Should Initial Combination Therapy Be the Standard of Care in Pulmonary Arterial Hypertension? Yes. Chest, 2019, 156, 1039-1042.	0.4	6
835	First Description of the Hyperpneaâ€“Hypopnea Periodic Breathing in Patients with Interstitial Lung Disease-Obstructive Sleep Apnea: Treatment Implications in a Real-Life Setting. International Journal of Environmental Research and Public Health, 2019, 16, 4712.	1.2	9

#	Article	IF	Citations
836	A cross-sectional study of acute cor pulmonale in acute respiratory distress syndrome patients in China. Chinese Medical Journal, 2019, 132, 2842-2847.	0.9	0
837	Comparison of the capability of risk stratification evaluation between twoâ€•and threeâ€dimensional speckleâ€tracking strain in preâ€capillary pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	4
838	Vitamin D deficiency among patients with pulmonary hypertension. BMC Pulmonary Medicine, 2019, 19, 258.	0.8	13
839	Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management. Cardiovascular Drugs and Therapy, 2019, 33, 725-738.	1.3	6
840	Systemic sclerosis. , 2019, , 291-329.		0
841	The global view. Current Opinion in Pulmonary Medicine, 2019, 25, 391-397.	1.2	3
842	Congenital Portosystemic Shunts. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 615-622.	0.9	37
843	Prediction value of pulmonary hypertension in newly identified left ventricular dysfunction among adult patients after patent ductus arteriosus closure. Pulmonary Circulation, 2019, 9, 1-8.	0.8	0
844	Elevated serum circ_0068481 levels as a potential diagnostic and prognostic indicator in idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-9.	0.8	28
845	Mutually reinforcing effects of genetic variants and interferonâ€Î² 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients. Pulmonary Circulation, 2019, 9, 1-6.	0.8	9
846	Efficacy and Safety of Bronchial Artery Embolization on Hemoptysis in Chronic Thromboembolic Pulmonary Hypertension: A Pilot Prospective Cohort Study. Critical Care Medicine, 2019, 47, e182-e189.	0.4	11
847	The right treatment for the right ventricle. Current Opinion in Pulmonary Medicine, 2019, 25, 410-417.	1.2	15
848	The role of rehabilitation in patients with pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2019, 25, 398-404.	1.2	5
849	ACOG Practice Bulletin No. 212: Pregnancy and Heart Disease. Obstetrics and Gynecology, 2019, 134, 881-882.	1.2	24
850	Reassessment of the Accuracy of Cardiac Doppler Pulmonary Artery Pressure Measurements in Ventilated ICU Patients: A Simultaneous Doppler-Catheterization Study*. Critical Care Medicine, 2019, 47, 41-48.	0.4	18
851	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. European Respiratory Journal, 2019, 54, 1900585.	3.1	15
853	Un an aprÃ¨s le congrÃ¨s mondial, quels changements dans la prise en charge de lâ€™hypertension pulmonaire ?. Revue Des Maladies Respiratoires Actualites, 2019, 11, 123-128.	0.0	0
854	Outcomes and risk factors identification in urgent lung transplantation: a multicentric study. Journal of Thoracic Disease, 2019, 11, 4746-4754.	0.6	6

#	Article	IF	Citations
855	Advanced imaging in pulmonary hypertension: emerging techniques and applications. International Journal of Cardiovascular Imaging, 2019, 35, 1407-1420.	0.7	23
856	Two distinct clinical phenotypes of pulmonary arterial hypertension secondary to systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 148-150.	0.5	24
857	Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogrenâ€™s syndrome: a retrospective cohort study. Clinical Rheumatology, 2019, 38, 477-485.	1.0	10
858	Anticoagulation in the cardiac patient: A concise review. European Journal of Haematology, 2019, 102, 3-19.	1.1	9
859	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	5.2	122
860	The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 306-314.	0.3	32
861	Myeloid angiogenic cells exhibit impaired migration, reduced expression of endothelial markers, and increased apoptosis in idiopathic pulmonary arterial hypertension. Canadian Journal of Physiology and Pharmacology, 2019, 97, 306-312.	0.7	4
862	MicroRNA-150 relieves vascular remodeling and fibrosis in hypoxia-induced pulmonary hypertension. Biomedicine and Pharmacotherapy, 2019, 109, 1740-1749.	2.5	69
863	Functional interaction between PDGFÎ² and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L445-L455.	1.3	12
864	Lupus and the Cardiopulmonary System. , 2019, , 418-433.		0
865	Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure. Life Sciences, 2019, 219, 82-89.	2.0	7
866	Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. Respiratory Medicine, 2019, 146, 23-27.	1.3	1
867	Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. European Respiratory Journal, 2019, 53, 1801371.	3.1	72
868	The added value of comorbidities inÂpredicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. European Respiratory Journal, 2019, 53, 1801587.	3.1	50
869	Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus by the Mexican College of Rheumatology. ReumatologÃa ClÃnica (English Edition), 2019, 15, 3-20.	0.2	4
870	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	3.1	110
871	Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. Journal of Heart and Lung Transplantation, 2019, 38, 43-50.	0.3	25
872	Frequency, Predictors, and Prognostic Impact of Pulmonary Artery Aneurysms in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2019, 123, 474-481.	0.7	14

#	Article	IF	Citations
873	Initial combination therapy with ambrisentanâ€¯+â€¯tadalafil on pulmonary arterial hypertensionâ€'related hospitalization in the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 194-202.	0.3	19
874	Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. Thorax, 2019, 74, 380-389.	2.7	34
875	Autophagy and its role in pulmonary hypertension. Aging Clinical and Experimental Research, 2019, 31, 1027-1033.	1.4	5
876	Pulmonary arterial hypertension: In Asia, as elsewhere, still a lethal disease despite modern treatment. Respirology, 2019, 24, 99-100.	1.3	1
877	Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801787.	3.1	23
878	Imatinib for right heart failure in COPD. Pulmonary Circulation, 2019, 9, 1-3.	0.8	3
879	Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 239-248.	5.2	116
880	Pulmonary arterial hypertension in systemic sclerosis: Diagnosis and treatment according to the European Society of Cardiology and European Respiratory Society 2015 guidelines. Journal of Scleroderma and Related Disorders, 2019, 4, 35-42.	1.0	10
881	Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?. Lancet Respiratory Medicine,the, 2019, 7, 191-193.	5.2	1
882	The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach. American Heart Journal, 2019, 208, 91-99.	1.2	24
883	Pulmonary Hypertension in Noncardiac Surgical Patients. , 2019, , 138-164.		3
884	Carotid chemoreflex activity restrains postâ€exercise cardiac autonomic control in healthy humans and in patients with pulmonary arterial hypertension. Journal of Physiology, 2019, 597, 1347-1360.	1.3	12
885	Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. Arthritis and Rheumatology, 2019, 71, 805-816.	2.9	25
886	Therapy for Pulmonary Arterial Hypertension in Adults. Chest, 2019, 155, 565-586.	0.4	216
887	Multibeat Right Ventricularâ€"Arterial Coupling during a Positive Acute Vasoreactivity Test. American Journal of Respiratory and Critical Care Medicine, 2019, 199, e41-e42.	2.5	8
888	Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review. Multiple Sclerosis and Related Disorders, 2019, 28, 273-275.	0.9	9
889	An update on current and emerging treatments for pulmonary arterial hypertension in childhood and adolescence. Expert Review of Respiratory Medicine, 2019, 13, 205-215.	1.0	3
890	Pulmonary vascular resistance index: Getting the units right and why it matters. Clinical Cardiology, 2019, 42, 334-338.	0.7	15

#	Article	IF	Citations
891	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. Circulation Research, 2019, 124, 846-855.	2.0	81
892	Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload. Circulation: Heart Failure, 2019, 12, e005512.	1.6	158
893	Preserving right ventricular function in patients with pulmonary arterial hypertension: Single centre experience with a cardiac magnetic resonance imagingâ€guided treatment strategy. Pulmonary Circulation, 2019, 9, 1-7.	0.8	4
894	Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. European Respiratory Journal, 2019, 53, 1800081.	3.1	49
895	Twik-2^{â^'/â^'} mouse demonstrates pulmonary vascular heterogeneity in intracellular pathways for vasocontractility. Physiological Reports, 2019, 7, e13950.	0.7	7
896	Characterization and regulation of wildâ€type and mutant TASKâ€1 two pore domain potassium channels indicated in pulmonary arterial hypertension. Journal of Physiology, 2019, 597, 1087-1101.	1.3	35
897	Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. Heart Lung and Circulation, 2019, 28, 1655-1663.	0.2	9
898	Follow-Up Echocardiography of the Right Ventricle in Pulmonary ArterialÂHypertension. JACC: Cardiovascular Imaging, 2019, 12, 2112-2114.	2.3	0
899	Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. Clinical Rheumatology, 2019, 38, 1117-1124.	1.0	7
900	Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801889.	3.1	614
901	Pulmonary hypertension due to left heartÂdisease. European Respiratory Journal, 2019, 53, 1801897.	3.1	389
902	Genetics and genomics of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801899.	3.1	306
903	Pathophysiology of the right ventricle andÂof the pulmonary circulation in pulmonary hypertension: an update. European Respiratory Journal, 2019, 53, 1801900.	3.1	315
904	Diagnosis of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801904.	3.1	333
905	Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801906.	3.1	144
906	Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801908.	3.1	142
907	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801913.	3.1	2,583
908	Chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801915.	3.1	607

#	Article	IF	Citations
909	Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. European Respiratory Journal, 2019, 53, 1801916.	3.1	399
910	The importance of patient perspectives in pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801919.	3.1	85
911	Ulnar Artery Occlusion and Severity Markers of Vasculopathy in Systemic Sclerosis: A Multicenter Crossâ€Sectional Study. Arthritis and Rheumatology, 2019, 71, 983-990.	2.9	25
912	Pulmonary arterial hypertension in adult-onset Still's disease: A case series and systematic review of the literature. Seminars in Arthritis and Rheumatism, 2019, 49, 162-170.	1.6	16
913	Development and Validation of a Questionnaire to Measure Patientâ€™s Experiences of Health Care in Pulmonary Arterial Hypertension Outpatient Clinics. Heart Lung and Circulation, 2019, 28, 1074-1081.	0.2	4
914	Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacological Research, 2019, 144, 390-408.	3.1	54
916	Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients. Frontiers of Medicine, 2019, 13, 259-266.	1.5	11
917	Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH. Pulmonary Circulation, 2020, 10, 1-12.	0.8	6
918	Exercise right heart catheterization predicts outcome in asymptomatic degenerative aortic stenosis. Revista Espanola De Cardiologia (English Ed), 2020, 73, 457-462.	0.4	2
919	Quality of Life is Related to Haemodynamics in Precapillary Pulmonary Hypertension. Heart Lung and Circulation, 2020, 29, 142-148.	0.2	11
920	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. Cardiovascular Research, 2020, 116, 686-697.	1.8	54
921	Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH). Heart Lung and Circulation, 2020, 29, 337-344.	0.2	29
922	Validity of transit timeâ€“based blood pressure measurements in patients with and without heart failure or pulmonary arterial hypertension across different breathing maneuvers. Sleep and Breathing, 2020, 24, 221-230.	0.9	5
923	Intimacy, contraception, and pregnancy prevention in patients with pulmonary arterial hypertension: are we counseling our patients?. Pulmonary Circulation, 2020, 10, 204589401878525.	0.8	9
924	Changes in Estimated Glomerular Filtration after Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. CardioRenal Medicine, 2020, 10, 22-31.	0.7	12
925	Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1-L9.	1.3	13
926	Pulmonary arterial hypertension in systemic sclerosisâ€”when criteria and pathobiology differ. Rheumatology, 2020, 59, 1177-1179.	0.9	2
927	Effects of inorganic nitrate in a rat model of monocrotalineâ€induced pulmonary arterial hypertension. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 99-109.	1.2	6

#	Article	IF	Citations
928	Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis. Respirology, 2020, 25, 644-650.	1.3	16
929	In vitro assessment of Pâ€gp and BCRP transporterâ€mediated drugâ€“drug interactions of riociguat with direct oral anticoagulants. Fundamental and Clinical Pharmacology, 2020, 34, 109-119.	1.0	18
931	Longâ€term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics. Pulmonary Circulation, 2020, 10, 1-9.	0.8	1
932	Association Between High FSH, Low Progesterone, and Idiopathic Pulmonary Arterial Hypertension in Women of Reproductive Age. American Journal of Hypertension, 2020, 33, 99-105.	1.0	6
933	The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension. Lung, 2020, 198, 65-86.	1.4	10
934	Role of Nrf2 in the pathogenesis of respiratory diseases. Respiratory Investigation, 2020, 58, 28-35.	0.9	51
935	Uncovering the mechanisms of exertional dyspnoea in combined pulmonary fibrosis and emphysema. European Respiratory Journal, 2020, 55, 1901319.	3.1	16
936	TRPV4 channel mediates adventitial fibroblast activation and adventitial remodeling in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L135-L146.	1.3	26
937	Pregnancy in myositis and scleroderma. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 64, 59-67.	1.4	17
938	Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 458-468.	2.5	99
939	Association of right atrial conduit phase with right ventricular lusitropic function in pulmonary hypertension. International Journal of Cardiovascular Imaging, 2020, 36, 633-642.	0.7	16
940	Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report. BMC Pulmonary Medicine, 2020, 20, 8.	0.8	8
941	Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. Respiratory Research, 2020, 21, 12.	1.4	29
942	Reappraisal of Inflammatory Biomarkers in Heart Failure. Current Heart Failure Reports, 2020, 17, 9-19.	1.3	21
943	Validation of Automated Perfusionâ€Weighted Phaseâ€Resolved Functional Lung (PREFUL)â€MRI in Patients With Pulmonary Diseases. Journal of Magnetic Resonance Imaging, 2020, 52, 103-114.	1.9	39
944	Pulmonary vascular imaging characteristics after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2020, 39, 248-256.	0.3	16
945	Anti-enolaseï¼‘antibodies from a patient with systemic lupus erythematosus accompanied by pulmonary arterial hypertension promote migration of pulmonary artery smooth muscle cells. Immunology Letters, 2020, 218, 22-29.	1.1	2
946	The value of three-dimensional echocardiography in risk stratification in pulmonary arterial hypertension: a cross-sectional study. International Journal of Cardiovascular Imaging, 2020, 36, 577-584.	0.7	7

#	Article	IF	Citations
947	Positive Airway Pressure in Obesity Hypoventilation: Getting to the Heart of the Matter. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 509-511.	2.5	1
948	Right ventricular function correlates of right atrial strain in pulmonary hypertension: a combined cardiac magnetic resonance and conductance catheter study. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H156-H164.	1.5	42
949	Evaluation of the Incidence of Chronic Thromboembolic Pulmonary Hypertension 1ÂYear After First Episode of Acute Pulmonary Embolism: A Cohort Study. Lung, 2020, 198, 59-64.	1.4	7
950	Enfermedad tromboembÃ³lica crÃ³nica pulmonar. Archivos De Bronconeumologia, 2020, 56, 314-321.	0.4	8
951	Systemic sclerosis in pregnancy. Obstetric Medicine, 2020, 13, 105-111.	0.5	10
952	Survival Improved in Patients AgedÂâ‰ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest, 2020, 157, 945-954.	0.4	13
953	Melatonin inhibits inflammasome-associated activation of endothelium and macrophages attenuating pulmonary arterial hypertension. Cardiovascular Research, 2020, 116, 2156-2169.	1.8	37
954	Feasibility and safety of the antecubital venous access for right heart catheterization in patients with pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-6.	0.8	2
955	Pulmonary Arterial Hypertension: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. Journal of Pain and Symptom Management, 2020, 59, 932-943.	0.6	10
956	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 707-717.	2.5	89
957	Plasma metabolomic profile in chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-11.	0.8	26
958	Association between splenectomy and portal hypertension in the development of pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-9.	0.8	3
959	Increased pulmonary blood volume variation in patients with heart failure compared to healthy controls: a noninvasive, quantitative measure of heart failure. Journal of Applied Physiology, 2020, 128, 324-337.	1.2	4
960	Is There Value in Repeating Inhaled Nitric Oxide Vasoreactivity Tests in Patients with Pulmonary Arterial Hypertension?. Lung, 2020, 198, 87-94.	1.4	7
961	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. , 2020, 11, 1623.		29
962	Thromboembolic complications in adult congenital heart disease: the knowns and the unknowns. Clinical Research in Cardiology, 2021, 110, 1380-1391.	1.5	7
964	Right ventriculoâ€“pulmonary arterial uncoupling and poor outcomes in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-11.	0.8	5
965	Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-5.	0.8	14

#	Article	IF	Citations
966	Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-11.	0.8	12
967	Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy. Journal of the American College of Cardiology, 2020, 76, 916-926.	1.2	46
968	Evaluation and management of pulmonary arterial hypertension. Respiratory Medicine, 2020, 171, 106099.	1.3	43
969	Novel technique of repairing right partial anomalous pulmonary venous connection with intact atrial septum using in situ interatrial septum as a flap in a 68-year-old-woman: a case report. Journal of Cardiothoracic Surgery, 2020, 15, 269.	0.4	0
970	Pressures at an All-Time High. Circulation, 2020, 142, 1294-1298.	1.6	0
971	Treatment of severe stable COPD: the multidimensional approach of treatable traits. ERJ Open Research, 2020, 6, 00322-2019.	1.1	21
972	Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials. Cardiology in the Young, 2020, 30, 1882-1889.	0.4	6
973	Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension. Journal of Pharmacy Practice, 2020, , 089719002096129.	0.5	4
974	ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Research, 2020, 6, 00304-2020.	1.1	2
976	Looking Rightward in Acute Left Heart Failure. Journal of Cardiac Failure, 2020, 26, 821-823.	0.7	0
977	The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction. International Journal of Medical Sciences, 2020, 17, 2594-2602.	1.1	9
978	Early return of reflected waves increases right ventricular wall stress in chronic thromboembolic pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H1438-H1450.	1.5	18
979	Floating the invisible swan: noninvasive prediction of haemodynamics. European Respiratory Journal, 2020, 55, 1902385.	3.1	0
980	Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentanâ€'tadalafil in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2020, 39, 1389-1397.	0.3	24
981	SLC6A4 gene L/S polymorphism and susceptibility to pulmonary arterial hypertension: a meta-analysis. Journal of International Medical Research, 2020, 48, 030006052093530.	0.4	2
982	Soluble ST2 protein as a new biomarker in patientswith precapillary pulmonary hypertension. Archives of Medical Science, 2020, , .	0.4	4
983	Integrative analysis reveals key mRNA and long non-coding RNA interaction in idiopathic pulmonary arterial hypertension. Archives of Medical Science, 2020, , .	0.4	0
984	Pulmonary capillary hemangiomatosis-predominant vasculopathy in a patient with rheumatoid arthritis-associated interstitial lung disease: An autopsy report. Respiratory Medicine Case Reports, 2020, 31, 101215.	0.2	0

#	Article	IF	Citations
986	Relationship of Wnt pathway activity and organ involvement in scleroderma types. International Journal of Rheumatic Diseases, 2020, 23, 1558-1567.	0.9	1
987	Deranged Lung Perfusion Pattern in Patients With Heart Failure Normalizes After Heart Transplantation. Circulation: Cardiovascular Imaging, 2020, 13, e011102.	1.3	2
988	Targeted therapy with phosphodiesterase 5Âinhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review. Pulmonary Circulation, 2020, 10, 1-8.	0.8	2
989	Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesteraseâ€5Âinhibitors alone or in combination with other specific therapy: a registryâ€based study. Pulmonary Circulation, 2020, 10, 1-9.	0.8	0
990	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. Journal of Heart and Lung Transplantation, 2020, 39, 1435-1444.	0.3	104
991	Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart, 2020, 106, 1638-1645.	1.2	39
992	Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. Chest, 2020, 158, 2270-2274.	0.4	12
993	Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty â€“ A randomized controlled study. IJC Heart and Vasculature, 2020, 29, 100579.	0.6	7
994	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. Canadian Journal of Cardiology, 2020, 36, 977-992.	0.8	29
995	Prognostic Value of Cardiac Magnetic Resonanceâ€“Derived Right Ventricular Remodeling Parameters in Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2020, 13, e010568.	1.3	33
996	Pulmonal-arterielle Hypertonie und chronisch-thromboembolische pulmonale Hypertonie: Eine immunologische Perspektive. Karger Kompass Pneumologie, 2020, 8, 126-139.	0.0	0
997	Alteration of Extracellular Superoxide Dismutase in Idiopathic Pulmonary Arterial Hypertension. Frontiers in Medicine, 2020, 7, 509.	1.2	10
998	Carcinoembryonic antigen levels are increased with pulmonary output in pulmonary hypertension due to congenital heart disease. Journal of International Medical Research, 2020, 48, 030006052096437.	0.4	3
999	Longâ€term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertensionâ€”procedural safety and systemâ€related complications. Pulmonary Circulation, 2020, 10, 1-4.	0.8	2
1000	Factors Associated with Ineffectiveness of Sildenafil Treatment in Patients with End-Stage Heart Failure and Elevated Pulmonary Vascular Resistance. Journal of Clinical Medicine, 2020, 9, 3539.	1.0	1
1001	Cardiac Magnetic Resonance in Pulmonary Hypertensionâ€”an Update. Current Cardiovascular Imaging Reports, 2020, 13, 30.	0.4	16
1002	Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension. Lung, 2020, 198, 933-938.	1.4	14
1003	Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction. Cardiovascular Diagnosis and Therapy, 2020, 10, 1580-1603.	0.7	35

#	Article	IF	Citations
1004	Treatment-related biomarkers in pulmonary hypertension patients on oral therapies. Respiratory Research, 2020, 21, 304.	1.4	3
1005	Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. European Heart Journal, 2021, 42, 2284-2295.	1.0	51
1006	Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Thrombolysis, 2021, 52, 48-58.	1.0	11
1007	Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVIDâ€19. Pulmonary Circulation, 2020, 10, 1-7.	0.8	11
1008	â€˜There and Back Againâ€™â€”Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. Genes, 2020, 11, 1408.	1.0	11
1009	COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Research, 2020, 6, 00520-2020.	1.1	40
1010	The Long and Winding Road of Atrial Septostomy. Diagnostics, 2020, 10, 971.	1.3	2
1011	â€œFit for Surgery? What's New in Preoperative Assessment of the High-Risk Patient Undergoing Pulmonary Resectionâ€• Journal of Cardiothoracic and Vascular Anesthesia, 2020, 35, 3760-3773.	0.6	6
1012	Correlation Between N-Terminal Pro-Brain Natriuretic Peptide Levels and Cardiopulmonary Exercise Testing in Patients With Pre-Capillary Pulmonary Hypertension: A Pilot Study. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2020, 14, 117954842095404.	0.5	2
1013	Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile. Journal of Clinical Medicine, 2020, 9, 3608.	1.0	12
1014	A successful case of heart transplantation concurrent with pulmonary thromboendarterectomy. Perfusion (United Kingdom), 2021, 36, 879-882.	0.5	0
1015	Noninvasive Prediction of Elevated Wedge Pressure in Pulmonary Hypertension Patients Without Clear Signs of Leftâ€Sided Heart Disease: External Validation of the OPTICS Risk Score. Journal of the American Heart Association, 2020, 9, e015992.	1.6	14
1016	Cardiopulmonary exercise testing â€“ refining the clinical perspective by combining assessments. Expert Review of Cardiovascular Therapy, 2020, 18, 563-576.	0.6	17
1017	DNGR1-Creâ€“mediated Deletion of Tnfaip3/A20 in Conventional Dendritic Cells Induces Pulmonary Hypertension in Mice. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 665-680.	1.4	14
1018	A case of pulmonary arterial hypertension with chronic hepatitis that resulted in hepatosplenomegaly after administration of prostaglandin I2. Journal of Cardiology Cases, 2020, 21, 182-185.	0.2	1
1019	Blood carbon dioxide tension and risk in pulmonary arterial hypertension. International Journal of Cardiology, 2020, 318, 131-137.	0.8	12
1020	Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. Circulation, 2020, 142, 1464-1484.	1.6	96
1021	Impact of the updated hemodynamic definitions on diagnosis rates of pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-8.	0.8	4

#	Article	IF	Citations
1022	Impact of SARSâ€CoVâ€2 pandemic on pulmonary hypertension outâ€patient clinics in Germany: a multiâ€centre study. Pulmonary Circulation, 2020, 10, 1-3.	0.8	15
1023	Vitamin D deficiency downregulates TASK-1 channels and induces pulmonary vascular dysfunction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L627-L640.	1.3	19
1024	Multimodal Imaging Mass Spectrometry to Identify Markers of Pulmonary Arterial Hypertension in Human Lung Tissue Using MALDI-ToF, ToF-SIMS, and Hybrid SIMS. Analytical Chemistry, 2020, 92, 12079-12087.	3.2	33
1025	Use of Treprostinil in Pediatric Pulmonary Hypertension: Case Reports and Review of the Literature. Journal of Cardiovascular Pharmacology, 2020, 76, 23-31.	0.8	6
1026	Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). Pulmonary Circulation, 2020, 10, 1-10.	0.8	4
1027	Evolving spectrum of treatment for CTEPH. Current Opinion in Pulmonary Medicine, 2020, 26, 406-413.	1.2	6
1028	Clinical relevance of adding intravascular ultrasound to coronary angiography for the diagnosis of extrinsic left main coronary artery compression by a pulmonary artery aneurysm in pulmonary hypertension. Catheterization and Cardiovascular Interventions, 2021, 98, 691-700.	0.7	6
1029	Clinical trials in group 3 pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2020, 26, 391-396.	1.2	5
1030	4 Indications. , 2020, , .		0
1031	Phase Angle Evaluation of Lung Disease Patients and Its Relationship with Nutritional and Functional Parameters. Journal of the American College of Nutrition, 2021, 40, 529-534.	1.1	7
1032	Respiratory and cardiopulmonary limitations to aerobic exercise capacity in adults born preterm. Journal of Applied Physiology, 2020, 129, 718-724.	1.2	17
1033	Current Understanding of Circulating Biomarkers in Pulmonary Hypertension Due to Left Heart Disease. Frontiers in Medicine, 2020, 7, 570016.	1.2	5
1034	Discrepancies in Assessing Diastolic Function in Pre-Clinical Heart Failure Using Different Algorithmsâ€"A Primary Care Study. Diagnostics, 2020, 10, 850.	1.3	6
1035	Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2020, 76, 2155-2169.	1.2	51
1036	Is pulmonary arterial hypertension associated with interferon-Î² therapy for multiple sclerosis reversible? A case study to explore the complexity. ERJ Open Research, 2020, 6, 00328-2019.	1.1	0
1037	Prognostic Value of Gamma-Glutamyltransferase in Male Patients With Idiopathic Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2020, 7, 580908.	1.1	6
1038	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 214-225.	0.2	3
1039	The Future Application of Organ-on-a-Chip Technologies as Proving Grounds for MicroBioRobots. Micromachines, 2020, 11, 947.	1.4	9

#	Article	IF	Citations
1040	Expression Quantitative Trait Locus Mapping in Pulmonary Arterial Hypertension. Genes, 2020, 11, 1247.	1.0	3
1041	Feasibility of a Noninvasive Operability Assessment in Chronic Thromboembolic Pulmonary Hypertension under Real-World Practice. Diagnostics, 2020, 10, 855.	1.3	5
1042	Exercise Hemodynamics in the Prognosis of Patients with Pulmonary Arterial Hypertension. Respiration, 2020, 99, 678-685.	1.2	2
1043	Altitude Travel in Patients With Pulmonary Hypertension: Randomized Pilot-Trial Evaluating Nocturnal Oxygen Therapy. Frontiers in Medicine, 2020, 7, 502.	1.2	9
1044	Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. Arthritis Care and Research, 2020, , .	1.5	13
1045	Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in realâ€world clinical practice: interim data from postâ€marketing surveillance in Japan. Pulmonary Circulation, 2020, 10, 1-9.	0.8	7
1046	Pulmonary Vascular Disease and Cardiopulmonary Exercise Testing. Frontiers in Physiology, 2020, 11, 964.	1.3	13
1047	Pulmonary Hypertension: A Brief Guide for Clinicians. Mayo Clinic Proceedings, 2020, 95, 1978-1988.	1.4	137
1048	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. Archivos De Bronconeumologia, 2020, 56, 578-585.	0.4	5
1050	Characterization of rare ABCC8 variants identified in Spanish pulmonary arterial hypertension patients. Scientific Reports, 2020, 10, 15135.	1.6	19
1051	A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. Annals of the American Thoracic Society, 2020, 17, 1576-1582.	1.5	47
1052	Allopurinol in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease . International Journal of COPD, 2020, Volume 15, 2015-2024.	0.9	3
1053	Association Between Systemic and Pulmonary Vascular Dysfunction in COPD . International Journal of COPD, 2020, Volume 15, 2037-2047.	0.9	14
1054	Heart Rate Reduction Improves Right Ventricular Function and Fibrosis in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 843-855.	1.4	10
1055	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-10.	0.8	5
1056	Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2021, 34, 251-261.	0.7	5
1057	Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. Journal of Medicinal Chemistry, 2020, 63, 15153-15186.	2.9	20
1059	Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies. Pulmonary Circulation, 2020, 10, 204589402096383.	0.8	5

#	Article	IF	Citations
1060	Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study. Pulmonary Circulation, 2020, 10, 1-4.	0.8	7
1061	Pulmonary thromboendarterectomy in Portugal: Initial experience. Revista Portuguesa De Cardiologia, 2020, 39, 505-512.	0.2	6
1062	Left ventricular dysfunction and reversible pulmonary hypertension secondary to severe pneumonia in a background of sepsis: a case report and review of the literature. Annals of Palliative Medicine, 2020, 9, 3629-3642.	0.5	4
1063	Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertensionâ€"a Systematic Review. Annals of Pharmacotherapy, 2021, 55, 995-1009.	0.9	8
1064	Right Atrial Pressure During Exercise Predicts Survival in Patients With Pulmonary Hypertension. Journal of the American Heart Association, 2020, 9, e018123.	1.6	8
1065	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000673.	3.1	35
1066	Pulmonary arterial hypertension with below threshold pulmonary vascular resistance. European Respiratory Journal, 2020, 56, 1901654.	3.1	15
1067	New Insights into the Implication of Mitochondrial Dysfunction in Tissue, Peripheral Blood Mononuclear Cells, and Platelets during Lung Diseases. Journal of Clinical Medicine, 2020, 9, 1253.	1.0	9
1068	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 586-594.	2.5	45
1069	Evaluation of pulmonary hypertension by right heart catheterisation: does timing matter?. European Respiratory Journal, 2020, 56, 1901892.	3.1	9
1070	Exercise intolerance in chronic thromboembolic pulmonary hypertension after pulmonary angioplasty. European Respiratory Journal, 2020, 56, 1901982.	3.1	22
1071	Risk stratification in pulmonary arterial hypertension using Bayesian analysis. European Respiratory Journal, 2020, 56, 2000008.	3.1	38
1072	The impact of increased pulmonary arterial pressure on outcomes after transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2020, 96, E723-E734.	0.7	10
1073	Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 2000041.	3.1	48
1074	Correspondence regarding â€œT-box protein 4 mutation causing pulmonary arterial hypertension and lung diseaseâ€• a single-centre case series. European Respiratory Journal, 2020, 55, 1902272.	3.1	6
1075	Chronic thromboembolic pulmonary hypertension in Saudi Arabia: preliminary results from the SAUDIPH registry. ERJ Open Research, 2020, 6, 00218-2019.	1.1	5
1076	A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000513.	3.1	42
1077	Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa. Cardiovascular Diagnosis and Therapy, 2020, 10, 316-324.	0.7	19

#	Article	IF	Citations
1078	Cardiac Intravoxel Incoherent Motion Diffusionâ€Weighted Magnetic Resonance Imaging With T1 Mapping to Assess Myocardial Perfusion and Fibrosis in Systemic Sclerosis: Association With Cardiac Events From a Prospective Cohort Study. Arthritis and Rheumatology, 2020, 72, 1571-1580.	2.9	24
1079	Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration. European Respiratory Journal, 2020, 55, 2001047.	3.1	3
1080	Chronic thromboembolic pulmonary hypertension: interventional approaches. Heart, 2020, 106, 1525-1531.	1.2	2
1081	Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005993.	0.9	7
1082	Comparative therapeutic effect of the L-arginine and sildenafil on beta-thalassemia children with increased tricuspid regurgitant jet velocity. Pediatric Hematology Oncology Journal, 2020, 5, 25-29.	0.1	2
1083	Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?. European Respiratory Journal, 2020, 55, 2000700.	3.1	1
1084	Eisenmenger Syndrome in Pregnancy: A Management Conundrum. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 2813-2822.	0.6	12
1085	An update on the diagnosis and treatment of pediatric pulmonary hypertension. Expert Opinion on Pharmacotherapy, 2020, 21, 1253-1268.	0.9	5
1086	Two-dimensional speckle tracking echocardiography detected interventricular dyssynchrony predicts exercise capacity and disease severity in pre-capillary pulmonary hypertension. Annals of Translational Medicine, 2020, 8, 456-456.	0.7	2
1087	Early left atrial dysfunction in idiopathic pulmonary fibrosis patients without chronic right heart failure. International Journal of Cardiovascular Imaging, 2020, 36, 1711-1723.	0.7	13
1088	Pulmonary capillary haemangiomatosis: a distinct entity?. European Respiratory Review, 2020, 29, 190168.	3.0	17
1089	Performance of pulmonary artery dimensions measured on high-resolution computed tomography scan for identifying pulmonary hypertension. ERJ Open Research, 2020, 6, 00232-2019.	1.1	8
1090	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 843-852.	2.5	12
1091	Long term use of anticoagulant therapy for patients with pulmonary embolism. Expert Review of Hematology, 2020, 13, 709-718.	1.0	0
1092	Cardiac Troponin I Predicts Elevated B-type Natriuretic Peptide in Patients Treated with Anthracycline-Containing Chemotherapy. Oncology, 2020, 98, 653-660.	0.9	6
1093	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. European Respiratory Journal, 2020, 56, 2000279.	3.1	28
1094	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review.. European Journal of Internal Medicine, 2020, 78, 17-25.	1.0	29
1096	Pulmonary chronic thromboembolic disease. Archivos De Bronconeumologia, 2020, 56, 314-321.	0.4	2

#	Article	IF	Citations
1097	Epidemiology and mortality of connective tissue disease-associated pulmonary arterial hypertension: A national cohort study in taiwan. Seminars in Arthritis and Rheumatism, 2020, 50, 957-962.	1.6	15
1098	Residual Pulmonary Hypertension More than 20 Years after Repair of Shunt Lesions. Medicina (Lithuania), 2020, 56, 297.	0.8	2
1099	Advanced Diagnosis and Therapy for Pulmonary Arterial Hypertension. Nano LIFE, 2020, 10, 2040003.	0.6	2
1100	Balloon Pulmonary Angioplasty with Stent Implantation as a Treatment of Proximal Chronic Thromboembolic Pulmonary Hypertension. Diagnostics, 2020, 10, 363.	1.3	10
1101	Cardiac Considerations in Chronic Lung Disease. Respiratory Medicine, 2020, , .	0.1	2
1102	Chest CT scan: The best predictor of mortality in advanced pulmonary sarcoidosis?. Respiratory Medicine, 2020, 170, 106059.	1.3	1
1103	Pregnancy outcomes in patients with pulmonary arterial hypertension. Medicine (United States), 2020, 99, e20285.	0.4	32
1104	Congenital Heart Disease and Pulmonary Hypertension. Cardiology Clinics, 2020, 38, 445-456.	0.9	11
1105	Magnetic resonance imaging of pulmonary arterial compliance after pulmonary endarterectomy. European Respiratory Journal, 2020, 55, 1902171.	3.1	3
1106	Long-term health-related quality of life after surgery in patients with chronic thromboembolic pulmonary hypertension. Quality of Life Research, 2020, 29, 2111-2118.	1.5	13
1107	Under Pressure: A New Section ofCirculation: Heart FailureHighlighting Invasive Hemodynamics. Circulation: Heart Failure, 2020, 13, e006927.	1.6	0
1108	Effect of Elevated Pulmonary Artery Systolic Pressure on Short-Term Prognosis in Patients With Acute Myocardial Infarction. Angiology, 2020, 71, 567-572.	0.8	13
1109	Long-term survival outcome for pre-capillary pulmonary hypertension at a Japanese single center. Canadian Journal of Physiology and Pharmacology, 2020, 98, 644-652.	0.7	5
1110	Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease. Chest, 2020, 158, 350-358.	0.4	9
1111	Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology, 2020, 73, 130-139.	1.8	78
1112	Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension. Physiological Reports, 2020, 8, e14389.	0.7	7
1113	Early left ventricular remodeling and subclinical cardiac dysfunction in systemic lupus erythematosus: a three-dimensional speckle tracking study. International Journal of Cardiovascular Imaging, 2020, 36, 1227-1235.	0.7	13
1114	A Prospective, Comparative Study of Ventilationâ€“Perfusion Planar Imaging and Ventilationâ€“Perfusion SPECT for Chronic Thromboembolic Pulmonary Hypertension. Journal of Nuclear Medicine, 2020, 61, 1832-1838.	2.8	16

#	Article	IF	Citations
1115	Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?. Lung, 2020, 198, 547-554.	1.4	13
1116	Treating pulmonary hypertension in the elderly. Expert Opinion on Pharmacotherapy, 2020, 21, 1193-1200.	0.9	5
1117	Renal protective effect of sodium ferulate on pulmonary hypertension patients undergoing computed tomography pulmonary angiography. Pulmonary Circulation, 2020, 10, 1-7.	0.8	1
1118	Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD. Chest, 2020, 158, 722-734.	0.4	24
1119	Response to: Direct oral anticoagulants: Still too early for prime time after pulmonary endarterectomy?. Journal of Thrombosis and Haemostasis, 2020, 18, 759-761.	1.9	0
1120	Direct oral anticoagulants: Still too early for prime time after pulmonary endarteriectomy?. Journal of Thrombosis and Haemostasis, 2020, 18, 758-759.	1.9	1
1121	Clinical and Instrumental Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension according to the Russian National Registry. BioMed Research International, 2020, 2020, 1-12.	0.9	16
1122	Ethical considerations of thoracic transplant and circulatory support during the COVID-19 pandemic: A closer look at pulmonary vascular disease. Journal of Heart and Lung Transplantation, 2020, 39, 852-853.	0.3	0
1123	Cardiovascular Risk in Systemic Sclerosis. Current Treatment Options in Rheumatology, 2020, 6, 282-298.	0.6	0
1124	Complications in Idiopathic Pulmonary Fibrosis: Focus on Their Clinical and Radiological Features. Diagnostics, 2020, 10, 450.	1.3	10
1125	Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2020, 21, 4827.	1.8	8
1126	Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 878-880.	2.5	0
1127	Anomalous origin of right pulmonary artery: diagnosis, treatment, and follow-up in an adult patient. Cardiology in the Young, 2020, 30, 1199-1201.	0.4	1
1128	Mechanisms of Exercise Limitation and Prevalence of Pulmonary Hypertension in Pulmonary Langerhans Cell Histiocytosis. Chest, 2020, 158, 2440-2448.	0.4	11
1129	Efficacy and safety of Sildenafil treatment in pulmonary hypertension caused by chronic obstructive pulmonary disease: A meta-analysis. Life Sciences, 2020, 257, 118001.	2.0	11
1130	Pulmonary arterial hypertension associated with primary SjÃ¶gren's syndrome: a multicentre cohort study from China. European Respiratory Journal, 2020, 56, 1902157.	3.1	27
1131	Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension. Chest, 2020, 158, 2546-2555.	0.4	11
1132	Thoracic Visceral Adipose Tissue Area and Pulmonary Hypertension in Lung Transplant Candidates. The Lung Transplant Body Composition Study. Annals of the American Thoracic Society, 2020, 17, 1393-1400.	1.5	9

#	Article	IF	Citations
1133	Downregulation of PGI2 pathway in Pulmonary Hypertension Group-III patients. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 160, 102158.	1.0	4
1134	Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2020, 9, 410.	1.0	23
1135	The impact of high-flow nasal cannula oxygen therapy on exercise capacity in fibrotic interstitial lung disease: a proof-of-concept randomized controlled crossover trial. BMC Pulmonary Medicine, 2020, 20, 51.	0.8	15
1136	Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective. Journal of Clinical Medicine, 2020, 9, 561.	1.0	31
1137	Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. , 2020, 209, 107511.		63
1138	Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study. European Respiratory Journal, 2020, 55, 1901700.	3.1	28
1139	Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901761.	3.1	48
1140	Sex differences of hemodynamics during acute vasoreactivity testing to predict the outcomes of chronic thromboembolic pulmonary hypertension. Clinical Respiratory Journal, 2020, 14, 611-621.	0.6	5
1141	Identification of a pulmonary arterial hypertension (PAH) patient cohort and study of its burden of illness in Programme de MÃ©dicalisation des SystÃ¨mes d'information (PMSI). International Journal of Cardiology, 2020, 306, 175-180.	0.8	6
1142	An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 1421-1427.	1.6	9
1143	Cardiopulmonary exercise test indices of respiratory buffering before and after aerobic exercise training in women with pulmonary hypertension: Differentiation by magnitudes of change in six-minute walk test performance. Respiratory Medicine, 2020, 164, 105900.	1.3	5
1144	Correlation between Doppler echocardiography and right heart catheterization assessment of systolic pulmonary artery pressure in patients with severe aortic stenosis. Echocardiography, 2020, 37, 380-387.	0.3	15
1145	Balloon Pulmonary Angioplasty as a Treatment in Chronic Thromboembolic Pulmonary Hypertension: Past, Present, and Future. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 7.	0.4	8
1146	Transcriptome-wide map of m6A circRNAs identified in a rat model of hypoxia mediated pulmonary hypertension. BMC Genomics, 2020, 21, 39.	1.2	56
1147	Systemic sclerosis: Advances towards stratified medicine. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101469.	1.4	9
1148	Quantification of right ventricular extracellular volume in pulmonary hypertension using cardiac magnetic resonance imaging. Diagnostic and Interventional Imaging, 2020, 101, 311-320.	1.8	14
1149	Impact of Nutrition on Pulmonary Arterial Hypertension. Nutrients, 2020, 12, 169.	1.7	28
1150	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447.	1.0	108

#	Article	IF	Citations
1151	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309.	0.3	39
1152	Test-retest reliability and validity of the timed up and go test and 30-second sit to stand test in patients with pulmonary hypertension. International Journal of Cardiology, 2020, 304, 159-163.	0.8	30
1153	RNA Signaling in Pulmonary Arterial Hypertensionâ€"A Double-Stranded Sword. International Journal of Molecular Sciences, 2020, 21, 3124.	1.8	9
1154	Lung function in relation to six-minute walk test in pulmonary hypertension. European Clinical Respiratory Journal, 2020, 7, 1745492.	0.7	1
1155	Angiotensin converting enzyme 2 and angiotensin (1â€"7) axis in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 1902416.	3.1	29
1156	Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension. JAMA Cardiology, 2020, 5, 677.	3.0	26
1157	Clinical Update on Pulmonary Hypertension. Journal of Investigative Medicine, 2020, 68, 821-827.	0.7	46
1158	Identification of Cardiac MRI and Bio-Marker Thresholds for One-Year Survival in Pre-Capillary Pulmonary Hypertension: Prospective Study. Medicina (Lithuania), 2020, 56, 167.	0.8	3
1159	Assessment of electrocardiographic markers of acute and longâ€term hemodynamic improvement in patients with pulmonary hypertension. Annals of Noninvasive Electrocardiology, 2020, 25, e12758.	0.5	11
1160	Atrial Septal Defect with Eisenmenger Syndrome: A Rare Presentation. Case Reports in Cardiology, 2020, 2020, 1-4.	0.1	2
1161	Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges. Heart Lung and Circulation, 2020, 29, 1459-1468.	0.2	2
1162	Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results. Cardiology in the Young, 2020, 30, 681-685.	0.4	8
1163	Pulmonary vascular diseases. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, S2-S5.	0.2	0
1164	Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival. European Heart Journal, 2020, 41, 1918-1929.	1.0	53
1165	The â€˜great waitâ€™ for diagnosis in pulmonary arterial hypertension. Respirology, 2020, 25, 790-792.	1.3	8
1166	Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Annals of the Rheumatic Diseases, 2020, 79, 626-634.	0.5	34
1167	Genetics of pulmonary hypertension and high-altitude pulmonary edema. Journal of Applied Physiology, 2020, 128, 1432-1438.	1.2	15
1168	Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 201, e26-e51.	2.5	521

#	Article	IF	Citations
1169	Exercise right heart catheterization before and after balloon pulmonary angioplasty in inoperable patients with chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-9.	0.8	9
1170	Significance of Pulmonary Vascular Resistance and Diastolic Pressure Gradient on the New Definition of Combined Post-Capillary Pulmonary Hypertension. International Heart Journal, 2020, 61, 301-307.	0.5	8
1171	â€œTreat and repairâ€•strategy for shunt lesions: a critical review. Pulmonary Circulation, 2020, 10, 1-9.	0.8	18
1172	Long-term treatment of venous thromboembolism. Blood, 2020, 135, 317-325.	0.6	44
1173	Pulmonary artery denervation for pulmonary arterial hypertension. Trends in Cardiovascular Medicine, 2021, 31, 252-260.	2.3	15
1174	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. European Respiratory Journal, 2021, 57, 2000124.	3.1	29
1175	Current and future treatments of pulmonary arterial hypertension. British Journal of Pharmacology, 2021, 178, 6-30.	2.7	104
1176	The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis. Internal and Emergency Medicine, 2021, 16, 941-947.	1.0	4
1177	Sleep-related breathing disorders and pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002258.	3.1	56
1178	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovascular Research, 2021, 117, 1391-1401.	1.8	23
1179	Chronic thromboembolic pulmonary hypertension in Spain: a decade of change. Revista Espanola De Cardiologia (English Ed), 2021, 74, 384-392.	0.4	6
1180	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. European Respiratory Journal, 2021, 57, 2002208.	3.1	12
1181	Increased pulmonary serotonin transporter in patients with chronic obstructive pulmonary disease who developed pulmonary hypertension. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1081-1092.	3.3	4
1182	Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging, 2021, 14, 931-942.	2.3	73
1183	Myocardial deformation assessment in patients with precapillary pulmonary hypertension: A cardiac magnetic resonance study. Diagnostic and Interventional Imaging, 2021, 102, 153-161.	1.8	8
1184	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest, 2021, 159, 1197-1207.	0.4	14
1185	The role of balloon pulmonary angioplasty and pulmonary endarterectomy: Is chronic thromboembolic pulmonary hypertension still a life-threatening disease?. International Journal of Cardiology, 2021, 326, 170-177.	0.8	18
1186	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2003201.	3.1	25

#	Article	IF	Citations
1187	The Association of CT-measured Cardiac Indices with Lung Involvement and Clinical Outcome in Patients with COVID-19. Academic Radiology, 2021, 28, 8-17.	1.3	32
1188	BTS Clinical Statement on pulmonary sarcoidosis. Thorax, 2021, 76, 4-20.	2.7	90
1189	Perinuclear anti-neutrophil cytoplasmic antibody in systemic lupus erythematosus indicates more severe condition. Clinical Biochemistry, 2021, 89, 38-43.	0.8	2
1190	Pulmonary hypertension in connective tissue diseases, new evidence and challenges. European Journal of Clinical Investigation, 2021, 51, e13453.	1.7	28
1191	Management of Pulmonary Arterial Hypertension. Current Cardiovascular Risk Reports, 2021, 15, 2.	0.8	36
1192	Diagnosis and management of connective tissue diseaseâ€associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*. Respirology, 2021, 26, 23-51.	1.3	45
1193	Correlation Between Doppler Echocardiography and Right Heart Catheterisation-Derived Systolic and Mean Pulmonary Artery Pressures: Determinants of Discrepancies Between the Two Methods. Heart Lung and Circulation, 2021, 30, 656-664.	0.2	5
1194	Keeping Patients with End-Stage Liver Disease Alive While Awaiting Transplant. Clinics in Liver Disease, 2021, 25, 103-120.	1.0	5
1195	Inhaled iloprost as third addâ€on therapy in idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-3.	0.8	4
1196	Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulmonary Circulation, 2021, 11, 1-12.	0.8	84
1197	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	1.3	23
1198	Endocan as a potential biomarker of disease severity and exacerbations in COPD. Clinical Respiratory Journal, 2021, 15, 445-453.	0.6	5
1199	Incidence and long-term outcomes of pregnant women complicated with pulmonary arterial hypertension during different pregnancies: A prospective cohort study from China. International Journal of Cardiology, 2021, 326, 178-183.	0.8	11
1200	Reply to: â€œManagement of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?â€• Journal of Hepatology, 2021, 74, 238-239.	1.8	0
1201	Clinical utility of ventilatory and gas exchange evaluation during lowâ€intensity exercise for risk stratification and prognostication in pulmonary arterial hypertension. Respirology, 2021, 26, 264-272.	1.3	7
1202	In-Depth Analysis of a Case of Persistent Severe Chronic Thromboembolic Pulmonary Hypertension. Cardiovascular Revascularization Medicine, 2021, 28, 212-214.	0.3	0
1203	Targeting transforming growth factor-Î² receptors in pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002341.	3.1	67
1204	Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk-Stratify Patients with Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2021, 18, 34-43.	1.5	13

#	Article	IF	Citations
1205	Characteristics and longâ€term survival of patients with chronic thromboembolic pulmonary hypertension in China. Respirology, 2021, 26, 196-203.	1.3	21
1206	Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. European Respiratory Journal, 2021, 57, 2001120.	3.1	22
1207	Autogenous mitochondria transplantation for treatment of right heart failure. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e111-e121.	0.4	30
1208	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 295-304.	2.9	26
1209	Nailfold videocapillaroscopy: a novel possible surrogate marker for the evaluation of peripheral microangiopathy in pulmonary arterial hypertension. Scandinavian Journal of Rheumatology, 2021, 50, 85-94.	0.6	6
1210	Platelet count trends and response to fondaparinux in a cohort of heparin-induced thrombocytopenia suspected patients after pulmonary endarterectomy. Journal of Thrombosis and Thrombolysis, 2021, 51, 703-710.	1.0	4
1211	Computed tomography appearances of the lung parenchyma in pulmonary hypertension. British Journal of Radiology, 2021, 94, 20200830.	1.0	6
1212	Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis. Chest, 2021, 159, 781-790.	0.4	20
1213	Associated factors of early-onset pulmonary hypertension and clinical difference between early- and late-onset pulmonary hypertension in Thai systemic sclerosis. Modern Rheumatology, 2021, 31, 649-656.	0.9	2
1214	Effects of nasal high flow on sympathovagal balance, sleep, and sleep-related breathing in patients with precapillary pulmonary hypertension. Sleep and Breathing, 2021, 25, 705-717.	0.9	2
1215	Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 484-492.	2.5	41
1216	Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. British Journal of Pharmacology, 2021, 178, 90-107.	2.7	40
1218	Der Wolf im Schafspelz. , 2021, , 350-355.		0
1219	Burden of pulmonary arterial hypertension in England: retrospective HES database analysis. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662199504.	1.0	5
1220	Non-Invasive Assessment of Pulmonary Vasculopathy. Hearts, 2021, 2, 5-14.	0.4	1
1221	Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1â€“7)-Mas Axis in Pulmonary Arterial Hypertension. Cardiovascular Drugs and Therapy, 2022, 36, 363-370.	1.3	9
1222	Does kidney function matter in pulmonary thromboembolism management?. Cardiology Journal, 2022, 29, 858-865.	0.5	2
1223	Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated. European Respiratory Journal, 2021, 57, 2004258.	3.1	0

#	Article	IF	Citations
1224	Long-term survival of a patient with uterine cancer-induced pulmonary tumor thrombotic microangiopathy following treatment with platinum-based chemotherapy and bevacizumab: A case report. Respiratory Medicine Case Reports, 2021, 33, 101447.	0.2	1
1225	Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty. Diagnostics, 2021, 11, 133.	1.3	8
1226	Extrinsic compression of coronary and pulmonary vasculature. Cardiovascular Diagnosis and Therapy, 2021, 11, 1125-1139.	0.7	3
1227	Sleep-Disordered Breathing and Nocturnal Hypoxemia in Precapillary Pulmonary Hypertension: Prevalence, Pathophysiological Determinants, and Clinical Consequences. Respiration, 2021, 100, 865-876.	1.2	15
1228	Pulmonary Hypertension: Transition Challenges in the Current Therapeutic Era. Respiratory Medicine, 2021, , 145-165.	0.1	1
1229	Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial hypertension using AOSâ„¢ dry powder inhaler device. Pulmonary Circulation, 2021, 11, 1-9.	0.8	12
1230	Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. European Respiratory Journal, 2021, 57, 2004455.	3.1	42
1231	Pulmonale Hypertonie. , 2021, , 271-279.		0
1232	Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR). BMC Pulmonary Medicine, 2021, 21, 28.	0.8	2
1233	Repair of Partial Atrioventricular Septal Defects in Adults: A Single Center Experience. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 469-478.	0.4	7
1234	The VË™E/VË™co 2 Slope During Maximal Treadmill Cardiopulmonary Exercise Testing. Journal of Cardiopulmonary Rehabilitation and Prevention, 2021, 41, 194-198.	1.2	18
1235	The efficacy of bosentan combined with vardenafil in the treatment of postoperative pulmonary hypertension in children with congenital heart disease. Medicine (United States), 2021, 100, e23896.	0.4	5
1236	Dyspnoea and diffuse pulmonary nodules in a patient with pulmonary veno-occlusive disease: a case report and literature review. Journal of International Medical Research, 2021, 49, 030006052098668.	0.4	1
1237	ERS International Congress 2020: highlights from the General Pneumology Assembly. ERJ Open Research, 2021, 7, 00841-2020.	1.1	3
1238	ERS International Congress 2020: highlights from the Thoracic Surgery and Transplantation Assembly. ERJ Open Research, 2021, 7, 00743-2020.	1.1	0
1239	Effectiveness and safety of exercise training and rehabilitation in chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. Annals of Palliative Medicine, 2021, 10, 8134-8146.	0.5	5
1241	Vasodilatory action of trans â€4â€methoxyâ€Î²â€nitrostyrene in rat isolated pulmonary artery. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 717-725.	0.9	2
1242	Impact of the revised hemodynamic definition on the diagnosis of precapillary pulmonary hypertension: a retrospective single-center study in China. Cardiovascular Diagnosis and Therapy, 2021, 11, 1047-1057.	0.7	3

#	Article	IF	Citations
1243	The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease. Diagnostics, 2021, 11, 311.	1.3	12
1245	Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms. Cells, 2021, 10, 477.	1.8	16
1246	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (2020). Eurasian Heart Journal, 2021, , 6-43.	0.2	20
1247	The pathophysiological role of novel pulmonary arterial hypertension geneSOX17. European Respiratory Journal, 2021, 58, 2004172.	3.1	16
1248	Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2021, 177, 106293.	1.3	11
1249	The patient tells it! The importance of patient's quality of life perception in pulmonary arterial hypertension risk assessment. European Respiratory Journal, 2021, 57, 2004376.	3.1	1
1250	Chronic Thromboembolic Disease: Epidemiology, Assessment with Invasive Cardiopulmonary Exercise Testing, and Options for Management. Structural Heart, 2021, 5, 120-127.	0.2	6
1252	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	1.3	13
1253	Comorbidities and mortality risk factors for patients with bronchiectasis. Expert Review of Respiratory Medicine, 2021, 15, 623-634.	1.0	9
1254	Angiotensin-Converting Enzyme 2 Activator Ameliorates Severe Pulmonary Hypertension in a Rat Model of Left Pneumonectomy Combined With VEGF Inhibition. Frontiers in Medicine, 2021, 8, 619133.	1.2	8
1255	The predictive value of minute ventilation versus carbon dioxide production in pulmonary hypertension associated with left heart disease. Annals of Translational Medicine, 2021, 9, 351-351.	0.7	4
1256	Association of daily physical activity with psychosocial aspects and functional capacity in patients with pulmonary arterial hypertension: a crossâ€sectional study. Pulmonary Circulation, 2021, 11, 1-9.	0.8	12
1257	Endothelin receptor antagonists for pulmonary arterial hypertension. The Cochrane Library, 2021, 2021, CD004434.	1.5	10
1258	Pregnancy in pulmonary arterial hypertension: Midterm outcomes of mothers and offspring. Journal of Heart and Lung Transplantation, 2021, 40, 229-233.	0.3	28
1259	The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression. Cells, 2021, 10, 737.	1.8	13
1260	Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology, 2021, 61, 309-318.	0.9	8
1261	Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. ACR Open Rheumatology, 2021, 3, 295-304.	0.9	9
1262	Personalized Medicine for Pulmonary Hypertension:. Clinics in Chest Medicine, 2021, 42, 207-216.	0.8	3

#	Article	IF	Citations
1263	Potts shunt as an effective palliation for patients with end stage pulmonary arterial hypertension. Indian Heart Journal, 2021, 73, 196-204.	0.2	5
1264	Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion. ESC Heart Failure, 2021, 8, 1901-1914.	1.4	9
1265	Computed tomography angiographic parameters of pulmonary artery as prognostic factors of residual pulmonary hypertension after pulmonary endarterectomy. Journal of International Medical Research, 2021, 49, 030006052110020.	0.4	0
1266	Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps. Journal of the American Heart Association, 2021, 10, e017684.	1.6	10
1267	Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 675-677.	2.5	4
1268	More welcome data on pulmonary hypertension in South Africa. African Journal of Thoracic and Critical Care Medicine, 2021, 27, 3.	0.3	0
1269	Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 531-549.	3.6	43
1270	Plasma exosomal miR-596: a novel biomarker predicts survival in patients with idiopathic pulmonary artery hypertension. Journal of International Medical Research, 2021, 49, 030006052110023.	0.4	8
1271	The Diagnosis and Treatment of Pulmonary Fibrosis. Deutsches Ärzteblatt International, 2021, 118, .	0.6	10
1272	Outcome of aortic stenosis according to invasive cardiac damage staging after transcatheter aortic valve replacement. Clinical Research in Cardiology, 2021, 110, 699-710.	1.5	10
1273	Combined pre- and post-capillary pulmonary hypertension: The clinical implications for patients with heart failure. PLoS ONE, 2021, 16, e0247987.	1.1	10
1274	Pulmonary Vascular Diseases Associated with Infectious Diseaseâ€"Schistosomiasis and Human Immunodeficiency Viruses. Clinics in Chest Medicine, 2021, 42, 71-80.	0.8	2
1275	Detection of a rare cause of pulmonary hypertension by multimodality imaging: Left ventricular endomyocardial fibrosis. Journal of Clinical Ultrasound, 2021, 49, 520-524.	0.4	1
1276	Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2021, 10, 1024.	1.0	19
1277	Neurohormonal modulation in pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2004633.	3.1	12
1278	Pulmonary hypertension: Spectrum of disease, clinical presentation and treatment outcomes at the main respiratory pulmonary hypertension clinic in KwaZuluâ€'Natal Province, South Africa. African Journal of Thoracic and Critical Care Medicine, 2021, 27, 6.	0.3	2
1279	Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology. International Journal of Molecular Sciences, 2021, 22, 3471.	1.8	16
1280	Development of an optimized risk score to predict shortâ€term death among acute myocardial infarction patients in rural China. Clinical Cardiology, 2021, 44, 699-707.	0.7	8

#	Article	IF	Citations
1281	Do Right Heart Hemodynamic Improvements Persist After Pulmonary Thromboendarterectomy?. Seminars in Thoracic and Cardiovascular Surgery, 2022, 34, 80-89.	0.4	3
1282	Balloon Pulmonary Angioplasty in Technically Operable and Technically Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Clinical Medicine, 2021, 10, 1038.	1.0	16
1283	Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction. Journal of Thoracic Disease, 2021, 13, 1466-1475.	0.6	2
1284	Advanced Imaging in Pulmonary Vascular Disease. Clinics in Chest Medicine, 2021, 42, 101-112.	0.8	0
1285	Cancer antigen-125 is a predictor of mortality in patients with pulmonary arterial hypertension. Clinical Biochemistry, 2021, 89, 58-62.	0.8	3
1286	Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study. Pulmonary Circulation, 2021, 11, 1-9.	0.8	5
1287	Expression of miR-93-5p as a Potential Predictor of the Severity of Chronic Thromboembolic Pulmonary Hypertension. BioMed Research International, 2021, 2021, 1-7.	0.9	5
1288	Analysis of the 2020 European Society of Cardiology (ESC) Guidelines for the Management of Adults With Congenital Heart Disease (ACHD). Journal of Cardiothoracic and Vascular Anesthesia, 2021, , .	0.6	2
1289	Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment. ERJ Open Research, 2021, 7, 00854-2020.	1.1	14
1290	Infantile thiamine deficiency: Redefining the clinical patterns. Nutrition, 2021, 84, 111097.	1.1	9
1291	Advances in predicting patient survival in pulmonary sarcoidosis. Expert Opinion on Orphan Drugs, 2021, 9, 113-122.	0.5	1
1292	A New and More Sensitive Method to Integrate the Desaturation Distance Ratio During a 6-Minute Walking Test in Chronic Respiratory Diseases: Physiological Correlates. Archivos De Bronconeumologia, 2022, 58, 188-190.	0.4	3
1293	Predictive value of incidental right ventricular abnormalities identified on SPECT for mortality and pulmonary hypertension. Journal of Nuclear Cardiology, 2022, 29, 1903-1914.	1.4	3
1294	Circulating NT-proANP level is a predictor of mortality for systemic sclerosis: a retrospective study of an Italian cohort. Expert Review of Clinical Immunology, 2021, 17, 661-666.	1.3	5
1295	Prediction Models and Scores in Adult Congenital Heart Disease. Current Pharmaceutical Design, 2021, 27, 1232-1244.	0.9	11
1296	The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis. Frontiers in Pharmacology, 2021, 12, 668902.	1.6	3
1297	Echocardiographic assessment of chamber size and ventricular function during the first year after heart transplantation. Clinical Physiology and Functional Imaging, 2021, 41, 355-365.	0.5	5
1298	Health-related quality of life and disease progression in pulmonary arterial hypertension patients: a 3-year study. ERJ Open Research, 2021, 7, 00617-2020.	1.1	7

#	Article	IF	Citations
1299	Advances in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-9.	0.8	31
1301	Time trends of pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-9.	0.8	8
1302	Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease. PLoS ONE, 2021, 16, e0249435.	1.1	1
1303	Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: stateâ€ofâ€theâ€art 2020. Pulmonary Circulation, 2021, 11, 1-6.	0.8	32
1304	Monotherapy in patients with pulmonary arterial hypertension at four German PH centres. BMC Pulmonary Medicine, 2021, 21, 130.	0.8	5
1306	Soluble guanylate cyclase stimulator, trans-4-methoxy-Î²-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats. European Journal of Pharmacology, 2021, 897, 173948.	1.7	1
1307	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 1528.	1.0	17
1308	Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respiratory Research, 2021, 22, 109.	1.4	65
1309	Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease. Pulmonary Circulation, 2021, 11, 1-12.	0.8	7
1310	Inadequate Dosage May Lead to the Recurrence of Postoperative Pulmonary Hypertension in Patients With Congenital Heart Disease. Frontiers in Pharmacology, 2021, 12, 660405.	1.6	3
1311	The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients. Pharmaceuticals, 2021, 14, 403.	1.7	17
1312	Glutaminolysis: A Driver of Vascular and Cardiac Remodeling in Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 667446.	1.1	9
1314	Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment. Singapore Medical Journal, 2021, 62, 199-203.	0.3	0
1315	Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension â€“ A review of the past, present and future. Respiratory Medicine, 2021, 179, 106336.	1.3	8
1316	Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. European Respiratory Journal, 2021, 58, 2004066.	3.1	14
1317	Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms. European Respiratory Review, 2021, 30, 200284.	3.0	16
1318	Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis. European Respiratory Review, 2021, 30, 200321.	3.0	22
1319	Pulmonary arterial hypertension in systemic sclerosis. Presse Medicale, 2021, 50, 104062.	0.8	6

#	Article	IF	Citations
1320	Optimizing the diagnosis and assessment of chronic thromboembolic pulmonary hypertension with advancing imaging modalities. Pulmonary Circulation, 2021, 11, 1-12.	0.8	7
1321	A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression?. European Respiratory Journal, 2021, 57, 2004354.	3.1	9
1322	Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension. Thorax, 2021, 76, 1209-1218.	2.7	12
1323	Right ventricular expression of NTâ€proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension. ESC Heart Failure, 2021, 8, 3082-3092.	1.4	7
1324	The tailor-made treatment in a particular case of pulmonary hypertension in thalassaemia intermedia: a case report. European Heart Journal - Case Reports, 2021, 5, ytab193.	0.3	0
1325	The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension. International Journal of Molecular Sciences, 2021, 22, 4980.	1.8	30
1326	Endocan and Circulating Progenitor Cells in Women with Systemic Sclerosis: Association with Inflammation and Pulmonary Hypertension. Biomedicines, 2021, 9, 533.	1.4	12
1327	Mild pulmonary hypertension and premature mortality among 154â€Š956 men and women undergoing routine echocardiography. European Respiratory Journal, 2022, 59, 2100832.	3.1	12
1328	Adjusting to the New Normal: Echocardiography to Find Pulmonary Hypertension. EClinicalMedicine, 2021, 35, 100867.	3.2	0
1329	Does Duke Activity Status Index help predicting functional exercise capacity and long-term prognosis in patients with pulmonary hypertension?. Respiratory Medicine, 2021, 181, 106375.	1.3	1
1330	Restoration of Vitamin D Levels Improves Endothelial Function and Increases TASK-Like K+ Currents in Pulmonary Arterial Hypertension Associated with Vitamin D Deficiency. Biomolecules, 2021, 11, 795.	1.8	8
1331	Patient Journey and Disease-Related Burden in Japanese Patients WithÂChronic Thromboembolic Pulmonary Hypertension: A Mixed Methods Study. Value in Health Regional Issues, 2021, 24, 17-23.	0.5	2
1332	Impact of post-capillary pulmonary hypertension on mortality in interstitial lung disease. Respiratory Investigation, 2021, 59, 342-349.	0.9	7
1333	Nailfold videocapillaroscopic changes in patients with pulmonary arterial hypertension associated with connective tissue diseases. Rheumatology International, 2021, 41, 1289-1298.	1.5	5
1334	Role of angiopoietin-2 in venous thrombus resolution and chronic thromboembolic disease. European Respiratory Journal, 2021, 58, 2004196.	3.1	14
1335	Echocardiographic Prognosis Relevance of Attenuated Right Heart Remodeling in Idiopathic Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 650848.	1.1	2
1336	Right ventricular pressure-volume loop shape and systolic pressure change in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L715-L725.	1.3	21
1337	Right ventricular free-wall longitudinal speckle tracking strain as a prognostic criterion of adverse outcomes in patients with pulmonary hypertension: a systematic review and meta-analysis. Russian Journal of Cardiology, 2021, 26, 4417.	0.4	4

#	Article	IF	Citations
1338	Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study. International Journal of General Medicine, 2021, Volume 14, 2101-2107.	0.8	2
1339	Development and Validation of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data. Chest, 2021, 159, 1986-1994.	0.4	10
1340	C1q/TNF-related protein-9 ameliorates hypoxia-induced pulmonary hypertension by regulating secretion of endothelin-1 and nitric oxide mediated by AMPK in rats. Scientific Reports, 2021, 11, 11372.	1.6	10
1341	Pulmonary hypertension and home-based (PHAHB) exercise intervention: protocol for a feasibility study. BMJ Open, 2021, 11, e045460.	0.8	5
1342	Plasma markers in pulmonary hypertension subgroups correlate with patient survival. Respiratory Research, 2021, 22, 137.	1.4	21
1343	Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact. Diagnostics, 2021, 11, 911.	1.3	16
1344	New risk model is able to identify patients with a low risk of progression in systemic sclerosis. RMD Open, 2021, 7, e001524.	1.8	3
1345	Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 628284.	1.1	5
1346	Elevated pulmonary vascular resistance predicts mortality in COPD patients. European Respiratory Journal, 2021, 58, 2100944.	3.1	47
1347	Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. British Journal of Haematology, 2021, 194, 393-402.	1.2	22
1348	Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, doubleâ€blind placeboâ€controlled study. Pulmonary Circulation, 2021, 11, 1-8.	0.8	10
1349	Cardiovascular complications in cystic fibrosis: A review of the literature. Journal of Cystic Fibrosis, 2022, 21, 18-25.	0.3	25
1350	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Research and Therapy, 2021, 23, 170.	1.6	30
1351	Application of [18F]FLTâ€PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2Âmutation carriers. Pulmonary Circulation, 2021, 11, 1-9.	0.8	1
1352	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584.	5.2	85
1353	Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. Current Opinion in Pulmonary Medicine, 2021, 27, 396-404.	1.2	16
1354	Evolution of CT findings after anticoagulant treatment for acute pulmonary embolism in patients with and without an ultimate diagnosis of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 58, 2100699.	3.1	16
1355	Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart. Clinical Research in Cardiology, 2022, 111, 393-405.	1.5	5

#	Article	IF	Citations
1356	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854.	2.5	94
1357	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1472-1487.	2.5	68
1358	The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2021, 165, 157-161.	0.2	4
1359	The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels. Frontiers in Pharmacology, 2021, 12, 705421.	1.6	1
1360	Impact of SARS-CoV-2-Pandemic on Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2021, 12, 668647.	1.3	9
1361	Diverse Right Ventricular Remodeling Evaluated by <scp>MRI</scp> and Prognosis in Eisenmenger Syndrome With Different Shunt Locations. Journal of Magnetic Resonance Imaging, 2022, 55, 1478-1488.	1.9	6
1362	Left ventricular global longitudinal strain predicts elevated cardiac pressures and poor clinical outcomes in patients with non-ischemic dilated cardiomyopathy. Cardiovascular Ultrasound, 2021, 19, 21.	0.5	9
1363	Establishing expert consensus for the optimal approach to holistic risk-management in pulmonary arterial hypertension: a Delphi process and narrative review. Expert Review of Respiratory Medicine, 2021, 15, 1493-1503.	1.0	0
1364	Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-9.	0.8	11
1365	Safety and efficacy of balloon pulmonary angioplasty in a Portuguese pulmonary hypertension expert center: A step in the right direction. Revista Portuguesa De Cardiologia, 2021, 40, 739-740.	0.2	0
1367	Novel Genetic and Molecular Pathways in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease. Cells, 2021, 10, 1488.	1.8	17
1368	Risk Factors for Prolonged Mechanical Ventilation After Pulmonary Endarterectomy: 7 Years' Experience From an Experienced Hospital in China. Frontiers in Surgery, 2021, 8, 679273.	0.6	3
1369	Postpulmonary embolism syndrome. Current Opinion in Pulmonary Medicine, 2021, 27, 335-341.	1.2	5
1370	Accuracy of echocardiographically estimated pulmonary artery pressure in dogs with myxomatous mitral valve disease. Journal of Veterinary Cardiology, 2021, 35, 90-100.	0.3	6
1371	One Autopsy Case of Localized Scleroderma with Pulmonary Arterial Hypertensionwith Pleurisy and Pericarditis. Journal of the Nihon University Medical Association, 2021, 80, 121-125.	0.0	0
1372	A case of sigmoidectomy for sigmoid colon cancer with severe pulmonary arterial hypertension associated with mixed tissue connected disease: A case report. International Journal of Surgery Case Reports, 2021, 83, 105906.	0.2	0
1373	Pulmonary endarterectomy. Indian Journal of Thoracic and Cardiovascular Surgery, 2021, 37, 662-672.	0.2	0
1374	Comparison of dual-energy computer tomography and dynamic contrast-enhanced MRI for evaluating lung perfusion defects in chronic thromboembolic pulmonary hypertension. PLoS ONE, 2021, 16, e0251740.	1.1	7

#	Article	IF	Citations
1375	Does community size or commute time affect severity of illness at diagnosis or quality of care in a centralized care model of pulmonary hypertension?. International Journal of Cardiology, 2021, 332, 175-181.	0.8	0
1376	Assessment of oxygenation after balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2021, 333, 188-194.	0.8	8
1377	The soluble guanylate cyclase stimulator, 1-nitro-2-phenylethane, reverses monocrotaline-induced pulmonary arterial hypertension in rats. Life Sciences, 2021, 275, 119334.	2.0	2
1378	Time for precision medicine in systemic sclerosis-associated pulmonary arterial hypertension. European Respiratory Journal, 2021, 57, 2100205.	3.1	2
1379	SeguranÃ§a e eficÃ¡cia da angioplastia pulmonar por balÃ£o em Portugal num centro de referÃªncia em hipertensÃ£o pulmonar. Revista Portuguesa De Cardiologia, 2021, 40, 727-738.	0.2	2
1380	An adaptation strategy to urban heat: hospital rooms with radiant cooling accelerate patient recovery. ERJ Open Research, 2021, 7, 00881-2020.	1.1	5
1381	Management of Pulmonary Hypertension Due to Chronic Lung Disease. Methodist DeBakey Cardiovascular Journal, 2021, 17, 124.	0.5	3
1382	Better Outcomes in Pulmonary Arterial Hypertension After Repair of Congenital Heart Disease, Compared With Idiopathic Pulmonary Arterial Hypertension. CJC Open, 2021, 3, 872-879.	0.7	4
1383	Echocardiographic, Biochemical, and Electrocardiographic Correlates Associated With Progressive Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 705666.	1.1	5
1384	Factors contributing to exercise capacity in chronic thromboembolic pulmonary hypertension with near-normal hemodynamics. Journal of Heart and Lung Transplantation, 2021, 40, 677-686.	0.3	11
1385	Halofuginone, a promising drug for treatment of pulmonary hypertension. British Journal of Pharmacology, 2021, 178, 3373-3394.	2.7	15
1386	Screening asymptomatic BMPR2 mutation carriers: a new frontier for pulmonary hypertension physicians?. European Respiratory Journal, 2021, 58, 2100286.	3.1	2
1387	Raising the bar to ultradisciplinary collaborations in management of chronic thromboembolic pulmonary hypertension. Turkish Journal of Thoracic and Cardiovascular Surgery, 2021, 29, 417-431.	0.2	2
1388	When more speaks to less: New insights into arrhythmias in pulmonary hypertension from long term continuous monitoring. International Journal of Cardiology, 2021, 334, 123-124.	0.8	0
1389	Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification. Pulmonary Circulation, 2021, 11, 1-8.	0.8	1
1390	The Role of Four-Dimensional Automatic Right Ventricular Quantification Technology to Determine RV Function and Hemodynamics in Patients With Pulmonary Hypertension Compared With Right Heart Catheterization. Frontiers in Cardiovascular Medicine, 2021, 8, 628610.	1.1	1
1391	Ventilatory efficiency in pulmonary vascular diseases. European Respiratory Review, 2021, 30, 200214.	3.0	26
1392	Rare clinical case of the diagnosis of idiopathic pulmonary artery hypertension. I P Pavlov Russian Medical Biological Herald, 2021, 29, 299-304.	0.2	0

#	Article	IF	Citations
1393	Optimal Tricuspid Regurgitation Velocity to Screen for Pulmonary Hypertension in Tertiary Referral Centers. Chest, 2021, 160, 2209-2219.	0.4	5
1394	Role of Selexipag in Chronic Obstructive Pulmonary Disease (COPD) Patients With Out-of-Proportion Pulmonary Hypertension. Cureus, 2021, 13, e16520.	0.2	1
1395	Metalloproteinases and their inhibitors are associated with pulmonary arterial stiffness and ventricular function in pediatric pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H242-H252.	1.5	11
1396	The wide spectrum of Î²â€thalassaemia intermediaâ€induced pulmonary hypertension: two case reports on the possible role of specific pulmonary arterial hypertension therapy. Pulmonary Circulation, 2021, 11, 1-4.	0.8	1
1397	Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis. Advances in Rheumatology, 2021, 61, 43.	0.8	9
1398	Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiographyâ€based cluster analysis. American Journal of Hematology, 2021, 96, 1166-1175.	2.0	5
1399	Whatâ€™s new in pulmonary hypertension clinical research: lessons from the best abstracts at the 2020 American Thoracic Society International Conference. Pulmonary Circulation, 2021, 11, 1-27.	0.8	4
1400	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. Chest, 2021, 160, 277-286.	0.4	21
1401	Impact of pulmonary hypertension on arteriovenous fistula failure of hemodialysis patients: A 10â€‰years follow-up cohort study. Journal of Vascular Access, 2021, , 112972982110274.	0.5	2
1402	The Evolution of Risk Assessment in Pulmonary Arterial Hypertension. Methodist DeBakey Cardiovascular Journal, 2021, 17, 134.	0.5	0
1403	In situ Pulmonary Artery Thrombosis: A Previously Overlooked Disease. Frontiers in Pharmacology, 2021, 12, 671589.	1.6	21
1404	Chronic Thromboembolic Pulmonary Hypertension: A Comprehensive Review and Multidisciplinary Approach to Surgical Treatment. Methodist DeBakey Cardiovascular Journal, 2021, 17, 18.	0.5	5
1405	Evaluation, Diagnosis, and Classification of Pulmonary Hypertension. Methodist DeBakey Cardiovascular Journal, 2021, 17, 86.	0.5	14
1406	Polycythemia Vera Associated with Pulmonary Hypertension and Diffuse Large B-Cell Lymphoma: A Case Report. American Journal of Case Reports, 2021, 22, e932956.	0.3	0
1407	Circulating Cell Biomarkers in Pulmonary Arterial Hypertension: Relationship with Clinical Heterogeneity and Therapeutic Response. Cells, 2021, 10, 1688.	1.8	8
1408	Noninvasive Hemodynamic Evaluation at Rest in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 423-434.	1.0	0
1410	Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. Arthritis and Rheumatology, 2021, 73, 1731-1737.	2.9	20
1411	Pulmonary artery pressure is associated with mid-term major adverse cardiovascular events and postprocedure pericardial effusion in atrial fibrillation patients undergoing left atrial appendage occlusion. Annals of Translational Medicine, 2021, 9, 1324-1324.	0.7	1

#	Article	IF	Citations
1412	A 57-year-old man with rapidly progressive pulmonary hypertension. Monaldi Archives for Chest Disease, 2021, , .	0.3	2
1413	Can a patient with pulmonary hypertension travel safely by plane?. , 2021, 25, S29-S30.		0
1414	The Prognostic Value of Right Atrial Strain Imaging in Patients with Precapillary Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2021, 34, 851-861.e1.	1.2	25
1415	Effect of spironolactone use in pulmonary arterial hypertension â€“ analysis from pivotal trial databases. Pulmonary Circulation, 2021, 11, 1-11.	0.8	5
1416	Ð¡omputed tomography in assessing the severity of patients with chronic thromboembolic pulmonary hypertension. Arterial Hypertension (Russian Federation), 2021, 27, 333-340.	0.1	0
1417	Congenital heart disease and air travel. , 2021, 25, S18-S19.		0
1418	The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension. ERJ Open Research, 2021, 7, 00378-2021.	1.1	5
1419	Efficacy and Safety of Percutaneous Pulmonary Artery Subtotal Occlusion and Chronic Total Occlusion Intervention in Chronic Thromboembolic Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 2021, 14, e010243.	1.4	28
1420	Pulmonary Hypertension in the Context ofÂHeart Failure With Preserved Ejection Fraction. Chest, 2021, 160, 2232-2246.	0.4	14
1421	Chronic thromboembolic pulmonary hypertension anno 2021. Current Opinion in Cardiology, 2021, 36, 711-719.	0.8	4
1422	Pulmonary veno-occlusive disease in childhoodâ€”a rare disease not to be missed. Cardiovascular Diagnosis and Therapy, 2021, 11, 1070-1079.	0.7	1
1423	Altitude exposure in pediatric pulmonary hypertensionâ€”are we ready for (flight) recommendations?. Cardiovascular Diagnosis and Therapy, 2021, 11, 1122-1136.	0.7	4
1424	Ion channels as convergence points in the pathology of pulmonary arterial hypertension. Biochemical Society Transactions, 2021, 49, 1855-1865.	1.6	7
1426	Selexipag for pulmonary arterial hypertension in a wide range of adult congenital heart disease. International Journal of Cardiology Congenital Heart Disease, 2021, 4, 100144.	0.2	5
1428	Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow. European Respiratory Journal, 2021, 58, 2102008.	3.1	6
1429	External validation of different clinical and echocardiographic scores to distinguish postâ€•from precapillary pulmonary hypertension. Echocardiography, 2021, 38, 1558-1566.	0.3	0
1430	Blueberry extract improves redox balance and functional parameters in the right ventricle from rats with pulmonary arterial hypertension. European Journal of Nutrition, 2021, , 1.	1.8	2
1431	Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315.	1.5	8

#	Article	IF	Citations
1432	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. Journal of Heart and Lung Transplantation, 2021, 40, 1301-1326.	0.3	36
1433	The definition of pulmonary hypertension: history, practical implications and current controversies. Breathe, 2021, 17, 210076.	0.6	5
1434	Liver dysfunction in idiopathic pulmonary arterial hypertension: prevalence, characteristics and prognostic significance, a retrospective cohort study in China. BMJ Open, 2021, 11, e045165.	0.8	2
1435	Special considerations for pulmonary rehabilitation in conditions other than COPD. , 2021, , 145-164.		3
1436	Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 719058.	1.1	15
1437	Inhibition of microRNA-30a alleviates vascular remodeling in pulmonary arterial hypertension. Molecular Therapy - Nucleic Acids, 2021, 26, 678-693.	2.3	8
1438	Causal relation of tricuspid regurgitation for heart failure outcomes: a mediation analysis of echocardiographic predictors. European Heart Journal Open, 2021, 1, .	0.9	2
1439	Clinical impact of new diagnostic criteria for postcapillary pulmonary hypertension. International Journal of Cardiology, 2021, 339, 166.	0.8	0
1440	Comorbid patient with chronic obstructive pulmonary disease and coronary heart disease: opportunities for early diagnosis of pulmonary hypertension in outpatient settings. Meditsinskiy Sovet, 2021, , 146-153.	0.1	0
1441	Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 3010.	0.4	0
1443	The prediction of right atrial pressure using electrocardiogram: a novel approach. ESC Heart Failure, 2021, , .	1.4	3
1444	Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019. Hypertension, 2021, 78, 1168-1184.	1.3	6
1445	Assessment of Clinical Usefulness of Resting Electrocardiogram (PH-ECG Score) in Monitoring the Efficacy of Balloon Pulmonary Angioplasty (BPA) in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Journal of Clinical Medicine, 2021, 10, 4548.	1.0	2
1446	Pulmonary hypertension in fibrosing idiopathic interstitial pneumonia: Uncertainties, challenges and opportunities. Journal of Heart and Lung Transplantation, 2021, 40, 872-881.	0.3	3
1447	Uptake and Patient Perspectives on Additional Testing for Novel Disease-Associated Genes: Lessons from a PAH Cohort. Genes, 2021, 12, 1540.	1.0	1
1448	A case of a middle-aged patient with a ventricular septal defect complicated by severe pulmonary hypertension-stepwise surgical repair with pulmonary vasodilators-. Journal of Cardiology Cases, 2021, 24, 131-135.	0.2	1
1449	Noninvasive Risk Score to Screen for Pulmonary Hypertension With Elevated Pulmonary Vascular Resistance in Diseases of Chronic Volume Overload. American Journal of Cardiology, 2021, 159, 113-120.	0.7	0
1450	Performance of a 3D convolutional neural network in the detection of hypoperfusion at CT pulmonary angiography in patients with chronic pulmonary embolism: a feasibility study. European Radiology Experimental, 2021, 5, 45.	1.7	5

#	Article	IF	Citations
1451	Outcomes monitoring in pulmonary endarterectomy: Paving the road to success. Revista Portuguesa De Cardiologia, 2021, 40, 753-753.	0.2	0
1452	Right Ventricular Shape Feature Quantification for Evaluation of Pulmonary Hypertension: Feasibility and Preliminary Associations With Clinical Outcome. Journal of Biomechanical Engineering, 2022, 144, .	0.6	3
1453	Pulmonary arterial hypertension (PAH) from autopsy study: T-cells, B-cells and mastocytes detection as morphological evidence of immunologically mediated pathogenesis. Pathology Research and Practice, 2021, 225, 153552.	1.0	7
1454	Right ventricular function as assessed by cardiac magnetic resonance imagingâ€derived strain parameters compared to highâ€fidelity micromanometer catheter measurements. Pulmonary Circulation, 2021, 11, 1-10.	0.8	4
1455	Role of echocardiography in evaluating patients with pulmonary hypertension secondary to congenital heart diseases in economically developing countries. Progress in Pediatric Cardiology, 2021, , 101449.	0.2	0
1456	Assessment of right ventricle in pulmonary arterial hypertension with three-dimensional echocardiography and cardiovascular magnetic resonance. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 929-936.	0.6	3
1457	Endothelial dysfunction and hypercoagulability in severe sickle-cell acute chest syndrome. ERJ Open Research, 2021, 7, 00496-2021.	1.1	1
1458	Unenhanced computed tomography as a diagnostic tool in suspected pulmonary hypertension: a retrospective cross-sectional pilot study. Wellcome Open Research, 0, 6, 249.	0.9	2
1459	Epidemiology and Management of Chronic Thromboembolic Pulmonary Hypertension in Greece. Real-World Data from the Hellenic Pulmonary Hypertension Registry (HOPE). Journal of Clinical Medicine, 2021, 10, 4547.	1.0	8
1460	Pulmonary hypertension associated with busulfan. Pulmonary Circulation, 2021, 11, 1-12.	0.8	3
1461	Physical Activity and Its Association with Traditional Outcome Measures in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2022, 19, 572-582.	1.5	6
1462	Characteristics and Risk Factors of Pulmonary Hypertension in Patients With Hyperthyroidism. Endocrine Practice, 2021, 27, 918-924.	1.1	7
1463	Looking forward: key initiatives to improve the care of rare diseases and streamline the delivery of medicines and vaccines in Europe. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L616-L618.	1.3	2
1464	Novel molecular insights and public omics data in pulmonary hypertension. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166200.	1.8	6
1465	Pulmonary hypertension. Annals of Allergy, Asthma and Immunology, 2021, 127, 512-513.	0.5	0
1466	Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines. Lancet Respiratory Medicine,the, 2021, 9, 1185-1191.	5.2	13
1467	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2021, 78, 1393-1403.	1.2	90
1468	EPAS1 (Endothelial PAS Domain Protein 1) Orchestrates Transactivation of Endothelial ICAM1 (Intercellular Adhesion Molecule 1) by Small Nucleolar RNA Host Gene 5 (SNHG5) to Promote Hypoxic Pulmonary Hypertension. Hypertension, 2021, 78, 1080-1091.	1.3	9

#	Article	IF	Citations
1469	The association between sleep-related breathing disorders and pre-capillary pulmonary hypertension: A chicken and egg question. Respiratory Medicine and Research, 2021, 80, 100835.	0.4	3
1470	Group 2 Pulmonary Hypertension: Clinical Features and Treatment. , 2022, , 665-677.		0
1471	Group 4 PHâ€"Chronic Thromboembolic Pulmonary Hypertension. , 2022, , 691-699.		0
1472	Lungs. , 2022, , 243-256.		0
1473	Cardiac Catheterization in Pulmonary Hypertension. , 2022, , 605-615.		0
1474	Clinical Features of Pulmonary Hypertension and Right Heart Failure. , 2022, , 552-559.		0
1475	Palliative Care in Pulmonary Arterial Hypertension. Respiratory Medicine, 2021, , 255-279.	0.1	0
1476	An Introduction to Advanced Lung Disease. Respiratory Medicine, 2021, , 11-25.	0.1	0
1477	Systemic Sclerosis and Pulmonary Disease. Advances in Experimental Medicine and Biology, 2021, 1303, 173-182.	0.8	4
1478	Disease progression in systemic sclerosis. Rheumatology, 2021, 60, 1565-1567.	0.9	6
1479	Pulmonary and Critical Care Medicine. , 2021, , 325-338.		0
1480	Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group. , 2021, , 1-24.		0
1481	Pulmonary Arterial Hypertension. , 2021, , 223-234.		0
1482	Predicting mortality during long-term follow-up in pulmonary arterial hypertension. ERJ Open Research, 2021, 7, 00837-2020.	1.1	20
1483	Serum and pulmonary uric acid in pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000332.	3.1	28
1484	Adult-Onset Stillâ€™s Disease. Rare Diseases of the Immune System, 2020, , 93-132.	0.1	5
1485	Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. Respiratory Medicine, 2020, , 79-96.	0.1	1
1486	Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis. Respiratory Medicine, 2020, , 89-108.	0.1	1

#	Article	IF	Citations
1487	Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis. Internal and Emergency Medicine, 2021, 16, 349-357.	1.0	5
1488	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. Archivos De Bronconeumologia, 2020, 56, 578-585.	0.4	10
1489	Borderline pulmonary hypertension associated with chronic hypercapnia in chronic pulmonary disease. Respiratory Physiology and Neurobiology, 2019, 262, 20-25.	0.7	3
1491	High Right Ventricular Afterload Is Associated with Impaired Exercise Tolerance in Patients with Left Ventricular Assist Devices. ASAIO Journal, 2021, 67, 39-45.	0.9	12
1492	New targets for pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2017, 23, 377-385.	1.2	16
1493	Cardiac Magnetic Resonanceâ€“Derived Indexed Volumes and Volume Ratios of the Cardiac Chambers Discriminating Group 2 Pulmonary Hypertension From Other World Health Organization Groups. Journal of Computer Assisted Tomography, 2021, 45, 59-64.	0.5	4
1494	Heart Valve Abnormalities in Systemic Sclerosis Patients. Journal of Clinical Rheumatology, 2022, 28, e95-e101.	0.5	9
1495	Long-term Outcomes and Survival in Moderate-severe Portopulmonary Hypertension After Liver Transplant. Transplantation, 2021, 105, 346-353.	0.5	17
1496	Ante-mortem diagnosis of pulmonary tumour thrombotic microangiopathy in a patient with unrecognised extramammary Paget's disease. BMJ Case Reports, 2016, 2016, bcr2016216666.	0.2	11
1497	Could Dual-Energy CT Become the â€œOne-Stop Shopâ€•Modality in Pulmonary Hypertension Workup?. Radiology: Cardiothoracic Imaging, 2020, 2, e200603.	0.9	1
1498	T<scp>ranslational</scp>A<scp>dvances</scp><scp>in</scp><scp>the</scp>F<scp>ield</scp><scp>of</scp>P<scp>ulmonary</scp>H on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 292-301.	2.5	42
1499	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218.	3.9	208
1500	The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 384-390.	0.8	8
1501	Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. European Respiratory Journal, 2021, 57, 2002591.	3.1	40
1502	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	3.1	287
1503	Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. European Respiratory Journal, 2021, 58, 2004229.	3.1	50
1504	Emerging role of cardiovascular magnetic resonance imaging in the management of pulmonary hypertension. European Respiratory Review, 2020, 29, 190138.	3.0	19
1505	The risks of applying normative values in paediatric cardiopulmonary exercise testing: a case report. ERJ Open Research, 2020, 6, 00333-2020.	1.1	4

#	Article	IF	Citations
1506	Patterns of cardiopulmonary response to exercise in pulmonary vascular diseases. , 0, , 160-174.		2
1507	Adaptation and validation of the quality of life assessment of the Cambridge pulmonary hypertension outcome review (CAMPHOR) for Brazil. Journal of Patient-Reported Outcomes, 2020, 4, 43.	0.9	7
1508	Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patientsã€€â€• A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study â€•. Circulation Journal, 2020, 84, 1866-1874.	0.7	9
1509	Significant Clinical Indexes of Exercise-Induced Pulmonary Hypertension in Patients With Connective Tissue Disease. Circulation Reports, 2019, 1, 610-616.	0.4	3
1510	Psychometric Validation of a Japanese Version of the emPHasis-10 Questionnaire, a Patient-Reported Outcome Measure for Pulmonary Hypertensionã€€â€• Multicenter Study in Japan â€•. Circulation Reports, 2020, 2, 255-259.	0.4	5
1511	Exercise tolerance improves after pulmonary rehabilitation in pulmonary hypertension patients. Journal of Exercise Rehabilitation, 2017, 13, 214-217.	0.4	16
1512	Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: State of the art. World Journal of Clinical Cases, 2020, 8, 2679-2702.	0.3	23
1513	Metabolic and genetic assessments interpret unexplained aggressive pulmonary hypertension induced by methylmalonic acidemia: A case report. World Journal of Clinical Cases, 2020, 8, 1137-1141.	0.3	2
1514	Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability. PLoS ONE, 2017, 12, e0184227.	1.1	21
1515	Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database. PLoS ONE, 2017, 12, e0187734.	1.1	21
1516	Accuracy and reproducibility of CT right-to-left ventricular diameter measurement in patients with acute pulmonary embolism. PLoS ONE, 2017, 12, e0188862.	1.1	28
1517	Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching. PLoS ONE, 2018, 13, e0191239.	1.1	15
1518	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. PLoS ONE, 2018, 13, e0195047.	1.1	8
1519	Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment. PLoS ONE, 2020, 15, e0233063.	1.1	10
1520	Pulmonary Arterial Hypertension in Women. Methodist DeBakey Cardiovascular Journal, 2021, 13, 224.	0.5	14
1521	THE COMMITTEE OF EXPERTS OF THE RUSSIAN SOCIETY OF CARDIOLOGY (RSC). SECTION OF CARDIOVASCULAR DISEASES IN PREGNANT WOMEN. NATIONAL GUIDELINES FOR DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES DURING PREGNANCY 2018. NEW REVISION: JULY, 2018 (TEXT IS AVAILABLE IN) Tj ETQq1 1 0.78431	0.4	7
1522	Pulmonary hypertension as a risk assessment factor for unfavorable outcome in patients with COVID-19. Russian Journal of Cardiology, 2020, 25, 4136.	0.4	6
1523	Demographic and clinical characteristics of pulmonary arterial hypertension caused by schistosomiasis are indistinguishable from other etiologies. Revista Da Sociedade Brasileira De Medicina Tropical, 2020, 53, e20190418.	0.4	5

#	Article	IF	Citations
1525	Acute vasoreactivity testing predicts outcome of idiopathic pulmonary arterial hypertension patients with a negative acute response. Annals of Translational Medicine, 2020, 8, 1650-1650.	0.7	2
1526	The role of genomics and genetics in pulmonary arterial hypertension. Global Cardiology Science & Practice, 2020, 2020, e202013.	0.3	5
1527	Pulmonary hypertension: Proteins in the blood. Global Cardiology Science & Practice, 2020, 2020, e202007.	0.3	2
1528	Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it. Advances in Pulmonary Hypertension, 2018, 16, 125-135.	0.1	12
1529	Center-based Care for Pulmonary Hypertension: A European Perspective. Advances in Pulmonary Hypertension, 2018, 16, 170-174.	0.1	5
1530	Update on the PHA Pulmonary Hypertension Care Center Network: Early Experience With the National Accreditation Program. Advances in Pulmonary Hypertension, 2018, 16, 179-184.	0.1	6
1531	The Pulmonary Hypertension Association Registry: Rationale, Design, and Role in Quality Improvement. Advances in Pulmonary Hypertension, 2018, 16, 185-188.	0.1	23
1532	Tyrosine Kinase Inhibitorâ€“Induced Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2018, 17, 69-74.	0.1	3
1533	The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets. Current Medicinal Chemistry, 2020, 27, 7168-7188.	1.2	27
1534	MR-proADM and MR-proANP levels in patients with acute pulmonary embolism. Journal of Medical Biochemistry, 2019, 39, 328-335.	0.7	3
1535	Pulmonary complications in patients with liver cirrhosis. Journal of Translational Internal Medicine, 2020, 8, 150-158.	1.0	19
1537	Pulmonary Arterial Hypertension in Connective Tissue Disorders: The emerging role of screening and early diagnosis. A position paper for Greek Rheumatologists. Mediterranean Journal of Rheumatology, 2019, 30, 90-93.	0.3	4
1538	Peripheral Microangiopathy in Patients with Precapillary Pulmonary Hypertension: Correlation with Cardiac Function and Patientsâ€™ Functional Capacity. Study Design and Rationale. Mediterranean Journal of Rheumatology, 2020, 31, 369.	0.3	8
1540	Pulmonary Hypertension. Deutsches Ärzteblatt International, 2017, 114, 73-84.	0.6	87
1541	Individualized home-based exercise program for idiopathic pulmonary arterial hypertension patients: a preliminary study. Cor Et Vasa, 2019, 61, e403-e410.	0.1	5
1542	(COVID-19 in disorders of pulmonary circulation). Cor Et Vasa, 2020, 62, 19-21.	0.1	1
1543	Right Heart Size and Right Ventricular Reserve in Pulmonary Hypertension: Impact on Management and Prognosis. Diagnostics, 2020, 10, 1110.	1.3	6
1544	Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2020, 9, 448.	1.0	20

#	Article	IF	Citations
1545	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. Eurasian Heart Journal, 2020, , 78-122.	0.2	54
1546	Evaluating suspected pulmonary hypertension: A structured approach. Cleveland Clinic Journal of Medicine, 2018, 85, 468-480.	0.6	5
1547	Pulmonary arterial hypertension in Saudi patients with systemic sclerosis: Clinical and hemodynamic characteristics and mortality. Annals of Thoracic Medicine, 2019, 14, 83.	0.7	2
1548	Prevalence of pulmonary artery hypertension in patients of chronic obstructive pulmonary disease and its correlation with stages of chronic obstructive pulmonary disease, exercising capacity, and quality of life. Journal of Family Medicine and Primary Care, 2018, 7, 53.	0.3	11
1549	Central extracorporeal membrane oxygenation and early rehabilitation for persistent severe pulmonary hypertension following pulmonary endarterectomy. Acute and Critical Care, 2019, 34, 158-164.	0.6	2
1550	Atrial flow regulator for severe drug resistant pulmonary arterial hypertension after congenital heart defect correction. Cardiology Journal, 2019, 26, 102-104.	0.5	9
1551	On the search for the right definition of heart failure with preserved ejection fraction. Cardiology Journal, 2020, 27, 449-468.	0.5	13
1552	Pulmonary Arterial Hypertension: A Two-Dimensional Echocardiographic Approach from Screening to Prognosis. Archives of Cardiovascular Imaging, 2016, 4, .	0.2	1
1553	Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up. Cardiovascular Journal of Africa, 2018, 29, 208-212.	0.2	14
1555	Lung Cavities in Chronic Thromboembolic Pulmonary Hypertension. Clinics, 2020, 75, e1373.	0.6	3
1556	Relationship between Peripheral Arterial Stiffness and Estimated Pulmonary Pressure by Echocardiography in Systemic Sclerosis. Acta Cardiologica Sinica, 2017, 33, 514-522.	0.1	2
1557	Clinical and physiological characteristics of, medically treated, chronic thromboembolic pulmonary hypertension patients in Saudi Arabia: A single center experience. Annals of Thoracic Medicine, 2021, 16, 347.	0.7	2
1558	Mortality in Systemic Sclerosisâ€“Associated Interstitial Lung Disease in Brazil. Journal of Clinical Rheumatology, 2022, 28, e532-e538.	0.5	5
1559	Pulmonary arterial hypertension: achievements and realities of modern treatment, a look into the future. Terapevticheskii Arkhiv, 2021, 93, 1009-1017.	0.2	3
1560	Characteristics of patients with chronic thromboembolic pulmonary hypertension according to the Russian National Registry. Terapevticheskii Arkhiv, 2021, 93, 1058-1065.	0.2	6
1561	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. European Respiratory Journal, 2022, 59, 2102024.	3.1	57
1562	â€œIt is the fear of exercise that stops meâ€•â€“ attitudes and dimensions influencing physical activity in pulmonary hypertension patients. Pulmonary Circulation, 2021, 11, 1-9.	0.8	2
1563	An Overview of miRNAs Involved in PASMC Phenotypic Switching in Pulmonary Hypertension. BioMed Research International, 2021, 2021, 1-18.	0.9	3

#	Article	IF	Citations
1564	AtualizaÃ§Ã£o no Tratamento da HipertensÃ£o Arterial Pulmonar. Arquivos Brasileiros De Cardiologia, 2021, 117, 750-764.	0.3	6
1565	Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort. European Respiratory Journal, 2022, 59, 2101017.	3.1	12
1566	Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era. European Respiratory Journal, 2022, 59, 2101552.	3.1	27
1567	A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines. Open Heart, 2021, 8, e001725.	0.9	3
1568	Effects of different anesthesia methods on maternal and neonatal outcomes in pregnant patients with pulmonary arterial hypertension: a meta-analysis. Archives of Gynecology and Obstetrics, 2021, , 1.	0.8	0
1569	Preoperative soluble cluster of differentiation 40 ligand level is associated with outcome of pulmonary endarterectomy. JTCVS Open, 2021, , .	0.2	0
1570	Connective Tissue Disease, Interstitial Lung Disease, and Pulmonary Hypertension (CTD PH-ILD): A Distinct Entity and Potential Opportunity. Advances in Pulmonary Hypertension, 2021, 20, 109-118.	0.1	0
1571	Mortality risk factors among hospitalized children with severe pertussis. BMC Infectious Diseases, 2021, 21, 1057.	1.3	5
1572	Initial Triple Combination Therapy for Intermediate and High-Risk Pulmonary Arterial Hypertension: Standard of Care or Still too Soon to Tell?. American Journal of Respiratory and Critical Care Medicine, 2021, , .	2.5	1
1573	Catheter-Directed Therapies in Patients with Pulmonary Embolism: Predictive Factors of In-Hospital Mortality and Long-Term Follow-Up. Journal of Clinical Medicine, 2021, 10, 4716.	1.0	0
1574	The Right Ventricular-Pulmonary Arterial Coupling and Diastolic Function Response to Therapy in Pulmonary Arterial Hypertension. Chest, 2022, 161, 1048-1059.	0.4	9
1575	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	1.6	5
1576	Reply to: Jin et al. and Sun et al.. American Journal of Respiratory and Critical Care Medicine, 2021, , .	2.5	0
1577	Interventricular septal curvature as an additional echocardiographic parameter for evaluating chronic thromboembolic pulmonary hypertension: a single-center retrospective study. BMC Pulmonary Medicine, 2021, 21, 328.	0.8	1
1578	ZIP12 Contributes to Hypoxic Pulmonary Hypertension by Driving Phenotypic Switching of Pulmonary Artery Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2022, 79, 235-243.	0.8	8
1579	Pulmonary arterial hypertension. Nursing, 2021, 51, 37-43.	0.2	0
1580	Pulmonary Veno-occlusive Disease. Advances in Pulmonary Hypertension, 2015, 14, 155-160.	0.1	0
1581	Re: En kvinne iÂ70-Ã¥rene med dekompensert hjertesvikt under operasjon. Tidsskrift for Den Norske Laegeforening, 2015, 135, 1921-1922.	0.2	0

#	Article	IF	Citations
1582	Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment. Advances in Pulmonary Hypertension, 2015, 14, 138-144.	0.1	1
1583	What do the â€œnewâ€•Pulmonary Hypertension Guidelines tell us: should we change our practice?. Anatolian Journal of Cardiology, 2015, 15, 890-890.	0.5	0
1584	Pulmonary Arterial Hypertension Associated with Adult Congenital Heart Disease, when Inoperable becomes Operable: A Case Report. Journal of Pulmonary & Respiratory Medicine, 2016, 6, .	0.1	1
1585	Wood units Â· m2 or Wood units/m2: does it matter?. Anatolian Journal of Cardiology, 2016, 16, 360.	0.5	2
1586	Pulmonary Vascular Resistance in Patients With Pulmonary Hypertension: Importance of the Quadratic Velocity-Pressure Relationshipã€€â€“ Reply â€“. Circulation Journal, 2016, 80, 2563-2564.	0.7	0
1587	Cardiac Involvement: Evaluation and Management. , 2017, , 331-356.		0
1588	A Case of Pulmonary Arterial Hypertension Associated with Adult Hemophagocytic Lymphohistiocytosis. Pulmonary Circulation, 2016, 6, 614-615.	0.8	1
1589	Chronic thromboembolic pulmonary hypertension. Intervencni A Akutni Kardiologie, 2016, 15, 172-176.	0.0	0
1590	Who would think of pulmonary hypertension in the general practitioner's surgery?. MedicÃ¤na Pro Praxi, 2016, 13, 238-241.	0.0	0
1591	Heart rate variability in Eisenmenger syndrome and its correlation with echocardiographic parameters and plasma BNP, high sensitivity troponin-I level. Anatolian Journal of Cardiology, 2017, 17, 78-79.	0.5	2
1592	Systemic Sclerosis and Other Connective Tissue Diseases. Advances in Pulmonary Hypertension, 2017, 16, 55-60.	0.1	0
1594	Shunt Lesions. Congenital Heart Disease in Adolescents and Adults, 2017, , 129-140.	0.2	0
1595	Indications for Lung Transplantation. , 2017, , 1-20.		0
1596	Ask The Expert: What Are Some Pitfalls and Promises of the Current PAH Treatment Guidelines?. Advances in Pulmonary Hypertension, 2017, 15, 182-183.	0.1	0
1597	Congenital Heart Defects and Pulmonary Hypertension: The Heathâ€“Edwards Paradigm. Congenital Heart Disease in Adolescents and Adults, 2017, , 3-22.	0.2	1
1598	Drug interaction (40. Drug interactions in pulmonary arterial hypertension treatment). Okayama Igakkai Zasshi, 2017, 129, 187-193.	0.0	0
1599	Pulmonary Arterial Hypertension. , 2017, , .		0
1600	Hypertension pulmonaire. Revue Des Maladies Respiratoires Actualites, 2017, 9, S28-S34.	0.0	0

#	Article	IF	Citations
1601	The Road Toward Precision in PH: Personal Omics, Phenomics, and Wearablesâ€"Oh My!. Advances in Pulmonary Hypertension, 2018, 17, 141-147.	0.1	1
1602	Results of a Clinical Trial to Determine the Efficacy, Safety, and Tolerability of Intravenous Drip Infusion Therapy of a New Epoprostenol Formulation in Japanese Children with Pulmonary Arterial Hypertension. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2018, 34, 30-38.	0.0	0
1603	Successful treatment of late-onset pulmonary hypertension after atrial septal defect operation with macitentan: Our center experience. , 2018, 2, 001-003.		0
1604	Indications for Lung Transplantation. , 2018, , 759-778.		0
1605	V. Pulmonary Hypertension Associated with Respiratory Diseases. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 226-233.	0.0	0
1606	III. The Particularity of CTD-PH Management. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 214-218.	0.0	0
1607	The Pulmonary Hypertension Story. Cardiovascular Innovations and Applications, 2018, 3, .	0.1	0
1609	Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment. Systemic Hypertension, 2018, 15, 66-71.	0.1	1
1610	StratÃ©gies thÃ©rapeutiques dans lâ€™hypertension pulmonaire : peut-on encore faire mieux ?. Revue Des Maladies Respiratoires Actualites, 2018, 10, 144-148.	0.0	0
1612	Pulmonary hypertension associated with portal hypertension and pulmonary hypertension in sarcoididosis of breathing organs: complex pathogenetic relationships. Bulletin of Siberian Medicine, 2018, 17, 229-237.	0.1	0
1613	Evaluation of effectiveness and safety of the first Russian-manufactured generic bosentan use in patients with pulmonary arterial hypertension. Systemic Hypertension, 2018, 15, 53-58.	0.1	0
1615	The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!. Current Respiratory Medicine Reviews, 2019, 14, 189-203.	0.1	0
1616	Evaluation of Cardiac Parameters in Bone Marrow Transplant Patients: Effect of Pulmonary Artery Pressure on Survival. Turkish Journal of Haematology, 2019, 36, 19-24.	0.2	0
1617	ROLE OF RISK FACTORS FOR ARTERIAL HYPERTENSION IN PREGNANT WOMEN. Complex Issues of Cardiovascular Diseases, 2019, 8, 15-22.	0.3	0
1618	The effect of tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia on the cardiovascular system. OnCOReview, 2019, 9, 3-21.	0.1	0
1619	Expert Council resolution on pulmonary arterial hypertension (PAH) "Changing the paradigm of treating patients with pulmonary arterial hypertension". Terapevticheskii Arkhiv, 2019, 91, 114-116.	0.2	2
1621	Clinical case of delayed systemic sclerosis and pulmonary arterial hypertension diagnostics. ZaporoÅ¾skij Medicinskij Å½urnal, 2019, .	0.0	0
1622	Detection of systemic sclerosis in patients with pulmonary hypertension. Regional Blood Circulation and Microcirculation, 2019, 18, 48-54.	0.1	0

#	Article	IF	Citations
1623	El deficit de hierro en pacientes con hipertensiÃ³n arterial pulmonares altamente prevalente. , 2019, 87, 186-190.		1
1624	Goal-Oriented Sequential Combination Therapy Evaluated Using Cardiopulmonary Exercise Parameters for the Treatment of Newly Diagnosed Pulmonary Arterial Hypertensionã€€â€• Goal-Oriented Therapy Evaluated by Cardiopulmonary Exercise Testing for Pulmonary Arterial Hypertension (GOOD EYE) â€•. Circulation Reports, 2019, 1, 303-311.	0.4	3
1625	Evaluation of inflammatory and coagulation markers in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with comorbid hypercholesterolemia. Pulmonologiya, 2019, 29, 175-183.	0.2	0
1626	Tools of the Trade: How Do You Perform and Interpret an Exercise Test?. Advances in Pulmonary Hypertension, 2019, 18, 47-55.	0.1	0
1627	Association between obstructive sleep apnea and pulmonary hypertension (literature review). Hypertension, 2019, .	0.2	0
1628	Current Clinical Management and Basic Research in Pediatric Pulmonary Hypertension. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2019, 35, 136-152.	0.0	0
1629	Clinical Outcomes and Treatment Options in Patients With Pulmonary Hypertension Who Received Pulmonary Hypertension-Specific Drugsã€€â€• Single-Center Case Series â€•. Circulation Reports, 2019, 1, 389-395.	0.4	1
1630	A metaâ€‘analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase typeâ€‘5 inhibitors for pulmonary arterial hypertension. Experimental and Therapeutic Medicine, 2019, 18, 4740-4746.	0.8	1
1631	Case 1: The Evaluation of Chronic Thromboembolic Pulmonary Hypertension. Clinical Cases in Cardiology, 2020, , 1-10.	0.0	1
1632	The significance of risk stratification in pulmonary arterial hypertension. Intervencni A Akutni Kardiologie, 2019, 18, 26-29.	0.0	0
1633	Risk Stratificationâ€”What's My Risk? A Practitioner's Tool. Advances in Pulmonary Hypertension, 2019, 18, 84-86.	0.1	0
1634	Pulmonary involvement in antiphospholipid syndrome. , 2019, , 124-139.		0
1635	The lung in liver disease: hepatopulmonary syndrome and portopulmonary hypertension. , 2019, , 262-277.		0
1637	Pulmonary involvement in Takayasu arteritis and BehÃ§et disease. , 2019, , 210-227.		1
1638	Pulmonary hypertension in patients with sarcoidosis: A single center experience. Anatolian Journal of Cardiology, 2020, 25, 36-41.	0.5	2
1640	Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data. Rational Pharmacotherapy in Cardiology, 2020, 16, 317-323.	0.3	1
1641	Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. International Journal of Clinical Pharmacy, 2020, 42, 1128-1138.	1.0	4
1642	TÃ¼rkiyeâ€™de tersiyer bir merkezde sistemik skleroz hastalarÄ±nda pulmoner hipertansiyon taramasÄ±; kesitsel orjinal Ã§alÄ±ÅŸma. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0

#	Article	IF	Citations
1643	Chronic thromboembolic pulmonary hypertension secondary to implantable cardioverter defibrillator lead thrombus in a patient with Brugada syndrome: a rare complication requiring a multidisciplinary approach. BMJ Case Reports, 2020, 13, e234549.	0.2	0
1644	Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases. , 2020, , 167-183.		0
1645	Pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension and hemoglobinopathies. Jornal Brasileiro De Pneumologia, 2020, 46, e20190287-e20190287.	0.4	0
1646	Predictors of Long-term Outcomes in Patients With Connective Tissue Disease Associated With Pulmonary Arterial Hypertension. Journal of Clinical Rheumatology, 2021, 27, e371-e377.	0.5	2
1647	El cateterismo cardiaco derecho de esfuerzo predice eventos en los pacientes con estenosis aÃ³rtica degenerativa asintomÃ¡tica. Revista Espanola De Cardiologia, 2020, 73, 457-462.	0.6	1
1648	Fundamentals of diagnosis and treatment of pulmonary hypertension associated with left heart disease: a clinical case. Hypertension, 2020, 13, 39-55.	0.2	0
1649	Limitations and Flaws of Preclinical Pulmonary Hypertension Studies. Advances in Pulmonary Hypertension, 2020, 19, 47-54.	0.1	0
1650	Evolving Paradigms in the Treatment of Atrial Septal Defects with Pulmonary Arterial Hypertension (ASD-PAH). Cardiology in Review, 2020, Publish Ahead of Print, 305-309.	0.6	0
1651	Safety and efficacy of balloon pulmonary angioplasty in a Portuguese pulmonary hypertension expert center. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 727-737.	0.2	1
1652	The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China. Journal of Thrombosis and Thrombolysis, 2021, , 1.	1.0	3
1653	Supra-systemic pulmonary hypertension after complicated percutaneous mitral balloon valvuloplasty: a case report and review of literature. BMC Anesthesiology, 2021, 21, 258.	0.7	0
1654	Incidence, Risk Factors, and Outcomes of Atrial Arrhythmias in Adult Patients With Atrioventricular Septal Defect. JACC: Clinical Electrophysiology, 2022, 8, 331-340.	1.3	2
1655	Evaluation of heart rate variability in patients with different forms of pulmonary hypertension. Systemic Hypertension, 2021, 18, 147-152.	0.1	2
1656	Preoperative 2D-echocardiographic assessment of pulmonary arterial pressure in subgroups of liver transplantation recipients. Anesthesia and Pain Medicine, 2021, 16, 344-352.	0.5	0
1657	Effect of Group 2 Pulmonary Hypertension Subgroups on Outcomes: Impact of the Updated Definition of Pulmonary Hypertension. Heart Lung and Circulation, 2022, 31, 508-519.	0.2	1
1658	Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. Journal of Heart and Lung Transplantation, 2022, 41, 411-420.	0.3	4
1659	A clinically applicable strategy to estimate the in vivo distribution of mechanical material properties of the right ventricular wall. International Journal for Numerical Methods in Biomedical Engineering, 2022, 38, e3548.	1.0	1
1660	PeakP_{ET}CO₂ combined with FEV1/FVC predicts vasodilatorâ€responsive patients with idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-8.	0.8	0

#	Article	IF	Citations
1661	Prevalence of Micronutrient Deficiencies and Relationship with Clinical and Patient-Related Outcomes in Pulmonary Hypertension Types I and IV. Nutrients, 2021, 13, 3923.	1.7	8
1662	Pulmonary manifestations of chronic liver disease: a comprehensive review. Annals of Gastroenterology, 2020, 33, 237-249.	0.4	13
1663	Gender and Race Disparities in Pulmonary Hypertension Diagnosis and Treatment. Respiratory Medicine, 2020, , 195-202.	0.1	0
1664	Beyond Scleroderma: Pulmonary Arterial Hypertension in Patients with Other Connective Tissue Diseases. Respiratory Medicine, 2020, , 51-60.	0.1	0
1665	The investigation and diagnosis of pulmonary hypertension in adults with congenital heart disease. Journal of Congenital Cardiology, 2020, 4, .	0.5	1
1666	Transthoracic intracardiac catheters in perioperative management of pediatric cardiac surgery patients: a single-center experience. Asian Cardiovascular and Thoracic Annals, 2021, 29, 735-742.	0.2	2
1667	Pulmonary Hypertension and Pregnancy. Ukrainian Journal of Cardiovascular Surgery, 2020, , 74-83.	0.0	0
1668	Lung Resection and Pulmonary Hypertension. , 2022, , 523-532.		0
1669	Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Jornal Brasileiro De Pneumologia, 2020, 46, e20200204-e20200204.	0.4	3
1670	Multimodality Imaging of the Right Heart. Clinical Cases in Cardiology, 2020, , 43-70.	0.0	0
1671	Exercise Pulmonary Hypertension. Respiratory Medicine, 2020, , 1-27.	0.1	0
1672	Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. Respiratory Medicine, 2020, , 123-134.	0.1	1
1673	Controversies in the Management of Pulmonary Hypertension in the Setting of Lung Disease. Respiratory Medicine, 2020, , 109-122.	0.1	0
1674	Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension. Respiratory Medicine, 2020, , 147-171.	0.1	0
1675	Selected Disorders of the Respiratory System. , 2020, , 1-13.		0
1676	Therapeutic Advances in the Management of Pulmonary Arterial Hypertension. , 2020, , 1-23.		0
1678	Perioperative Management of Pulmonary Hypertension. A Review. The Journal of Critical Care Medicine, 2021, 7, 83-96.	0.3	6
1679	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Advances in Therapy, 2022, 39, 796-810.	1.3	12

#	Article	IF	Citations
1680	Gas exchange: the neglected piece in the PAH puzzle. European Respiratory Journal, 2021, 58, 2101407.	3.1	0
1681	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. European Respiratory Journal, 2022, 59, 2102419.	3.1	83
1682	Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters. Journal of Heart and Lung Transplantation, 2022, 41, 400-410.	0.3	12
1683	Response. Chest, 2021, 160, e541.	0.4	0
1684	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal, 2022, 60, 2102311.	3.1	124
1685	Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results. Pulmonary Circulation, 2021, 11, 1-8.	0.8	0
1686	Geriatric Nutritional Risk Index Is Associated With Prognosis in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Circulation Reports, 2020, 2, 372-377.	0.4	4
1688	Right heart failure. , 0, , 32-47.		0
1691	Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis. International Journal of Rheumatic Diseases, 2021, 24, 260-267.	0.9	4
1692	Importance of computed tomography in defining segmental disease in chronic thromboembolic pulmonary hypertension. ERJ Open Research, 2020, 6, 00461-2020.	1.1	8
1694	Pulmonary thromboendarterectomy in Portugal: Initial experience. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 505-512.	0.2	0
1695	The Challenges in Managing Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Acta Cardiologica Sinica, 2015, 31, 516-7.	0.1	1
1696	Clinical and hemodynamic profiles of elderly patients with pulmonary arterial hypertension: a single center, prospective study. Journal of Geriatric Cardiology, 2017, 14, 20-27.	0.2	5
1697	The Changing Landscape of Pulmonary Arterial Hypertension in 21 Century. Acta Cardiologica Sinica, 2017, 33, 510-513.	0.1	9
1698	Pulmonary hypertension and cardiac anesthesia: Anesthesiologist's perspective. Annals of Cardiac Anaesthesia, 2018, 21, 116-122.	0.3	15
1700	Bendopnea and Its Clinical Importance in Outpatient Patients with Pulmonary Arterial Hypertension. Acta Cardiologica Sinica, 2018, 34, 518-525.	0.1	5
1701	Plasma metabolomic profile in chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2020, 10, 2045894019890553.	0.8	11
1702	Changed hemodynamics in acute vasoreactivity testing: prognostic predictors in chronic thromboembolic pulmonary hypertension. American Journal of Translational Research (discontinued), 2020, 12, 959-973.	0.0	1

#	Article	IF	Citations
1703	Pulmonary Hypertension in Intensive Care Units: An Updated Review. Tanaffos, 2019, 18, 180-207.	0.5	7
1704	Pulmonary hypertension: From an orphan disease to a global epidemic. Global Cardiology Science & Practice, 2020, 2020, e202005.	0.3	3
1705	The haemodynamic assessment of patients with pulmonary arterial hypertension. Global Cardiology Science & Practice, 2020, 2020, e202004.	0.3	0
1706	Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy. Global Cardiology Science & Practice, 2020, 2020, e202008.	0.3	0
1707	Chronic thromboembolic pulmonary hypertension - still evolving. Global Cardiology Science & Practice, 2020, 2020, e202011.	0.3	1
1708	Echocardiographic evaluation of right ventricular-arterial coupling in pulmonary hypertension. American Journal of Cardiovascular Disease, 2020, 10, 272-283.	0.5	3
1709	Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies. Pulmonary Circulation, 2020, 10, 2045894020977025.	0.8	3
1710	ï¼œEditors' Choiceï¼ž Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population. Nagoya Journal of Medical Science, 2021, 83, 321-330.	0.6	0
1711	Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. American Journal of Cardiovascular Disease, 2021, 11, 330-347.	0.5	0
1712	Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case report. Medicine (United States), 2021, 100, e27334.	0.4	0
1713	Surgical Management of Chronic Thromboembolic Pulmonary Hypertension. Cardiology Clinics, 2022, 40, 89-101.	0.9	0
1714	Advanced Circulatory Support and Lung Transplantation in Pulmonary Hypertension. Cardiology Clinics, 2022, 40, 129-138.	0.9	3
1715	Safety and efficacy of balloon pulmonary angioplasty in a Portuguese pulmonary hypertension expert center: A step in the right direction. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 739-740.	0.2	0
1716	Post-interventional Evaluation and Follow-Up in Children With Patent Ductus Arteriosus Complicated With Moderate to Severe Pulmonary Arterial Hypertension: A Retrospective Study. Frontiers in Cardiovascular Medicine, 2021, 8, 693414.	1.1	3
1717	Right atrial function is associated with right venticular diastolic stiffness: RAâ€“RV interaction in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2101454.	3.1	15
1718	Development and Validation of a Nomogram for Predicting the Long-Term Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension. American Journal of Cardiology, 2022, 163, 109-116.	0.7	3
1719	A Feasibility Study on Using Single-Photon Emission Computed Tomography Pulmonary Perfusion/Ventilation Imaging for the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension and Patient Risk Assessment. International Journal of General Medicine, 2021, Volume 14, 8029-8038.	0.8	0
1720	Predictive value of chest HRCT for survival in idiopathic pulmonary arterial hypertension. Respiratory Research, 2021, 22, 293.	1.4	1

#	Article	IF	Citations
1721	Pulmonary arterial hypertension in the elderly population. Journal of the Chinese Medical Association, 2022, 85, 18-23.	0.6	3
1722	Predictive factors for concomitant pulmonary arterial hypertension at diagnosis of systemic lupus erythematosus in a Chinese population. International Journal of Rheumatic Diseases, 2021, 25, 76.	0.9	4
1723	Successful epoprostenol withdrawal and termination with an aid of the exercise stress test in pulmonary arterial hypertension. International Journal of Cardiology, 2022, 346, 80-85.	0.8	3
1724	The REPAIR Study. JACC: Cardiovascular Imaging, 2022, 15, 240-253.	2.3	28
1725	Pulmonary Hypertension in Thalassemia Patients. , 0, , .		0
1726	The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLEâ€PAH. FASEB Journal, 2021, 35, e22044.	0.2	15
1727	A Systematic Evaluation of the Quality, Accuracy, and Reliability of Internet Websites about Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2022, 19, 1404-1413.	1.5	9
1728	Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension. Respiratory Research, 2021, 22, 288.	1.4	6
1729	Screening for portopulmonary hypertension using computed tomographyâ€based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension. Hepatology Research, 2022, 52, 255-268.	1.8	8
1730	Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2022, 60, 2101694.	3.1	26
1731	Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension. Expert Review of Respiratory Medicine, 2022, 16, 57-66.	1.0	1
1732	Pulmonary Hypertension in Children across Africa: The Silent Threat. International Journal of Pediatrics (United Kingdom), 2021, 2021, 1-13.	0.2	2
1733	Comparison of Repetitive Cardiac Output Measurements at Rest and End-Exercise by Direct Fick Using Pulse Oximetry vs. Blood Gases in Patients With Pulmonary Hypertension. Frontiers in Medicine, 2021, 8, 776956.	1.2	3
1734	COVID-19 pandemic challenges: on the way to overcome obstacles in realization of PAH-specific therapy treatment goals. Eurasian Heart Journal, 2021, , 80-86.	0.2	0
1735	Balloon Pulmonary Angioplasty in Patients With Inoperable or Recurrent/Residual Chronic Thromboembolic Pulmonary Hypertension: A Single-Centre Initial Experience. Heart Lung and Circulation, 2022, 31, 520-529.	0.2	6
1736	Role of Store-Operated Ca2+ Entry in the Pulmonary Vascular Remodeling Occurring in Pulmonary Arterial Hypertension. Biomolecules, 2021, 11, 1781.	1.8	11
1738	Plasma metabolomics in the perioperative period of defect repair in patients with pulmonary arterial hypertension associated with congenital heart disease. Acta Pharmacologica Sinica, 2022, 43, 1710-1720.	2.8	12
1739	Visualizing Pulmonary Vascular Disease With CT Scanning. Chest, 2021, 160, 1998-1999.	0.4	1

#	Article	IF	Citations
1740	Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension. Frontiers in Pharmacology, 2021, 12, 773235.	1.6	11
1741	Langzeitsauerstofftherapie: Kernpunkte der Leitlinie. , 0, , .		0
1743	Prognostic Value of Follicle-Stimulating Hormone Levels in Predicting Survival in Men With Idiopathic Pulmonary Arterial Hypertension. American Journal of Men's Health, 2022, 16, 155798832110670.	0.7	2
1744	Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial. Journal of Heart and Lung Transplantation, 2022, 41, 563-567.	0.3	8
1745	The haemodynamic assessment of patients with pulmonary arterial hypertension. Global Cardiology Science & Practice, 2020, 2020, e202004.	0.3	1
1746	Pulmonary hypertension: From an orphan disease to a global epidemic. Global Cardiology Science & Practice, 2020, 2020, e202005.	0.3	10
1747	Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy. Global Cardiology Science & Practice, 2020, 2020, e202008.	0.3	1
1748	Chronic thromboembolic pulmonary hypertension â€“ still evolving. Global Cardiology Science & Practice, 2020, 2020, e202011.	0.3	4
1749	Outcomes monitoring in pulmonary endarterectomy: Paving the road to success. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 753-755.	0.2	0
1750	Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients. Medicine (United States), 2021, 100, e27334.	0.4	5
1751	Improved hospitalization rates in a specialty center for heart failure with preserved ejection fraction and pulmonary hypertension. Pulmonary Circulation, 2022, 12, .	0.8	1
1752	Biomarcadores biolÃ³gicos en las enfermedades respiratorias. Archivos De Bronconeumologia, 2022, 58, 323-333.	0.4	14
1753	The Roles of S100A4 and the EGF/EGFR Signaling Axis in Pulmonary Hypertension with Right Ventricular Hypertrophy. Biology, 2022, 11, 118.	1.3	3
1754	Off-Label Use and Inappropriate Dosing of Direct Oral Anticoagulants in Cardio-pulmonary Disease. Chest, 2022, , .	0.4	3
1755	Plateletâ€“Leucocyte Aggregates as Novel Biomarkers in Cardiovascular Diseases. Biology, 2022, 11, 224.	1.3	11
1756	Circulating Blood-Based Biomarkers in Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 383.	1.0	6
1757	Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodiesâ€™ types and titersâ€”cross-sectional study of Serbian cohort. Clinical Rheumatology, 2022, , 1.	1.0	3
1758	Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension. Cardiovascular Research, 2023, 119, 268-282.	1.8	4

#	Article	IF	Citations
1759	Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose. Internal Medicine, 2022, 61, 2263-2271.	0.3	4
1760	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: a multicentre registry. EuroIntervention, 2022, 17, 1104-1111.	1.4	23
1761	Ventricular mass discriminates pulmonary arterial hypertension as redefined at the SixthÂWorld Symposium on Pulmonary Hypertension. Pulmonary Circulation, 2022, 12, e12005.	0.8	3
1762	Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study. Clinical Rheumatology, 2022, 41, 1675-1686.	1.0	4
1763	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12028.	0.8	8
1764	Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic. Pulmonary Circulation, 2022, 12, e12038.	0.8	7
1765	A Clinical Approach to Multimodality Imaging in Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 794706.	1.1	6
1766	Thoracic bilateral sympathectomy as a new method of pulmonary arterial hypertension treatment: gaps of evidence. European Journal of Cardio-thoracic Surgery, 2022, , .	0.6	0
1767	Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 809594.	1.1	6
1768	Dual-Energy CT Pulmonary Angiography for the Assessment of Surgical Accessibility in Patients with Chronic Thromboembolic Pulmonary Hypertension. Diagnostics, 2022, 12, 228.	1.3	2
1769	Retrospective Evaluation of Platelet-Leukocyte Indices and Cardiac Surgical Outcomes in Acyanotic Heart Disease Patients with Pulmonary Hypertension (REPLICA-PH). Brazilian Journal of Cardiovascular Surgery, 2022, 37, .	0.2	3
1770	In replyâ€"Exercise-Based Cardiopulmonary Rehabilitation: A Suitable Addition to Pharmacological Therapy for Pulmonary Hypertension. Mayo Clinic Proceedings, 2022, 97, 191-192.	1.4	0
1771	Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America. Pulmonary Circulation, 2022, 12, e12012.	0.8	4
1772	Left Atrial Ablation for the Management of Atrial Tachyarrhythmias in Patients with Pulmonary Hypertension: A Case Series. HeartRhythm Case Reports, 2022, 8, 275-279.	0.2	1
1773	Circular RNAs in pulmonary hypertension: Emerging biological concepts and potential mechanism. Animal Models and Experimental Medicine, 2022, 5, 38-47.	1.3	20
1774	Effective Balloon Pulmonary Angioplasty in a Patient with Chronic Thromboembolic Complications after Ventriculoatrial Shunt for Hydrocephalus in von Hippelâ€"Lindau Disease. Medicina (Lithuania), 2022, 58, 185.	0.8	1
1775	Modern gold standard of cardiac output measurementÂâ€" A simplified bedside measurement of individual oxygen uptake in the cath lab. Journal of Basic and Clinical Physiology and Pharmacology, 2021, .	0.7	0
1776	Echocardiographic probability of pulmonary hypertension: a validation study. European Respiratory Journal, 2022, 60, 2102548.	3.1	27

#	Article	IF	Citations
1777	Selected Disorders of the Respiratory System. , 2022, , 1211-1223.		0
1778	Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension. International Heart Journal, 2022, 63, 99-105.	0.5	1
1779	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1102-1111.	2.5	35
1780	Severe Pulmonary Hypertension in COPD. Chest, 2022, 162, 202-212.	0.4	29
1781	Physical activity and its clinical correlates in chronic thromboembolic pulmonary hypertension.. Pulmonary Circulation, 2022, 12, e12048.	0.8	1
1782	Chronic thromboembolic pulmonary hypertension: a review of risk factors, management and current challenges. Expert Review of Cardiovascular Therapy, 2022, 20, 35-43.	0.6	7
1783	Nitric oxide: Clinical applications in critically ill patients. Nitric Oxide - Biology and Chemistry, 2022, 121, 20-33.	1.2	21
1784	Prevalence of musculoskeletal pain and its impact on quality of life and functional exercise capacity in patients with pulmonary arterial hypertension. Respiratory Medicine, 2022, 193, 106759.	1.3	1
1785	Magnetic resonance imaging in pulmonary hypertension: an overview of current applications and future perspectives. , 2022, 152, w30055.		7
1786	HipertensiÃ³n pulmonar en la enfermedad pulmonar intersticial. Archivos De Bronconeumologia, 2022, , .	0.4	0
1787	Childhood Trauma in Patients With PAHâ€"Prevalence, Impact on QoL, and Mental Healthâ€"A Preliminary Report. Frontiers in Psychiatry, 2022, 13, 812862.	1.3	0
1788	A case report of a 37-year-old woman with pulmonary arterial hypertension first presented during her 3rd pregnancy and favourable long-term vasoreactive response. European Heart Journal - Case Reports, 2022, 6, ytac031.	0.3	0
1789	Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study. Frontiers in Psychiatry, 2021, 12, 781532.	1.3	5
1790	Prevalence of pulmonary hypertension in COPD patients living at high altitude. Pulmonology, 2022, , .	1.0	7
1791	Metabotropic Glutamate Receptor 5 Blockade Attenuates Pathological Cardiac Remodeling in Pulmonary Arterial Hypertension. Clinical and Experimental Pharmacology and Physiology, 2022, , .	0.9	1
1792	Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation. European Respiratory Journal, 2022, 60, 2103087.	3.1	7
1793	Sex differences and altered mitophagy in experimental pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L761-L769.	1.3	5
1794	Ultrasonographic detection of enthesitis and its relation to clinical manifestations among Egyptian systemic sclerosis patients. Egyptian Rheumatology and Rehabilitation, 2022, 49, .	0.2	0

#	Article	IF	Citations
1796	Dynamic Changes in miR-21 Regulate Right Ventricular Dysfunction in Congenital Heart Disease-Related Pulmonary Arterial Hypertension. Cells, 2022, 11, 564.	1.8	4
1797	POINT: Did the World Symposium on Pulmonary Hypertension Get It Right in Redefining Abnormal Pulmonary Arterial Pressure? Yes. Chest, 2022, 161, 311-312.	0.4	2
1798	Rebuttal From Dr Kovacs. Chest, 2022, 161, 315-316.	0.4	0
1799	European Respiratory Society statement on long COVID follow-up. European Respiratory Journal, 2022, 60, 2102174.	3.1	81
1800	Influence of Upright Versus Supine Position on Resting and Exercise Hemodynamics in Patients Assessed for Pulmonary Hypertension. Journal of the American Heart Association, 2022, 11, e023839.	1.6	9
1801	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. European Respiratory Review, 2022, 31, 210165.	3.0	28
1802	Dyspnoea and cough in patients with systemic sclerosisâ€“associated interstitial lung disease in the SENSCIS trial. Rheumatology, 2022, 61, 4397-4408.	0.9	11
1803	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 716-721.	0.3	28
1804	Pharmacogenomic testing in paediatrics: Clinical implementation strategies. British Journal of Clinical Pharmacology, 2022, 88, 4297-4310.	1.1	12
1805	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 2021, 12, 7104.	5.8	21
1806	Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 385, 2361-2376.	13.9	241
1807	The use of pulmonary arterial hypertension therapies in Eisenmenger syndrome. Expert Review of Cardiovascular Therapy, 2021, 19, 1053-1061.	0.6	2
1810	The lung in autoimmune diseases: sarcoidosis. Handbook of Systemic Autoimmune Diseases, 2022, , 169-188.	0.1	0
1811	Genetic cause of pulmonary veno-occlusive disease. Lung India, 2022, 39, 191.	0.3	1
1812	Health Disparities and Differences in Health-Care-Utilization in Patients With Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2022, 13, 813506.	1.3	3
1813	[Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care. Archivos De Bronconeumologia, 2022, 58, T334-T344.	0.4	4
1814	Preoperative evaluation of pulmonary hypertension in lung transplant candidates: echocardiography versus right heart catheterization. BMC Cardiovascular Disorders, 2022, 22, 53.	0.7	6
1815	Common Variation in EDN1 Regulatory Regions Highlights the Role of PPARÎ³ as a Key Regulator of Endothelin in vitro. Frontiers in Cardiovascular Medicine, 2022, 9, 823133.	1.1	2

#	Article	IF	Citations
1816	[Translated article] Biological Biomarkers in Respiratory Diseases. Archivos De Bronconeumologia, 2022, 58, T323-T333.	0.4	11
1817	Association between Lung Fluid Levels Estimated by Remote Dielectric Sensing Values and Invasive Hemodynamic Measurements. Journal of Clinical Medicine, 2022, 11, 1208.	1.0	20
1818	Systemic sclerosis complicated by chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty: a case report. European Heart Journal - Case Reports, 2022, 6, ytac080.	0.3	1
1819	Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 826369.	1.1	8
1820	Prevalence of pulmonary hypertension on echocardiogram in children with severe obstructive sleep apnea. Journal of Clinical Sleep Medicine, 2022, 18, 1629-1637.	1.4	10
1821	Ventilation/perfusion imaging predicts response to balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Annals of Nuclear Medicine, 2022, 36, 515-522.	1.2	5
1822	A Novel Doppler TRPG/AcT Index Improves Echocardiographic Diagnosis of Pulmonary Hypertension after Pulmonary Embolism. Journal of Clinical Medicine, 2022, 11, 1072.	1.0	1
1823	ERS statement on chronic thromboembolic pulmonary hypertension. Pulmonologiya, 2022, 32, 13-52.	0.2	0
1824	Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities. Journal of Clinical Medicine, 2022, 11, 1084.	1.0	5
1825	68Ga-FAPI PET/CT for molecular assessment of fibroblast activation in right heart in pulmonary arterial hypertension: a single-center, pilot study. Journal of Nuclear Cardiology, 2023, 30, 495-503.	1.4	15
1826	Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review. Annals of Cardiothoracic Surgery, 2022, 11, 68-81.	0.6	9
1827	Impact of bridging with left ventricular assist device on right ventricular function following heart transplantation. ESC Heart Failure, 2022, 9, 1864-1874.	1.4	2
1828	Clinical characteristics associated with small airways disease in systemic sclerosis. Journal of Scleroderma and Related Disorders, 2022, 7, 239719832210838.	1.0	0
1829	Mxi1-0 Promotes Hypoxic Pulmonary Hypertension Via ERK/c-Myc-dependent Proliferation of Arterial Smooth Muscle Cells. Frontiers in Genetics, 2022, 13, 810157.	1.1	7
1830	CMR Measures of Left Atrial Volume Index and Right Ventricular Function Have Prognostic Value in Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Medicine, 2022, 9, 840196.	1.2	2
1831	Left main coronary artery compression by dilated pulmonary artery in pulmonary arterial hypertension: a systematic review and meta-analysis. Clinical Research in Cardiology, 2022, 111, 816-826.	1.5	1
1833	MRI Feature Tracking Strain in Pulmonary Hypertension: Utility of Combined Left Atrial Volumetric and Deformation Assessment in Distinguishing Post- From Pre-capillary Physiology. Frontiers in Cardiovascular Medicine, 2022, 9, 787656.	1.1	1
1834	The economic burden of pulmonary arterial hypertension in Spain. BMC Pulmonary Medicine, 2022, 22, 105.	0.8	5

#	Article	IF	Citations
1835	Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. European Respiratory Journal, 2022, 60, 2103181.	3.1	27
1836	Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment. Frontiers in Cardiovascular Medicine, 2022, 9, 797561.	1.1	7
1837	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. Frontiers in Medicine, 2022, 9, 851935.	1.2	4
1838	Non-invasive follow-up strategy after pulmonary endarterectomy for CTEPH. ERJ Open Research, 2022, 8, 00564-2021.	1.1	1
1839	Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data. Current Medical Research and Opinion, 2022, 38, 1019-1030.	0.9	1
1840	Pancreatic enlargement in a patient receiving therapy with vasodilators for pulmonary arterial hypertension: a case report. Abdominal Radiology, 2022, , 1.	1.0	2
1841	Clinical Features and Outcomes in AdultsÂWith Childhood Repair of PartialÂAtrioventricular Septal Defect. , 2022, 1, 100007.		1
1842	Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy. Annals of the American Thoracic Society, 2022, 19, 1236-1239.	1.5	1
1843	Balloon pulmonary angioplasty after pulmonary thromboendarterectomy. Annals of Cardiothoracic Surgery, 2022, 11, 192-194.	0.6	3
1844	Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 780-790.	0.3	13
1845	Progressive dyspnoea in a patient with idiopathic non-cirrhotic portal hypertension. Breathe, 2022, 18, 210168.	0.6	1
1846	Dual-energy CT lung perfusion characteristics in pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis (PVOD/PCH): preliminary experience in 63 patients. European Radiology, 2022, 32, 4574-4586.	2.3	8
1847	Pulmonary arterial hypertension: challenges and achievements 2021. Eurasian Heart Journal, 2022, , 80-89.	0.2	2
1848	Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Eurasian Heart Journal, 2022, , 6-79.	0.2	6
1849	Value of Cardiopulmonary Exercise Testing in Prognostic Assessment of Patients with Interstitial Lung Diseases. Journal of Clinical Medicine, 2022, 11, 1609.	1.0	1
1850	Recommendations from the ICM-VTE: General. Journal of Bone and Joint Surgery - Series A, 2022, 104, 4-162.	1.4	14
1851	Sarcoidosis-associated pulmonary hypertension. , 2022, , 234-255.		0
1852	Association Between the Presence of Pulmonary Hypertension Before Cardiovascular Surgery and the Nephroprotective Effect of Carperitide: A Retrospective Cohort Study. Cureus, 2022, 14, e22891.	0.2	0

#	Article	IF	Citations
1853	Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2022, 19, 1459-1468.	1.5	13
1854	Eisenmenger Syndrome. Journal of the American College of Cardiology, 2022, 79, 1183-1198.	1.2	19
1855	The Association of N-Terminal Pro-Brain Natriuretic Peptide With Time to Clinical Worsening in Hispanic Patients With Pulmonary Arterial Hypertension. Cardiology Research, 2022, 13, 73-80.	0.5	0
1857	Accuracy of Swanâ€'Ganz catheterizationâ€based assessment of right ventricular function: Validation study using highâ€fidelity micromanometryâ€derived values as reference. Pulmonary Circulation, 2022, 12, e12078.	0.8	3
1858	Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulmonary Circulation, 2022, 12, e12055.	0.8	6
1859	Inhaled iloprost induces longâ€term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy. Pulmonary Circulation, 2022, 12, e12074.	0.8	3
1860	Pulmonary Hypertension in Pregnancy: Challenges and Solutions. Integrated Blood Pressure Control, 2022, Volume 15, 33-41.	0.4	3
1861	Prognostic Role of Pulmonary Function in Patients With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2022, 11, e023422.	1.6	2
1862	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760.	2.5	27
1863	Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension. ERJ Open Research, 2022, 8, 00002-2022.	1.1	8
1864	Training and clinical testing of artificial intelligence derived right atrial cardiovascular magnetic resonance measurements. Journal of Cardiovascular Magnetic Resonance, 2022, 24, 25.	1.6	8
1865	Altered gut microbiota and its association with inflammation in patients with chronic thromboembolic pulmonary hypertension: a single-center observational study in Japan. BMC Pulmonary Medicine, 2022, 22, 138.	0.8	8
1866	Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension. Respiratory Medicine Case Reports, 2022, 37, 101646.	0.2	1
1867	Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study. Seminars in Arthritis and Rheumatism, 2022, 55, 151987.	1.6	12
1869	Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery. Pharmaceutics, 2021, 13, 2188.	2.0	4
1870	The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats. Cells, 2022, 11, 66.	1.8	5
1871	A modified perfusion protocol for pulmonary endarterectomy in a patient with a hematologic malignancy treated with a tyrosine kinase inhibitor. Perfusion (United Kingdom), 2023, 38, 418-421.	0.5	0
1873	Multidisciplinary Team Managements and Clinical Outcomes in Patients With Pulmonary Arterial Hypertension During the Perinatal Period. Frontiers in Cardiovascular Medicine, 2021, 8, 795765.	1.1	5

#	Article	IF	Citations
1874	The assessment of pulmonary arterial pressure and its clinical relevance: a 100-year journey from Europe, over the United States to Australia. European Respiratory Journal, 2022, 59, 2102064.	3.1	1
1875	Estimation of Pulmonary Arterial Wave Reflection by Echo-Doppler: A Preliminary Study in Dogs With Experimentally-Induced Acute Pulmonary Embolism. Frontiers in Physiology, 2021, 12, 752550.	1.3	0
1876	Cardiac assessments of bottlenose dolphins (Tursiops truncatus) in the Northern Gulf of Mexico following exposure to Deepwater Horizon oil. PLoS ONE, 2021, 16, e0261112.	1.1	3
1877	Predictors of survival in portopulmonary hypertension: a 20-year experience. European Journal of Gastroenterology and Hepatology, 2022, 34, 449-456.	0.8	7
1878	Anti-Ro/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis. Modern Rheumatology, 2022, 32, 1086-1093.	0.9	3
1879	Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality. Arthritis Research and Therapy, 2021, 23, 295.	1.6	20
1880	Vascular Remodeling in Pulmonary Arterial Hypertension: The Potential Involvement of Innate and Adaptive Immunity. Frontiers in Medicine, 2021, 8, 806899.	1.2	20
1881	Triple oral combination therapy in patients with idiopathic pulmonary arterial hypertension and recurrent vessel dissection of inoperable pulmonary artery aneurysm. Cor Et Vasa, 2021, 63, 726-731.	0.1	1
1882	Prognostic significance of insulin resistance in pulmonary hypertension. ESC Heart Failure, 2022, 9, 318-326.	1.4	6
1883	Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases. Frontiers in Cardiovascular Medicine, 2021, 8, 803984.	1.1	4
1884	Secular and Regional Trends among Pulmonary Arterial Hypertension Clinical Trial Participants. Annals of the American Thoracic Society, 2022, 19, 952-961.	1.5	12
1885	Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 132.	1.0	6
1886	Clinical value of echocardiography in evaluating hemodynamics and right ventricular function in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty. Journal of Thoracic Disease, 2022, 14, 1401-1410.	0.6	1
1887	Pulmonary Hypertension in Children - New Insights of Diagnosis and Management. Revista Romana De Cardiologie, 2021, 31, 893-896.	0.0	0
1888	Pulmonary arterial load and ventriculaâ€“arterial coupling in pulmonary hypertension. , 2022, , 899-915.		0
1889	Therapeutic approaches to improve pulmonary arterial load and right ventriculaâ€“pulmonary arterial coupling. , 2022, , 935-958.		0
1890	Pulsatile hemodynamics and ventriculaâ€“arterial interactions in the pulmonary circulation: physiologic concepts. , 2022, , 883-897.		0
1891	Efficacy of intermittent inhaled iloprost in inoperable chronic thromboembolic pulmonary hypertension. Pulmonologiya, 2022, 32, 53-61.	0.2	0

#	Article	IF	Citations
1892	Predictors of Maternal Death Among Women With Pulmonary Hypertension in China From 2012 to 2020: A Retrospective Single-Center Study. Frontiers in Cardiovascular Medicine, 2022, 9, 814557.	1.1	2
1893	Anesthetic management of cesarean delivery of parturient with systemic lupus erythematosus associated with pulmonary arterial hypertension - A case report -. Anesthesia and Pain Medicine, 0, , .	0.5	0
1894	Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension in Greece: Data from the Hellenic Pulmonary Hypertension Registry. Journal of Clinical Medicine, 2022, 11, 2211.	1.0	6
1895	Is it Still â€˜Idiopathicâ€™?: Features of Autoimmunity in IPAH. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	0
1896	Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT). Pulmonary Circulation, 2022, 12, e12083.	0.8	2
1897	Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy. Chest, 2022, 162, 669-683.	0.4	5
1898	Comorbidities of sarcoidosis. Annals of Medicine, 2022, 54, 1014-1035.	1.5	24
1899	Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. Heart Failure Reviews, 2022, 27, 1991-2003.	1.7	15
1900	RC time (resistanceÂÃ—Âcompliance) is related to residual symptom after pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. IJC Heart and Vasculature, 2022, 40, 101031.	0.6	1
1901	Clinical value of lncRNA SOX2-OT in pulmonary arterial hypertension and its role in pulmonary artery smooth muscle cell proliferation, migration, apoptosis, and inflammatory. Heart and Lung: Journal of Acute and Critical Care, 2022, 55, 16-23.	0.8	6
1904	ECG in the clinical and prognostic evaluation of patients with pulmonary arterial hypertension: an underestimated value. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662210878.	1.0	6
1905	Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies. Pulmonary Circulation, 2020, 10, 1-10.	0.8	7
1908	Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021032.	0.2	2
1913	Correlation of Hemodynamic and Respiratory Parameters in Invasive Cardiopulmonary Exercise Testing (iCPET). Life, 2022, 12, 655.	1.1	2
1914	The impact of cardiovascular comorbidities associated with risk for left heart disease on idiopathic pulmonary arterial hypertension: Data from the Hellenic Pulmonary Hypertension Registry (HOPE). Pulmonary Circulation, 2022, 12, .	0.8	4
1915	Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension. Current Problems in Cardiology, 2023, 48, 101236.	1.1	6
1916	Riociguat in the Treatment of Pulmonary Arterial Hypertension in Mexico. Archives of Medical Research, 2022, , .	1.5	1
1917	Update on the roles of imaging in the management of chronic thromboembolic pulmonary hypertension. Journal of Cardiology, 2023, 81, 297-306.	0.8	2

#	Article	IF	Citations
1918	Evidence for a Role of CCR6+ T Cells in Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Immunology, 2022, 13, 861450.	2.2	4
1919	Recognizing pulmonary hypertension following pulmonary thromboendarterectomy: A practical guide for clinicians. Pulmonary Circulation, 2022, 12, .	0.8	4
1920	Clinical Profile and Risk Factors for Cardiac Death in Pediatric Patients With Primary Dilated Cardiomyopathy at a Tertiary Medical Center in China. Frontiers in Pediatrics, 2022, 10, 833434.	0.9	0
1921	Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?. Genes, 2022, 13, 759.	1.0	2
1922	Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?. Respiratory Medicine and Research, 2022, 81, 100893.	0.4	1
1923	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 573-583.	2.5	16
1924	Phenotyping exercise limitation of patients with Interstitial Fibrosing Lung Disease: the importance of exercise hemodynamics. Pulmonology, 2024, 30, 104-112.	1.0	0
1925	Pulmonary hypertension in developing countries: Limiting factors in time to diagnosis, specialised medications and contextualised recommendations. African Journal of Thoracic and Critical Care Medicine, 2022, 28, 28-32.	0.3	1
1926	Distinct Platelet Ribonucleic Acid Signatures in Patients with Pulmonary Hypertension. Annals of the American Thoracic Society, 2022, 19, 1650-1660.	1.5	3
1927	Outcome of mean pulmonary arterial pressure-based intensive treatment for patients with pulmonary arterial hypertension. Journal of Cardiology, 2022, 80, 432-440.	0.8	6
1928	Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response. Heart, 2022, 108, 1392-1400.	1.2	15
1929	Machine learning cardiac-MRI features predict mortality in newly diagnosed pulmonary arterial hypertension. European Heart Journal Digital Health, 2022, 3, 265-275.	0.7	11
1930	Non-Invasive Cardiac Output Determination Using Magnetic Resonance Imaging and Thermodilution in Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 2717.	1.0	2
1931	The Role of Sildenafil in Treating Brain Injuries in Adults and Neonates. Frontiers in Cellular Neuroscience, 2022, 16, .	1.8	5
1932	Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland. Open Heart, 2022, 9, e002023.	0.9	2
1933	EGR1 Is Implicated in Right Ventricular Cardiac Remodeling Associated with Pulmonary Hypertension. Biology, 2022, 11, 677.	1.3	6
1934	Hemodynamic effects of balloon pulmonary angioplasty for the treatment of total and subtotal pulmonary artery occlusions in inoperable chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2022, 361, 71-76.	0.8	4
1935	EXPERIENCE OF IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION PATIENTS MANAGEMENT IN URAL FEDERAL DISTRICT: FEATURES OFOUTPATIENT-HOSPITAL INTERACTIONS. Eurasian Heart Journal, 2019, , 14-28.	0.2	1

#	Article	IF	Citations
1936	Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study. Frontiers in Pharmacology, 2022, 13, .	1.6	4
1937	The accuracy and influencing factors of Doppler echocardiography in estimating pulmonary artery systolic pressure: comparison with right heart catheterization: a retrospective cross-sectional study. BMC Medical Imaging, 2022, 22, 91.	1.4	7
1938	Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going. Biology, 2022, 11, 759.	1.3	16
1939	Twenty-Year Experience and Outcomes in a National Pediatric Pulmonary Hypertension Service. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 758-766.	2.5	10
1940	The Long March to a Cure for Pulmonary Hypertension. JACC Asia, 2022, 2, 215-217.	0.5	0
1941	Right ventricular myocardial energetic model for evaluating right heart function in pulmonary arterial hypertension. Physiological Reports, 2022, 10, e15136.	0.7	1
1942	Effect of pulmonary hypertension on exercise capacity and gas exchange in patients with chronic obstructive pulmonary disease living at high altitude. Chronic Respiratory Disease, 2022, 19, 147997312211040.	1.0	2
1943	A rare clinical case of the patient with pulmonary hypertension associated with hereditary hemorrhagic telangiectasia. Case report. Terapevticheskii Arkhiv, 2022, 94, 538-543.	0.2	0
1944	When you hear hoofbeats, think zebras â€•pulmonary venoâ€•occlusive disease: a case report. Pulmonary Circulation, 0, , .	0.8	1
1945	Assessment for residual disease after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. ERJ Open Research, 2022, 8, 00572-2021.	1.1	2
1946	Heart rate recovery in 1 minute after the 6-minute walk test predicts adverse outcomes in pulmonary arterial hypertension. PLoS ONE, 2022, 17, e0268839.	1.1	3
1947	Pause at Your Own Peril: A Case Series on Rebound Pulmonary Hypertension. Cureus, 2022, , .	0.2	0
1948	Duration of regional cerebral oxygen saturation under 40% is a risk factor for neurological injury following pulmonary thromboendarterectomy: A prospective observational study. Journal of Cardiac Surgery, 0, , .	0.3	3
1949	Case Report: Successful Concomitant Pulmonary Thromboendarterectomy and Carotid Endarterectomy. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	0
1950	Various factors contribute to death in patients with different types of pulmonary hypertension: A retrospective pilot study from a single tertiary center. Respiratory Investigation, 2022, 60, 647-657.	0.9	3
1951	An emerging phenotype of pulmonary arterial hypertension patients carryingSOX17variants. European Respiratory Journal, 2022, 60, 2200656.	3.1	15
1952	Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). Eurasian Heart Journal, 2022, , 6-70.	0.2	1
1953	Chronic Thromboembolic Pulmonary Hypertension. Lung, 2022, 200, 283-299.	1.4	8

#	Article	IF	Citations
1954	Ultrasound-assisted catheter-directed thrombolysis versus anticoagulation alone for management of submassive pulmonary embolism. Journal of Cardiology, 2022, 80, 441-448.	0.8	5
1955	Managing pulmonary arterial hypertension: how to select and facilitate successful transplantation. Current Opinion in Organ Transplantation, 2022, 27, 169-176.	0.8	2
1956	Pulmonary hypertension in patients with pneumoconiosis with progressive massive fibrosis. Occupational and Environmental Medicine, 2022, 79, 723-728.	1.3	2
1957	A Brief Review on Gender Differences in Mexican-Mestizo Patients with Pulmonary Arterial Hypertension (PAH) at a Tertiary-Level Hospital. Current Problems in Cardiology, 2022, 47, 101275.	1.1	2
1958	To be or not to beâ€¦ treated with initial combination therapy, that is the (PAH) question. European Respiratory Journal, 2022, 59, 2200390.	3.1	2
1959	Research Advances in ET-1 Antagonistic Drugs in the Treatment of Pulmonary Hy-pertension. Advances in Clinical Medicine, 2022, 12, 4711-4715.	0.0	0
1960	Prognostic implication of noninvasive right ventricle-to-pulmonary artery coupling in chronic thromboembolic pulmonary hypertension. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211028.	1.1	5
1961	The Impact of Socioeconomic, Racial, and Ethnic Disparities on Pulmonary Hypertension Diagnosis and Treatment. Advances in Pulmonary Hypertension, 2022, 21, 30-34.	0.1	0
1962	Hispanic Ethnicity and Social Determinants of Health: Harnessing Data from The Pulmonary Hypertension Association Registry. Advances in Pulmonary Hypertension, 2022, 21, 44-48.	0.1	2
1963	Low incidence of restenosis after successful balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Cardiovascular Intervention and Therapeutics, 0, , .	1.2	2
1964	Right Ventricular Myocardial Work Characterization in Patients With Pulmonary Hypertension and Relation to Invasive Hemodynamic Parameters and Outcomes. American Journal of Cardiology, 2022, 177, 151-161.	0.7	15
1965	Clinical impact and prognosis of cryoglobulinemia and cryofibrinogenemia in systemic sclerosis. Autoimmunity Reviews, 2022, , 103133.	2.5	2
1966	Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units. European Respiratory Journal, 2022, 60, 2200107.	3.1	5
1967	Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. Journal of Health Economics and Outcomes Research, 2022, 9, 151-160.	0.6	1
1968	Risk Stratification and Outcomes in Patients With Pulmonary Hypertension: Insights into Right Ventricular Strain by <scp>MRI</scp> Feature tracking. Journal of Magnetic Resonance Imaging, 2023, 57, 545-556.	1.9	4
1969	Peripheral Blood T Cells of Patients with IPAH Have a Reduced Cytokine-Producing Capacity. International Journal of Molecular Sciences, 2022, 23, 6508.	1.8	6
1970	Editorial for â€œRisk Stratification and Outcomes in Patients with Pulmonary Hypertension: Insights into Right Ventricular Strain by MRI Featureâ€Trackingâ€• Journal of Magnetic Resonance Imaging, 2023, 57, 557-558.	1.9	0
1972	Neurofibromatosis type 1 and pulmonary arterial hypertension: A case report. Revista Portuguesa De Cardiologia, 2022, 41, 511.e1-511.e5.	0.2	2

#	Article	IF	Citations
1973	Therapy With Inhaled Treprostinil, Macitentan, and Tadalafil/Riociguat in High-Risk Pulmonary Arterial Hypertension. American Journal of Therapeutics, 0, Publish Ahead of Print, .	0.5	1
1974	Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. Journal of Health Economics and Outcomes Research, 2022, 9, .	0.6	0
1975	Platelet-leukocyte aggregate formation and inflammation in patients with pulmonary arterial hypertension and CTEPH. Platelets, 2022, 33, 1199-1207.	1.1	5
1976	Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis. Arthritis Research and Therapy, 2022, 24, .	1.6	2
1977	Serum miR-204 and miR-451 Expression and Diagnostic Value in Patients with Pulmonary Artery Hypertension Triggered by Congenital Heart Disease. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-7.	0.7	2
1978	Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension. Frontiers in Pharmacology, 0, 13, .	1.6	1
1979	Upregulation of Endothelin-1 May Predict Chemotherapy-Induced Cardiotoxicity in Women with Breast Cancer. Journal of Clinical Medicine, 2022, 11, 3547.	1.0	5
1980	Gaps of evidence in pulmonary arterial hypertension. International Journal of Cardiology, 2022, , .	0.8	0
1981	A Nomogram for Predicting the Risk of Pulmonary Hypertension for Patients with Chronic Obstructive Pulmonary Disease. International Journal of General Medicine, 0, Volume 15, 5751-5762.	0.8	3
1983	Percutaneous Treatments for Pulmonary Hypertension. Interventional Cardiology Clinics, 2022, 11, 293-305.	0.2	1
1984	Senescence in pulmonary arterial hypertension: is there a link?. Current Opinion in Pulmonary Medicine, 2022, 28, 303-306.	1.2	1
1985	Identification of autophagy-related biomarkers in patients with pulmonary arterial hypertension based on bioinformatics analysis. Open Medicine (Poland), 2022, 17, 1148-1157.	0.6	5
1987	Plasma level of antimony correlates with pulmonary arterial hypertension severity. Current Research in Toxicology, 2022, 3, 100080.	1.3	7
1990	Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). Eurasian Heart Journal, 2022, , 6-70.	0.2	0
1991	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respiratory Medicine,the, 2022, 10, 937-948.	5.2	57
1992	Clinical application of risk assessment in PAH: Expert center APRN recommendations. Pulmonary Circulation, 2022, 12, .	0.8	5
1993	Incidence and outcomes of pulmonary hypertension in the Ireland. BMJ Open Respiratory Research, 2022, 9, e001272.	1.2	1
1994	Progressive Dyspnea in a Woman with Congenital Heart Disease and Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2022, 19, 1221-1225.	1.5	0

#	Article	IF	Citations
1995	Mitochondrial Respiration in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2022, 11, 4132.	1.0	7
1996	Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report. Respiratory Medicine and Research, 2022, , 100943.	0.4	0
1997	Utility of Cardiac MRI Feature Tracking Strain Assessment in Chronic Thromboembolic Pulmonary Hypertension for Prediction of REVEAL 2.0 High Risk Status. Pulmonary Circulation, 0, , .	0.8	0
1998	Inhibition of immunoglobulin E attenuates pulmonary hypertension. , 2022, 1, 665-678.		3
1999	Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography. Journal of Clinical Medicine, 2022, 11, 4034.	1.0	7
2001	Evaluation of Dyspnea and Exercise Intolerance After Acute Pulmonary Embolism. Chest, 2023, 163, 933-941.	0.4	11
2002	Quantitative CT Evaluation of Small Pulmonary Vessels Has Functional and Prognostic Value in Pulmonary Hypertension. Radiology, 2022, 305, 431-440.	3.6	4
2003	Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough. European Respiratory Journal, 2022, 60, 2200581.	3.1	0
2004	Cross-cultural validation of the Chinese version of the EmPHasis-10 questionnaire in connective tissue disease patients with pulmonary arterial hypertension and its relationship with risk stratification. BMC Pulmonary Medicine, 2022, 22, .	0.8	1
2005	Autoimmunity to Sphingosine-1-Phosphate-Receptors in Systemic Sclerosis and Pulmonary Arterial Hypertension. Frontiers in Immunology, 0, 13, .	2.2	3
2006	Peripheral Microangiopathy Changes in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Data From a Multicenter Observational Study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
2007	Development of an Electronic Frailty Index for Predicting Mortality and Complications Analysis in Pulmonary Hypertension Using Random Survival Forest Model. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
2008	Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac index versus stroke volume index. European Respiratory Journal, 0, , 2200801.	3.1	1
2009	The effect of rehabilitation exercise on the expression of glutaminase and cardiopulmonary remodeling in pulmonary hypertension. Medicine in Novel Technology and Devices, 2022, 15, 100157.	0.9	0
2010	Clinician's Corner: Counseling Patients with Pulmonary Vascular Disease Traveling to High Altitude. High Altitude Medicine and Biology, 0, , .	0.5	2
2011	Acute on Chronic Thromboembolic Pulmonary Hypertension: Case Series and Review of Management. Journal of Clinical Medicine, 2022, 11, 4224.	1.0	3
2012	PULMONAR.Y ARTERIAL HYPERTENSION ASSOCIATED WITH A SYSTEMIC SCLEROSIS: REVIEW OF LITERATURE. Eurasian Heart Journal, 2015, , 32-39.	0.2	1
2013	Imaging Advances in Chronic Thromboembolic Pulmonary Hypertension. Seminars in Roentgenology, 2022, 57, 324-334.	0.2	1

#	Article	IF	Citations
2014	Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiativeâ€"Group 3 pulmonary hypertension. Pulmonary Circulation, 2022, 12, .	0.8	15
2015	Elucidating tricuspid Doppler signal interpolation and its implication for assessing pulmonary hypertension. Pulmonary Circulation, 2022, 12, .	0.8	0
2016	A framework of deep learning networks provides expert-level accuracy for the detection and prognostication of pulmonary arterial hypertension. European Heart Journal Cardiovascular Imaging, 2022, 23, 1447-1456.	0.5	10
2017	Patienten mit systemischer Sklerose und negativen antinukleÃren AntikÃ¶rpern haben ausgeprÃgte klinische Symptome: eine multizentrische CRDC-Kohorte in China. Zeitschrift Fur Rheumatologie, 2024, 83, 160-166.	0.5	2
2018	Lung allograft transbronchial cryobiopsy for critical ventilated patients: a randomised trial. European Respiratory Journal, 0, , 2102354.	3.1	3
2019	Elevated baseline serum creatine kinase in Thai early systemic sclerosis patients is associated with high incidence of cardiopulmonary complications and poor survival: an inception cohort study. Clinical Rheumatology, 2022, 41, 3055-3063.	1.0	3
2020	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2023, 61, 2200879.	3.1	445
2021	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis â€“ 2021 update. Full-length version. Respiratory Medicine and Research, 2023, 83, 100948.	0.4	1
2022	Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography. European Respiratory Journal, 2022, 60, 2200481.	3.1	1
2023	Right ventricular-pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism. European Respiratory Journal, 0, , 2200450.	3.1	5
2024	Evaluating cardiopulmonary function following acute pulmonary embolism. Expert Review of Cardiovascular Therapy, 2022, 20, 747-760.	0.6	1
2025	Identification of LTBP-2 as a plasma biomarker for right ventricular dysfunction in human pulmonary arterial hypertension. , 2022, 1, 748-760.		17
2026	Corrected MRI Pulmonary Transit Time for Identification of Combined Precapillary and Postcapillary Pulmonary Hypertension in Patients With Left Heart Disease. Journal of Magnetic Resonance Imaging, 2023, 57, 1518-1528.	1.9	3
2027	Farnesyl diphosphate synthase regulated endothelial proliferation and autophagy during rat pulmonary arterial hypertension induced by monocrotaline. Molecular Medicine, 2022, 28, .	1.9	5
2028	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2022, 43, 3618-3731.	1.0	1,033
2029	Coping styles associated with depression, health anxiety and health-related quality of life in pulmonary hypertension: cross-sectional analysis. BMJ Open, 2022, 12, e062564.	0.8	11
2030	Effects of oral anticoagulant therapy in patients with pulmonary diseases. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
2031	Chronic thromboembolic pulmonary hypertension: from pathogenesis to the choice of treatment tactics. Terapevticheskii Arkhiv, 2022, 94, 791-796.	0.2	2

#	Article	IF	Citations
2032	Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension - An analysis of FREEDOM-EV. Journal of Heart and Lung Transplantation, 2022, 41, 1572-1580.	0.3	8
2033	Rehabilitation in patients with chronic thromboembolic pulmonary hypertension. Terapevticheskii Arkhiv, 2022, 94, 903-907.	0.2	1
2034	Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia. JACC Asia, 2022, 2, 538-546.	0.5	14
2035	Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. American Journal of Respiratory and Critical Care Medicine, 2022, 206, e7-e41.	2.5	53
2036	Diversity of hemodynamic types in connective tissue disease associated pulmonary hypertension: more than a subgroup of pulmonary arterial hypertension. BMC Pulmonary Medicine, 2022, 22, .	0.8	2
2037	Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respiratory Medicine,the, 2022, 10, 961-971.	5.2	73
2038	Targeted Therapies in Patients with Pulmonary Arterial Hypertension Due to Congenital Heart Disease. Current Vascular Pharmacology, 2022, 20, 341-360.	0.8	0
2039	Prognostic Value of Exercise as Compared to Resting Pulmonary Hemodynamics in Patients with Normal or Mildly Elevated Pulmonary Arterial Pressure. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1418-1423.	2.5	9
2040	Solitary pulmonary capillary hemangioma mimicking a preinvasive malignant lesion in an asymptomatic middle-aged female patient. International Cancer Conference Journal, 0, , .	0.2	0
2041	Right Heart Catheterization (RHC): A Comprehensive Review of Provocation Tests and Hepatic Hemodynamics in Patients With Pulmonary Hypertension (PH). Current Problems in Cardiology, 2022, 47, 101351.	1.1	7
2043	The Challenge of Diagnosing and Managing Pulmonary Arterial Hypertension in Systemic Sclerosis with Interstitial Lung Disease. Pharmaceuticals, 2022, 15, 1042.	1.7	3
2044	Outcomes and Prognostic Factors of Pulmonary Hypertension Patients Undergoing Emergent Endotracheal Intubation. Journal of Intensive Care Medicine, 2023, 38, 280-289.	1.3	1
2045	Portopulmonary hypertension practice patterns after liver transplantation. Liver Transplantation, 2023, 29, 365-376.	1.3	2
2046	Right Heart Catheterizationâ€"To Do or Not To Do? Introducing a New Diagnostic Algorithm for Pulmonary Hypertension. Journal of the American Heart Association, 2022, 11, .	1.6	0
2047	Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension: determinants and clinical impact. Vascular Pharmacology, 2022, 146, 107099.	1.0	4
2048	Pulmonary vascular disease and exercise hemodynamics in chronic liver disease. Respiratory Medicine, 2022, 202, 106987.	1.3	3
2049	Risk assessment in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211125.	1.1	5
2050	Erkrankungen in der Schwangerschaft. Springer Reference Medizin, 2022, , 1-3.	0.0	0

#	Article	IF	Citations
2051	Hemodynamic indices in pulmonary hypertension: a narrative review. Cardiovascular Diagnosis and Therapy, 2022, 12, 693-707.	0.7	4
2052	Interpretable Prediction ofÂPulmonary Hypertension inÂNewborns Using Echocardiograms. Lecture Notes in Computer Science, 2022, , 529-542.	1.0	1
2053	Using a knowledge translation program to facilitate guidelineâ€Âand evidenceâ€based patient management: theÂPAHâ€QuERI Extension Program. Pulmonary Circulation, 2022, 12, .	0.8	0
2054	Riociguat in children with pulmonary arterial hypertension: The PATENTâ€“CHILD study. Pulmonary Circulation, 2022, 12, .	0.8	6
2055	Pulmonary Thromboendarterectomy: Patient Selection, Techniques, Outcomes, and Recent Advances. Advances in Pulmonary Hypertension, 2022, 21, 73-82.	0.1	0
2056	Prognostic Significance of the N-Terminal Pro-B-Type Natriuretic Peptide in Lung Transplant Candidates on the Waiting List. Diagnostics, 2022, 12, 2112.	1.3	0
2057	Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population. BMC Pulmonary Medicine, 2022, 22, .	0.8	5
2058	Pulmonary Hypertension in Sclerodermaâ€“ Evaluation and Management. Disease-a-Month, 2022, , 101468.	0.4	1
2059	The Oracle of the Auricle?. Chest, 2022, 162, 509-510.	0.4	1
2060	Echocardiographic Probability of Pulmonary Hypertension in Cardiac Surgery Patientsâ€”Occurrence and Association with Respiratory Adverse Eventsâ€”An Observational Prospective Single-Center Study. Journal of Clinical Medicine, 2022, 11, 5749.	1.0	1
2061	International Consensus Statement on Obstructive Sleep Apnea. International Forum of Allergy and Rhinology, 2023, 13, 1061-1482.	1.5	39
2062	Fully automatic cardiac four chamber and great vessel segmentation on CT pulmonary angiography using deep learning. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
2063	Clinical Characteristics of Patients Undergoing Right Heart Catheterizations in Community Hospitals. Journal of the American Heart Association, 2022, 11, .	1.6	4
2064	Pulmonary Vasodilator Response of Combined Inhaled Epoprostenol and Inhaled Milrinone in Cardiac Surgical Patients. Anesthesia and Analgesia, 2023, 136, 282-294.	1.1	9
2065	A novel method for measuring pulmonary artery pressure by high-frequency ultrasound-guided transthoracic puncture in rats. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
2067	The Lung Allocation Score Remains Inequitable for Patients with Pulmonary Arterial Hypertension, Even after the 2015 Revision. American Journal of Respiratory and Critical Care Medicine, 2023, 207, 300-311.	2.5	5
2068	Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. Respirology, 2023, 28, 262-272.	1.3	15
2069	Imaging in Women with Heart Failure: Sex-specific Characteristics and Current Challenges. Cardiac Failure Review, 0, 8, .	1.2	5

#	Article	IF	Citations
2070	Multiorgan ultrasonographic findings in patients with pulmonary embolism at diagnosis and clinical follow-up: a proof of concept study. Journal of Ultrasound, 0, , .	0.7	0
2071	Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension. Chest, 2023, 163, 407-418.	0.4	7
2072	Pregnant outcomes of critically ill pregnant patients with pulmonary hypertension: A multicenter retrospective study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
2073	Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients. Rheumatology, 2023, 62, 1552-1558.	0.9	2
2074	Exercise metabolomics in pulmonary arterial hypertension: Where pulmonary vascular metabolism meets exercise physiology. Frontiers in Physiology, 0, 13, .	1.3	3
2075	The Role of Pulmonary Function Test for Pulmonary Arterial Hypertension in Patients with Connective Tissue Disease. Disease Markers, 2022, 2022, 1-7.	0.6	0
2076	Improved Survival for Patients with Systemic Sclerosisâ€“associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry. American Journal of Respiratory and Critical Care Medicine, 2023, 207, 312-322.	2.5	11
2078	No â€œgreat divideâ€•in patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary endarterectomy?. European Journal of Cardio-thoracic Surgery, 2022, 62, .	0.6	0
2079	Balloon Pulmonary Angioplasty in the Management of Chronic Thromboembolic Pulmonary Hypertension. Radiographics, 2022, 42, 1881-1896.	1.4	3
2080	Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension. ERJ Open Research, 2022, 8, 00298-2022.	1.1	7
2081	Riociguat inhibits ultra large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients. Pulmonary Circulation, 0, , .	0.8	0
2082	Pulmonary hypertension: Linking inflammation and pulmonary arterial stiffening. Frontiers in Immunology, 0, 13, .	2.2	12
2083	Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag. Biomedicine Hub, 2022, 7, 115-124.	0.4	0
2084	Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease. International Journal of Hematology, 2023, 117, 90-99.	0.7	5
2085	Right ventricular outflow tract Doppler flow analysis and pulmonary arterial coupling by transthoracic echocardiography in sepsis: a retrospective exploratory study. Critical Care, 2022, 26, .	2.5	5
2086	Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction. Cardiology Clinics, 2022, 40, 533-540.	0.9	0
2087	Predicting cardiac index using the electrocardiogram in pulmonary hypertension patients. Research in Cardiovascular Medicine, 2022, 11, 76.	0.2	0
2088	Management of Pulmonary Hypertension Due to Brachycephalic Obstructive Airway Syndrome in a Dog. Journal of Veterinary Clinics, 2022, 39, 240-245.	0.2	1

#	Article	IF	Citations
2089	Pulmonary Hypertension Associated Genetic Variants in Sarcoidosis Associated Pulmonary Hypertension. Diagnostics, 2022, 12, 2564.	1.3	1
2090	Strategizing Drug Therapies in Pulmonary Hypertension for Improved Outcomes. Pharmaceuticals, 2022, 15, 1242.	1.7	5
2091	Effectiveness of echocardiographic evaluation of lung transplant candidates: Could it be an alternative to right heart catheterization?. Turkish Journal of Thoracic and Cardiovascular Surgery, 2022, 30, 584-592.	0.2	0
2092	Epidemiology and prevention of venous thromboembolism. Nature Reviews Cardiology, 2023, 20, 248-262.	6.1	52
2094	Quantification of the pulmonary vascular obstruction index on ventilation/perfusion lung scintigraphy: Comparison of a segmental visual scoring to the Meyer score. Frontiers in Medicine, 0, 9, .	1.2	1
2095	Comprehensive Review of Pulmonary Hypertension and Treatment Options in the Paediatric Population. Cureus, 2022, , .	0.2	0
2096	Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 6189.	1.0	2
2097	Bmpr2 mutant mice are an inadequate model for studying iron deficiency in pulmonary hypertension. Pulmonary Circulation, 2022, 12, .	0.8	2
2098	The Therapeutic Role of Rho Kinase Inhibitor, Fasudil, on Pulmonary Hypertension; a Systematic Review and Meta-Analysis. Drug Research, 2023, 73, 5-16.	0.7	2
2099	Safety of macitentan for the treatment of pulmonary hypertension: Realâ€world experience from the OPsumitÂ® USers Registry (OPUS) and OPsumitÂ® Historical USers cohort (OrPHeUS). Pulmonary Circulation, 2022, 12, .	0.8	6
2100	Prognostic Relevance of Cardiopulmonary Exercise Testing for Patients with Chronic Thromboembolic Pulmonary Hypertension. Journal of Cardiovascular Development and Disease, 2022, 9, 333.	0.8	2
2101	Does veno-arterial carbon dioxide gradient provide an adequate estimation of cardiac index in pulmonary hypertension?. European Heart Journal: Acute Cardiovascular Care, 0, , .	0.4	0
2102	2022 Brazilian Thoracic Association recommendations for long-term home oxygen therapy. Jornal Brasileiro De Pneumologia, 0, , e20220179.	0.4	2
2103	Chronic Thromboembolic Pulmonary Disease and Chronic Thromboembolic Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 936-945.	0.8	1
2104	Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. European Respiratory Journal, 2023, 61, 2201471.	3.1	10
2105	Portopulmonary Hypertension. Clinics in Liver Disease, 2023, 27, 71-84.	1.0	1
2106	Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. Journal of Heart and Lung Transplantation, 2023, 42, 102-114.	0.3	20
2107	Pulmonary arterial hypertension in pregnancy. BJA Education, 2023, 23, 24-31.	0.6	0

#	Article	IF	Citations
2108	Portopulmonary Hypertension in Nontransplanted Patients: Results of the Largest US Single-Institution Registry. Mayo Clinic Proceedings, 2022, 97, 2236-2247.	1.4	3
2109	Editorial: Calcium and pulmonary hypertension. Frontiers in Physiology, 0, 13, .	1.3	0
2110	Pulmonary artery pressure-directed therapies in pulmonary arterial hypertension?. Vascular Pharmacology, 2022, 147, 107124.	1.0	1
2111	Endothelial mechanosensing: A forgotten target to treat vascular remodeling in hypertension?. Biochemical Pharmacology, 2022, 206, 115290.	2.0	2
2112	Pulmonary Capillary Hemangiomatosis Versus Congestion. , 2022, , 341-344.		0
2113	Iron metabolism disorder regulated by BMP signaling in hypoxic pulmonary hypertension. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166589.	1.8	1
2114	Expert provider survey of longitudinal assessment in patients with pulmonary arterial hypertension. Heart and Lung: Journal of Acute and Critical Care, 2023, 58, 34-38.	0.8	1
2115	THE ROLE OF RIOCIGUAT IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE. Eurasian Heart Journal, 2019, , 134-143.	0.2	0
2116	Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	3
2117	Efficacy of Dynamic Chest Radiography for Chronic Thromboembolic Pulmonary Hypertension. Radiology, 2023, 306, .	3.6	9
2118	Extracorporeal membrane oxygenation as a bridge to transplant in neonates with fatal pulmonary conditions: A review. Paediatric Respiratory Reviews, 2022, 44, 31-39.	1.2	4
2119	Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction. Heart Failure Reviews, 2023, 28, 1009-1022.	1.7	6
2120	Prevalence and risk prediction value of tricuspid regurgitation by echocardiography in precapillary pulmonary hypertension. BMC Pulmonary Medicine, 2022, 22, .	0.8	1
2122	Prediction and prognosis of adverse maternal and foetal/neonatal outcomes in pulmonary hypertension: an observational study and nomogram construction. Respiratory Research, 2022, 23, .	1.4	3
2123	Association of Pulmonary Hypertension and Monoclonal Gammopathy of Undetermined Significance. Advances in Hematology, 2022, 2022, 1-8.	0.6	0
2124	Detection and evaluation of myocardial fibrosis in Eisenmenger syndrome using cardiovascular magnetic resonance late gadolinium enhancement and T1 mapping. Journal of Cardiovascular Magnetic Resonance, 2022, 24, .	1.6	0
2125	Does pulmonary hypertension affect early-term outcomes of off-pump coronary artery bypass surgery?. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2022, 68, 1747-1752.	0.3	2
2126	Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis. Heart Failure Clinics, 2023, 19, 45-54.	1.0	0

#	Article	IF	Citations
2127	2022 Update of indications and contraindications for lung transplantation in France. Respiratory Medicine and Research, 2023, 83, 100981.	0.4	0
2128	Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter study. Respiratory Medicine and Research, 2023, 83, 100945.	0.4	0
2129	Socioeconomically disadvantaged veterans experience treatment delays for pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, .	0.8	3
2130	PH Professional Network: The Role of the Advanced Practice Nurse With Patients Undergoing Pulmonary Thromboendarterectomy and Balloon Pulmonary Angioplasty for CTEPH. Advances in Pulmonary Hypertension, 2022, 21, 130-134.	0.1	0
2131	Efficacy and safety of oral pulmonary vasodilators in pulmonary venoâ€•occlusive disease. Pulmonary Circulation, 2022, 12, .	0.8	1
2132	Acute lung injury after balloon pulmonary angioplasty results in a similar haemodynamic response and possible clinical advantage at followâ€•up. Pulmonary Circulation, 2022, 12, .	0.8	0
2133	Adaptive versus maladaptive right ventricular remodelling. ESC Heart Failure, 2023, 10, 762-775.	1.4	14
2134	The evolving landscape of pulmonary arterial hypertension clinical trials. Lancet, The, 2022, 400, 1884-1898.	6.3	25
2136	A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease. BMC Pulmonary Medicine, 2022, 22, .	0.8	0
2137	Computational platform for doctorâ€“artificial intelligence cooperation in pulmonary arterial hypertension prognostication: a pilot study. ERJ Open Research, 2023, 9, 00484-2022.	1.1	3
2138	Long-Term Follow-up of Human Immunodeficiency Virus-Associated Pulmonary Hypertension: Clinical Features and Survival Outcomes of the Pan Africa Pulmonary Hypertension Cohort (PAPUCO). Open Forum Infectious Diseases, 2022, 9, .	0.4	5
2139	Long-term efficacy of specific therapy in patients with different clinical variants of pulmonary arterial hypertension associated with congenital heart disease. Systemic Hypertension, 2022, 19, 23-30.	0.1	0
2140	Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review of the Most Updated Literature. Journal of Clinical Medicine, 2022, 11, 6976.	1.0	3
2141	Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca²⁺ signaling. Physiological Reviews, 2023, 103, 1827-1897.	13.1	15
2143	Inhaled Epoprostenol and Milrinone Effect on Right Ventricular Pressure Waveform Monitoring. Canadian Journal of Cardiology, 2022, , .	0.8	3
2144	A machine learning approach to identifying patients with pulmonary hypertension using real-world electronic health records. International Journal of Cardiology, 2023, 374, 95-99.	0.8	8
2145	Pursuing functional biomarkers in complex disease: Focus on pulmonary arterial hypertension. American Heart Journal, 2023, 258, 96-113.	1.2	6
2146	Organization of pulmonary hypertension care in nonâ€expert care settings: Lessons learned from a multiâ€site study. Health Services Research, 0, , .	1.0	1

#	Article	IF	Citations
2147	State-of-the-art cardiac magnetic resonance in pulmonary hypertension: An update on diagnosis, risk stratification and treatment. Trends in Cardiovascular Medicine, 2022, , .	2.3	1
2148	Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
2149	Deletion of classical transient receptor potential 1, 3 and 6 alters pulmonary vasoconstriction in chronic hypoxia-induced pulmonary hypertension in mice. Frontiers in Physiology, 0, 13, .	1.3	1
2150	Association between Genotype, Presentation, and Outcome in Childhood Idiopathic and Hereditary Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2022, 11, 7331.	1.0	3
2151	Abnormal pulmonary hemodynamics during exercise is associated with exercise capacity in COPD. Respiratory Research, 2022, 23, .	1.4	2
2153	Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis. Annals of the Rheumatic Diseases, 2023, 82, 365-373.	0.5	12
2154	Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarker. Respiratory Research, 2022, 23, .	1.4	2
2155	Drug-Related Problems in Pulmonary Hypertension with Valvular Heart Disease. Therapeutics and Clinical Risk Management, 0, Volume 18, 1069-1079.	0.9	0
2156	Clinical and Predictive Value of Computed Tomography Angiography in High-Altitude Pulmonary Hypertension. JACC Asia, 2022, 2, 803-815.	0.5	1
2157	Apply pressure-strain loop to quantify myocardial work in pulmonary hypertension: A prospective cohort study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
2158	Diagnosis and management of pulmonary arterial hypertension. Breathe, 2022, 18, 220168.	0.6	1
2160	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-analysis. CardioVascular and Interventional Radiology, 2023, 46, 5-18.	0.9	5
2161	Acute Vasoreactivity Testing During Right Heart Catheterization in Chronic Thromboembolic Pulmonary Hypertension: Results from the Pulmonary Vascular Disease Phenomics Study. Pulmonary Circulation, 0, , .	0.8	3
2162	Cytokines as prognostic biomarkers in pulmonary arterial hypertension. European Respiratory Journal, 2023, 61, 2201232.	3.1	7
2163	Electrocardiogram, Echocardiogram and NT-proBNP in Screening for Thromboembolism Pulmonary Hypertension in Patients after Pulmonary Embolism. Journal of Clinical Medicine, 2022, 11, 7369.	1.0	1
2164	The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 608-616.	0.5	7
2165	Pregnancy outcomes in women with pulmonary hypertension: a retrospective study in China. BMC Pregnancy and Childbirth, 2023, 23, .	0.9	2
2166	Endotyping COPD: hypoxia-inducible factor-2 as a molecular â€œswitchâ€•between the vascular and airway phenotypes?. European Respiratory Review, 2023, 32, 220173.	3.0	4

#	Article	IF	Citations
2167	Phenotype of patients with pulmonary hypertension due to left heart disease: features of pathophysiology and differential diagnosis. Complex Issues of Cardiovascular Diseases, 2023, 11, 118-129.	0.3	1
2168	Effectiveness of Respiratory Muscle Training in Adults With Pulmonary Hypertension. A Systematic Review and Meta-Analysis. Heart Lung and Circulation, 2023, 32, 315-329.	0.2	1
2169	Endothelial IK and SK channel activation decreases pulmonary arterial pressure and vascular remodeling in pulmonary hypertension. Pulmonary Circulation, 2023, 13, .	0.8	4
2170	Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovascular Drugs and Therapy, 0, , .	1.3	0
2171	Metabolomic Signatures Associated With Pulmonary Arterial Hypertension Outcomes. Circulation Research, 2023, 132, 254-266.	2.0	11
2172	Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study. RMD Open, 2022, 8, e002673.	1.8	0
2173	Pediatric Population Pharmacokinetic Modeling and Exposureâ€“Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data. Journal of Clinical Pharmacology, 2023, 63, 593-603.	1.0	1
2174	Balloon pulmonary angioplasty: are we there yet? Lessons learned and unanswered questions. Breathe, 2022, 18, 220217.	0.6	1
2175	De-escalation of Oxygen Therapy and Medication in Patients With Chronic Thromboembolic Pulmonary Hypertension After Balloon Pulmonary Angioplasty. Canadian Journal of Cardiology, 2023, 39, 637-645.	0.8	1
2177	Usefulness of inhaled iloprost in managing exercise-induced pulmonary hypertension in a patient with systemic sclerosis-associated interstitial lung disease. Medicine, Case Reports and Study Protocols, 2023, 4, e0271.	0.0	0
2178	Exploration of physical activity knowledge, preferences and support needs among pulmonary hypertension patients. PLoS ONE, 2023, 18, e0277696.	1.1	1
2179	Updated definition of exercise pulmonary hypertension. Breathe, 2022, 18, 220232.	0.6	2
2180	Pulmoner Arteriyel Hipertansiyonlu Hastalarda Ä°nspiratuar Kas EÄŸitiminin Fonksiyonel Egzersiz Kapasitesi ve YaÅŸam Kalitesi Ãœzerine Etkisi: Bir Sistematik Derleme. Anadolu KliniÄŸi TÄ±p Bilimleri Dergisi, 0, , .	0.1	0
2181	Monitoring of Hemodynamics With Right Heart Catheterization in Children With Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2023, 12, .	1.6	2
2182	Quantitative Assessment of Right Ventricular Function in Patients With Systemic Lupus Erythematosus Using the Novel Non-invasive Pressureâ€“Strain Loop. Ultrasound in Medicine and Biology, 2023, 49, 1337-1344.	0.7	0
2183	Vitamin D attenuates elevated oxidative DNA damage in scleroderma patients with organ involvement: A prospective study. Journal of Steroid Biochemistry and Molecular Biology, 2023, 229, 106273.	1.2	0
2184	Characteristics of Right Ventricular to Pulmonary Arterial Coupling and Association With Functional Status Among Older Aged Adults from the Multi-Ethnic Study of Atherosclerosis. American Journal of Cardiology, 2023, 196, 41-51.	0.7	1
2185	SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. Circulation, 2023, 147, 1606-1621.	1.6	9

#	Article	IF	Citations
2186	Electrocardiogram Detection of Pulmonary Hypertension Using Deep Learning. Journal of Cardiac Failure, 2023, 29, 1017-1028.	0.7	7
2187	Pulmonary Vascular Reverse Remodeling After Left Ventricular Assist Device Implantation in Patients With Pulmonary Hypertension. ASAIO Journal, 2023, 69, 151-158.	0.9	3
2188	Predictors of Improvement in Exercise Tolerance After Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Journal of the American Heart Association, 2023, 12, .	1.6	1
2189	Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis. Cardiology in the Young, 2023, 33, 2297-2311.	0.4	0
2190	Physiological predictors of resting pulmonary hypertension associated with COPD: a retrospective analysis. Egyptian Journal of Bronchology, 2023, 17, .	0.3	2
2191	Low Rates of Reproductive Counseling Documentation in Women With Interstitial Pneumonia With Autoimmune Features. Journal of Clinical Rheumatology, 2023, 29, 145-150.	0.5	0
2192	In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicentre study. Rheumatology, 2023, 62, 3261-3267.	0.9	5
2193	Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults. Clinical Pharmacokinetics, 2023, 62, 321-333.	1.6	3
2194	Efficacy and Safety of Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension and Comorbid Chronic Obstructive Pulmonary Disease. Journal of the American Heart Association, 2023, 12, .	1.6	2
2195	Mitochondrial Dysfunction in Pulmonary Hypertension. Antioxidants, 2023, 12, 372.	2.2	4
2196	Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021. European Respiratory Review, 2023, 32, 220132.	3.0	6
2198	The role of aldehyde dehydrogenase 2 in cardiovascular disease. Nature Reviews Cardiology, 2023, 20, 495-509.	6.1	16
2199	Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial. Journal of Clinical Medicine, 2023, 12, 1571.	1.0	4
2201	Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension. International Journal of Molecular Sciences, 2023, 24, 3979.	1.8	7
2202	Lung Dual-Energy CT Perfusion Blood Volume as a Marker of Severity in Chronic Thromboembolic Pulmonary Hypertension. Diagnostics, 2023, 13, 769.	1.3	2
2203	Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator. European Heart Journal Open, 2023, 3, .	0.9	3
2204	Right Ventricular Function During Exercise After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension. Journal of the American Heart Association, 2023, 12, .	1.6	2
2205	New trends in pulmonary hypertension. European Respiratory Review, 2023, 32, 220211.	3.0	10

#	Article	IF	Citations
2206	Development of pulmonary arterial hypertension following long-term Qing-Dai use for ulcerative colitis. Journal of Cardiology Cases, 2023, 27, 218-221.	0.2	2
2207	Therapeutic Physical Exercise Programs in the Context of NASH Cirrhosis and Liver Transplantation: A Systematic Review. Metabolites, 2023, 13, 330.	1.3	4
2208	Effects of Acute Hypoxia on Heart Rate Variability in Patients with Pulmonary Vascular Disease. Journal of Clinical Medicine, 2023, 12, 1782.	1.0	0
2209	Cardiovascular disease and bone health in aging female rheumatic disease populations: A review. Women's Health, 2023, 19, 174550572311552.	0.7	3
2210	Pulmonalkreislauf. , 2022, , 97-105.		0
2211	Frequency and characterization of CTEPH and CTEPD according to the mPAP threshold > 20Âmm Hg: Retrospective analysis from data of a prospective PE aftercare program. Respiratory Medicine, 2023, 210, 107177.	1.3	9
2212	Fluid management in septic patients with pulmonary hypertension, review of the literature. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
2213	An expert overview of pulmonary fibrosis in sarcoidosis. Expert Review of Respiratory Medicine, 2023, 17, 119-130.	1.0	5
2214	Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation. Eurasian Heart Journal, 2023, , 94-99.	0.2	3
2215	Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2023, 42, 1082-1092.	0.3	1
2216	Electrocardiogram in patients with pulmonary hypertension. Journal of Electrocardiology, 2023, 79, 24-29.	0.4	7
2217	Mortality and prognostic factors in connective tissue diseaseâ€associated pulmonary arterial hypertension patients complicated with right heart failure. International Journal of Rheumatic Diseases, 2023, 26, 862-869.	0.9	1
2218	10-year survival of pulmonary arterial hypertension associated with connective tissue disease: insights from a multicentre PAH registry. Rheumatology, 2023, 62, 3555-3564.	0.9	3
2219	Potential Prognostic Value of Native T1 in Pulmonary Hypertension Patients. Life, 2023, 13, 775.	1.1	0
2220	Prognostic Value of Transthoracic Echocardiography in Children With Pulmonary Arterial Hypertension. Journal of the American Heart Association, 0, , .	1.6	0
2221	Age, sex and angiographic type-related phenotypic differences in inpatients with Takayasu arteritis: A 13-year retrospective study at a national referral center in China. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	2
2222	Epiphenomenon or Prognostically Relevant Interventional Target? A Novel Proportionality Framework for Severe Tricuspid Regurgitation. Journal of the American Heart Association, 2023, 12, .	1.6	2
2223	Exercise-based rehabilitation programmes for pulmonary hypertension. The Cochrane Library, 2023, 2023, .	1.5	3

#	Article	IF	Citations
2224	Impact of residual pulmonary hypertension on longâ€term outcomes after pulmonary endarterectomy in the modern era. Pulmonary Circulation, 2023, 13, .	0.8	1
2225	Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprostâ€"A Multicentre, Retrospective Study. International Journal of Molecular Sciences, 2023, 24, 6434.	1.8	2
2226	Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD). Pulmonary Circulation, 2023, 13, .	0.8	4
2227	Predicting Risk of 1-Year Hospitalization Among Patients with Pulmonary Arterial Hypertension. Advances in Therapy, 0, , .	1.3	0
2228	Pulmonary Vascular Manifestations of Hereditary Hemorrhagic Telangiectasia. , 2023, , 463-473.		0
2229	The Syndrome of Combined Pulmonary Fibrosis and Emphysema. , 2023, , 561-588.		0
2231	Refined Balloon Pulmonary AngioplastyÂin Chronic Thromboembolic Pulmonary Hypertension. , 2023, 2, 100291.		0
2232	Pulmonary Hypertension Associated with Anti-synthetase Syndrome: A Case Report and Literature Review. Internal Medicine, 2023, , .	0.3	0
2233	Incidence and prognostic significance of malignant arrhythmias during (repetitive) Holter electrocardiograms in patients with pulmonary hypertension. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
2234	Human Endogenous Retrovirus, SARS-CoV-2, and HIV Promote PAH via Inflammation and Growth Stimulation. International Journal of Molecular Sciences, 2023, 24, 7472.	1.8	3
2235	Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats. International Journal of Molecular Sciences, 2023, 24, 7478.	1.8	5
2236	Value of NT-proBNP and Galectin-3 as Biomarkers in the Follow-Up of Asymptomatic Elderly Patients with Severe Aortic Stenosis. Journal of Clinical Medicine, 2023, 12, 2987.	1.0	1
2237	Use of Preoperative Natriuretic Peptide in Predicting Mortality After Coronary Artery Bypass Grafting: A Systematic Review and Meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia, 2023, 37, 1785-1792.	0.6	2
2238	Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension. ERJ Open Research, 2023, 9, 00072-2023.	1.1	1
2239	Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension. Herz, 2023, 48, 259-265.	0.4	1
2240	Hemodynamic characteristics in patients with pulmonary hypertension and chronic obstructive pulmonary disease: A retrospective monocentric cohort study. Respiratory Medicine and Research, 2023, 83, 101008.	0.4	1
2241	Mental Health and Quality of Life in Pulmonary Embolism: A Literature Review. Advances in Respiratory Medicine, 2023, 91, 174-184.	0.5	2
2260	Pulmonary Vasculitides. , 2023, , 711-762.		0

#	Article	IF	Citations
2262	Pulmonary arterial hypertension. , 2023, , 180-191.		0
2274	Pulmonary Hypertension in Interstitial Lung Disease: Management Options to Move Beyond Supportive Care. Current Pulmonology Reports, 0, , .	0.5	0
2280	Respiratory Emergencies. , 2023, , 63-77.		0
2302	Closing Secundum ASD in the Setting of Pulmonary Hypertension: Treat-to-Close ASD. , 2023, , 105-113.		0
2311	Dynamic chest radiography for pulmonary vascular diseases: clinical applications and correlation with other imaging modalities. Japanese Journal of Radiology, 0, , .	1.0	1
2326	Pulmonary Hypertension in Adults with Congenital Heart Disease. , 2023, , 1-50.		0
2332	Pediatric Pulmonary Hypertension. , 2023, , 1-34.		0
2338	Preoperative pulmonary evaluation to prevent postoperative pulmonary complications. , 2023, 1, .		0
2340	A journey to vasculopathy in systemic sclerosis: focus on haemostasis and thrombosis. Clinical and Experimental Medicine, 2023, 23, 4057-4064.	1.9	0
2358	Lung Transplantation for Pulmonary Artery Hypertension. , 0, , .		0
2364	Right Heart Catheterization: The Role of Hemodynamic Assessment in the Diagnosis and Management of Pulmonary Arterial Hypertension. , 0, , .		0
2384	Arterial Vascular Diseases. , 2024, , 64-78.		0
2385	Chronisch thromboembolische pulmonale Hypertonie. Springer Reference Medizin, 2024, , 1-14.	0.0	0
2395	Classification and Clinical Features of Pulmonary Hypertension in Adults. , 0, , .		0
2404	Left Ventricular Diastolic Dysfunction. Updates in Hypertension and Cardiovascular Protection, 2023, , 245-265.	0.1	0